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CHAPTER I 
 
INTRODUCTION 
 
Approximately 10,000 trillion cell divisions happen in the typical human 
lifetime.  Cell division occurs via an ordered set of events collectively termed the 
cell division cycle.  During each cell division cycle, over 6 billion base pairs of 
DNA must be replicated during DNA synthesis (S-phase) and then segregated to 
each daughter cell during mitosis (M-phase). Cellular energy is focused on 
growth and preparation for S and M phases during the Gap 1 (G1) and Gap 2 
(G2) phases. Furthermore, the cell division cycle happens in the context of 
thousands of DNA lesions that occur in each cell each day.  In all but a few 
specialized cases, the goal is to create and maintain an identical genome for 
each cell in the body. The faithful replication and maintenance of the genome is 
essential for cellular viability and disease prevention. 
Maintaining the genome requires the concerted actions of cellular 
metabolism, cell cycle, and DNA repair activities that together constitute genome 
maintenance pathways (Figure 1.1). Enzymes like superoxide dismutase protect 
cellular molecules from the action of reactive oxygen species generated as a 
byproduct of cellular metabolism, thereby reducing the DNA damage burden in 
the cell (1).  DNA lesions that do occur are identified and repaired by multiple 
DNA repair systems that scan the genome looking for imperfections (2).  Many 
proteins work to ensure a single round of DNA replication is completed with
 2 
  
 
 
 
 
 
 
 
 
Figure 1.1. Genome maintenance requires the coordination of multiple 
cellular activities. (A) Multiple DNA repair pathways operate to remove DNA 
lesions caused by endogenous and exogenous genotoxic agents. (B) DNA repair 
and metabolism occurs in the context of chromatin.  Chromatin modifications 
regulate protein access to the DNA as well as signaling responses to DNA 
damage. (C) DNA replication must faithfully duplicate the DNA and chromatin 
structure once and only once per cell division cycle. (D) Proper spindle assembly 
and chromosome segregation during mitosis ensures each daughter cell receives 
a complete copy of the genome.  (E) Cell cycle checkpoints monitor DNA damage, 
replication, and mitosis. 
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minimal errors each cell cycle (3).  Proper chromosome segregation during 
mitosis requires spindle assembly, kinetochore attachment, and physical 
separation (4). All of these genome maintenance activities happen in the context 
of chromatin necessitating a large cohort of enzymes that control chromatin 
dynamics (5).   
Finally, many of these activities are coordinated through signaling 
pathways that constitute the DNA damage response (DDR).  DDR signaling 
regulates cell cycle checkpoints, DNA repair, DNA replication, and can promote 
the elimination of damaged cells from the cycling population through either 
apoptosis or senescence (6).   
In this chapter, I will briefly introduce the regulators of DDR signaling and 
how they are activated to coordinate genome maintenance pathways. Next, I will 
focus on the replication stress response, a DDR pathway that is required during 
DNA replication.  Many types of DNA damage present challenges to the 
completion of DNA replication. The essential function of the replication stress 
response is to promote activities that overcome these challenges to complete 
faithful duplication of the genome.  Finally, I will introduce the SNF2 family of 
proteins. The ATP-dependent activities of many SNF2 proteins are required in 
genome maintenance pathways.  Importantly, defects in SNF2 genome 
maintenance functions are associated with human disease.  My thesis work led 
to the identification of the SNF2 protein SMARCAL1 as a genome maintenance 
protein. I further characterized SMARCAL1 and determined that it functions as a 
component of the replication stress response. SMARCAL1 mutations cause the 
 4 
human disease Schimke immunosseous dysplasia (SIOD).  The data presented 
in this thesis suggests that loss of SMARCAL1 function in patients may cause 
DNA replication-associated genome instability that contributes to the phenotypes 
of SIOD.  
 
The DNA Damage Response 
 
The DDR is an evolutionarily conserved network of genome surveillance 
systems that senses aberrant DNA structures, transmits the DNA damage signal, 
and responds to DNA damage by coordinating cellular responses that promote 
genome maintenance (6-8). The cellular response to DNA damage varies 
depending on the type of DNA lesion.  The DNA damage-sensing component of 
DDR pathways dictates which DNA repair pathway will be used and recruits DDR 
kinases to initiate a DNA damage signal cascade. In fact, artificially concentrating 
sensor proteins in cells is sufficient to activate a DNA damage signal in the 
absence of DNA damage (9).  After sensing the damage, transmitting the DNA 
damage signal throughout the nucleus is critical to activate the proteins that carry 
out the response to DNA damage.   
 
DNA damage response kinases 
The major regulators of DDR signaling in mammalian cells are the protein 
kinases ataxia-telangiectasia mutated (ATM), ATM and Rad3-related (ATR), and 
DNA-dependent protein kinase (DNA-PK).  The DDR kinases ATM, ATR, and 
DNA-PK belong to a conserved family of phosphoinositide 3-like (PI3K)-related 
 5 
protein kinases (PIKKs).  All three share significant sequence homology and 
target an overlapping set of substrates involved in the DDR.  However, distinct 
types of DNA damage activate these kinases.   This distinction is dependent on 
the recruitment of DNA-PK, ATM, and ATR to DNA lesions by specific DNA 
damage-sensing proteins (Figure 1.2).  Localization to the site of DNA damage is 
required for activation of DDR kinases.  
DNA-PK and ATM are activated in response to rare occurrences of 
double-stranded DNA breaks (DSBs). The Mre11-Rad50-Nbs1 (MRN) complex 
and Ku70/80 heterodimer both bind DNA ends at DNA double stranded breaks 
(DSBs) and recruit ATM and DNA-PK, respectively. DNA-PK activation at DSBs 
promotes non-homologous end-joining repair (NHEJ) of DSBs (10). NHEJ repair 
seals breaks by ligating DNA ends at the expense of creating microdeletions. 
NHEJ activity is required to rejoin breaks generated during immunoglobulin class 
switch recombination.  This process is essential for lymphocyte development and 
requires both DNA-PK and ATM (11). 
ATM was first identified as the product of the gene that is mutated or lost 
in the human genetic disorder ataxia-telangiectasia (A-T).  Cells from A-T 
patients exhibit extreme sensitivity to DSB inducing agents. In response to DSBs, 
ATM enforces cell cycle checkpoints, promotes DSB repair, and when DSBs 
persist unrepaired, activates cell death pathways (12).  
ATR responds to DNA damage types that cause single-stranded DNA 
(ssDNA). The repair of base adducts, DNA crosslinks, and DSBs includes ssDNA 
intermediates that can activate ATR. However, ssDNA is most frequently
 6 
 
 
 
 
Figure 1.2. Localization to sites of DNA damage activates DDR kinases. 
DNA-PK, ATM, and ATR are protein kinases that regulated the activities of the 
DDR. By phosphorylating hundreds of overlapping substrates, they coordinate 
many cellular responses that preserve genome integrity.  DNA-PK and ATM are 
activated in response to DSB.  Ku70/80 and MRN bind DNA double-stranded 
ends and recruit DNA-PK and ATM to the damage site, respectively. ATR 
responds to damage that causes ssDNA, most frequently generated during DNA 
replication. RPA is a ssDNA binding protein. RPA-ssDNA recruits ATR through 
an interaction with ATRIP.  
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generated during DNA replication stress (mechanism discussed below).  RPA is 
a ssDNA binding protein that consist of three subunits, RPA1, RPA2, and RPA3.  
RPA binds ssDNA in the cell and interacts with many DNA processing proteins 
(13).  RPA-ssDNA binds ATR through its obligate binding partner, ATR-
interacting protein (ATRIP) and this is important for the localization of ATR to 
sites of DNA damage (14).  RPA-ssDNA is not sufficient for ATR activation at 
replication forks but it does coordinate the loading of the 9-1-1 complex, which is 
required for localizing the protein activator of ATR, topoisomerase-binding 
protein-1 (TOPBP1).  Once activated, ATR signaling coordinates many of the 
same activities as ATM, controlling cell cycle, repair, and when necessary 
activating pathways of apoptosis.  
Unlike DNA-PK and ATM, the ATR/ATRIP complex is essential for the 
viability of replicating cells and is activated every S-phase to respond to DNA 
replication stress (14-17).  The requirements for ATR activity during S phase 
emphasize that the genome is particularly sensitive to ssDNA accumulation 
during the process of DNA replication.  Furthermore, it indicates that ATR 
signaling is especially important to coordinate DDR activities that maintain the 
genome during replication. 
 
The Replication Stress Response 
 
 
Proliferating cells must complete S phase under challenging conditions 
where DNA lesions, DNA-protein barriers, and DNA secondary structures slow or 
inhibit replication fork progression causing an event referred to as replication 
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stress. The replication stress response is a component of the DDR that acts 
during every cell division cycle to overcome complex replication fork challenges 
and ultimately promote faithful and complete duplication of the genome. Failures 
in the response to replication stress result in the accumulation of mutations and 
genomic rearrangements. In this section, I will introduce the basic components of 
DNA replication and discuss possible mechanisms that preserve the integrity of 
replication forks that are challenged.  
 
DNA replication  
DNA replication initiates from replication origins dispersed throughout the 
genome.  Not all origins are used or ‘licensed’ for DNA replication in every cell 
cycle. Thus, marking replication origins competent for replication initiation 
requires an extensively regulated and ordered series of events (18-20).  For 
those origins that do initiate (or fire) each round of DNA replication, DNA 
unwinding and synthesis proceeds bi-directionally, forming a replication bubble 
with two diverging replication forks (Figure 1.3A). DNA synthesis begins at a free 
3’OH group of a short RNA primer synthesized by DNA polymerase alpha (!) on 
both strands. The two parental DNA strands are synthesized by different 
mechanisms due to the directionality of DNA synthesis (5’!3’). This means that 
nucleotides are only added to the 3’ end of elongating primers. The leading 
strand refers to the template strand that is synthesized in the direction of DNA 
unwinding or fork progression.  Synthesis on the lagging strand (parental strand 
complementary to the leading strand) is discontinuous and primers are
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Figure 1.3. Progression of bi-directional replication forks requires a 
functional replisome. (A) DNA replication initiates from origins of replication and 
proceeds bi-directionally.  Replication forks move in the direction of helicase 
unwinding. The two parental DNA strands at a replication fork are synthesized by 
different mechanisms. Leading strand synthesis is continuous in the direction of 
DNA unwinding. Lagging strand synthesis is discontinuous. Primers are 
elongated to form Okazaki fragments that are processed and ligated to one 
another. (B) Replication fork progression depends on maintaining a functional 
replisome.  
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repeatedly synthesized by polymerase-! and elongated by replicative 
polymerases.  This process forms Okazaki fragments that must be eventually 
ligated to complete DNA synthesis on the lagging strand.   
Replication fork progression depends on maintaining a functional complex 
of proteins that promote coupled DNA unwinding, DNA priming, and DNA 
synthesis.  The basic complex, referred to as the replisome (Figure 1.3B), 
contains the replicative helicase mini-chromosome maintenance proteins 2-7 
(MCM2-7), which unwinds the parental DNA in an ATP-dependent manner (21); 
the clamp loader, replication factor C (RFC) that loads the sliding clamp 
proliferating cell nuclear antigen (PCNA), which coordinates DNA polymerases at 
the fork enabling processive DNA replication (22); and three DNA polymerases, 
the polymerase-! primase and the replicative polymerases, polymerase-" and 
polymerase-#.  In addition to these core replisome components other proteins 
travel with the fork and function in fork progression (23-25). 
 
Sources of replication stress 
Once DNA replication initiates, obstructions on the DNA template that 
oppose replisome activities, either DNA synthesis or unwinding, halt the 
progression of the replication fork and cause fork stalling. Replicative 
polymerases can halt synthesis when faced with insufficient dNTP pools or 
lesions in the DNA template. In the case of limited dNTPs, polymerases cannot 
incorporate the next nucleotide leading to what is termed ‘uncoupling’ of helicase 
and polymerase functions. DNA unwinding of parental strands continues and 
 11 
ssDNA accumulates since parental strands are unwound but not copied (Figure 
1.4A). Which strand (leading or lagging) is inhibited likely determines the extent 
to which ssDNA accumulates (Figure 1.4B). Constant re-priming of synthesis on 
the lagging strand facilitates bypass synthesis downstream of the lesion. Thus 
significant uncoupling does not occur.  In Xenopus egg extracts, the bulk of new 
primers synthesized in response to chemical inhibitors of fork progression 
depend on the lagging strand polymerase (26).  The leading strand polymerase 
also supported primer synthesis but to a lesser extent, suggesting there may be 
larger stretches of ssDNA on the leading strand. DNA polymerases can also stall 
temporarily at DNA lesions like ultraviolet (UV) induced pyrimidine dimers and 
base adducts, and subsequently replicate past the lesion either by polymerase 
exchanges or template switching (Figure 1.4C)(reviewed in (27)).  
In some cases, replication stress inhibits DNA unwinding by the MCM2-7 
helicase. These blocks completely stall the replisome and do not generate 
significant amounts of ssDNA (Figure 1.4D). Chemical crosslinks between DNA 
strands that prevent DNA unwinding are detrimental to genome stability if not 
resolved. Removing and restarting DNA synthesis from such complex lesions 
requires a specialized DNA repair mechanism termed interstrand crosslink (ICL) 
repair that uses proteins involved in nucleotide excision repair, HR, and 
translesion synthesis (28). 
Although DNA repair pathways remove the majority of lesions before 
replication forks encounter them, the variety and frequency of DNA lesions insist 
that some DNA lesions will escape repair and encounter a replication fork. Thus, 
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Figure 1.4. Mechanisms of replication fork stalling. Fork stalling occurs when 
either DNA unwinding or DNA synthesis is inhibited. (A) When nucleotides 
(dNTPs) are low this can stall both polymerases and lead to uncoupling of 
helicase and polymerase activities. This generates ssDNA. (B) DNA lesions have 
different affects depending which strand they block. (C) Translesion synthesis 
(TLS) can promote synthesis past thymidine dimers caused by ultraviolet 
irradiation (T-T). (D) Depicts a chemical crosslink that inhibits MCM2-7 unwinding.  
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cells developed strategies to respond to fork stalling that are largely dependent 
on the nature of the lesion. I will focus my introduction on the response to 
replication fork challenges that lead to functional uncoupling of helicase and 
polymerase functions.  
 
Replication fork stability  
 In the absence of replication stress response pathways, stalled replication 
forks typically do not restart and accumulate aberrant DNA replication structures 
that eventually form DSBs.  These aberrant DNA structures were directly 
observed by electron microscopy in replication checkpoint deficient yeast 
mutants (29). Numerous studies analyzing the genetic requirements for avoiding 
such structures and DSB accumulation during S phase have established the 
concept of replication fork stability.  Stalled forks are actively stabilized by 
replication stress response factors.  Stable replication forks are replication forks 
that retain the ability to restart replication once replication blocks are removed.  
Stalled replication forks that do not restart are defined as collapsed forks.  
The frequency of fork collapse is much higher when fork-stabilizing functions are 
impaired. These forks are considered unstable and generally result in MUS81-
EME1 dependent DSBs. MUS81-EME1 is a structure specific endonuclease 
complex that cleaves replication- and recombination-associated DNA structures 
(30).   Although DSBs are associated with fork collapse, they are not the cause. 
In fact, DSB formation is an integral step in promoting the repair and restart of a 
subset of stalled replication forks. The current model is that aberrant replication 
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fork remodeling is the cause of fork collapse and that DSBs occur as a result of 
MUS81-EME1 cleavage of these structures.  
The underlying mechanisms of fork stability have mostly been derived 
from experiments using the fork stalling drug hydroxyurea (HU).  HU inhibits 
global replication by depleting cellular nucleotide pools, which stalls the DNA 
polymerase without affecting the DNA template.  The advantages of using HU 
over other DNA damaging agents are twofold. One, by inhibiting global 
replication HU potentially mimics the effects of all lesions that inhibit polymerases.  
And two, every ‘lesion’ can be effectively removed by simply removing the HU. 
These characteristics of HU provide the opportunity to examine general 
requirements for fork stability when forks are stalled over time.  Importantly, forks 
that are stalled for 2 hours are processed differently than forks stalled for 24 
hours (31).  It is not clear mechanistically when or how cells transition from one 
fork restart pathway to the other.  
 
Replication fork restart   
 Replication fork restart pathways are best characterized in bacterial 
replication systems.  This is primarily due to the fact that in combination with the 
ease of genetics in this system, DNA replication in bacteria is simple.  Duplication 
of the circular genome in bacteria initiates at one sequence-specific site.  If either 
replication fork is blocked irreversibly, DNA replication fails.  For this reason, 
bacteria must restart stalled or collapsed forks by any means, mutagenic or not. 
In E.coli the formation of Holliday junctions, or ‘chicken feet’, occurs at stalled 
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replication forks (Figure 1.5)(32). A Holliday junction is a mobile junction between 
four strands of DNA. This structure is also observed when pathways of 
replication fork stability are inhibited in eukaryotic cells, suggesting this may be a 
critical intermediate for many restart pathways. These structures are then 
processed by various mechanisms that reform the necessary DNA structures for 
replisome reloading and subsequent fork restart.  This evidence from bacteria 
indicates that extensive remodeling of stalled forks is necessary to facilitate fork 
restart. 
 
Fork remodeling  
 In general, fork remodeling is an ATP-dependent process that changes 
either the structure of template DNA or the newly synthesized (nascent) DNA, or 
both at stalled replication forks. Replication fork reversal is the general definition 
for the remodeling activities that generate chicken feet structures at stalled 
replication forks. Reversed forks were found (ex. Figure 1.6A) in yeast, frog, 
mouse, and human cells that were exposed to low doses of the topoisomerase I 
(TopI) inhibitor camptothecin (CPT) (33). CPT inhibition of Top1 induces torsional 
strain during DNA unwinding that slows replication fork progression. Inhibiting the 
fork reversal in these conditions results in fork collapse.  Thus, active fork 
reversal may be a mechanism for stabilizing forks during times of DNA torsional 
stress.  
Fork reversal requires the coordinated activities of DNA helicases and 
DNA translocases to unwind nascent and parental strands, re-anneal the nascent 
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Figure 1.5. Holliday junctions form at stalled replication forks. Holliday 
junctions are DNA structures that can form between to DNA duplexes that are 
complementary. The result is a 4-way DNA junction. They are commonly 
depicted as cruciform-like structures (left). The same structure can form at stalled 
replication forks, referred to as a chicken foot (right). Arrow points to the junction 
that is common between both models.   
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Figure 1.6. Remodeling activities required for fork reversal. (A) Image 
borrowed from (33) showing reversed fork by EM. (B) Fork remodeling by fork 
reversal is an ATP-dependent process requiring the activities of DNA 
translocases and DNA helicases. Reversal of the fork shown (top) requires 
coordinated steps of annealing and unwinding. Strand annealing is required to 
reanneal parental strands, unwinding of the nascent strands facilitates continued 
annealing of parental strands, and finally nascent strands are reannealed.  
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strands, and re-anneal parental strands (Figure 1.6B). Fork reversal into a 
Holliday junction occurs in two steps and there is the potential to restart the fork 
at either step (Figure 1.7). The first step in fork reversal involves remodeling 
theexcess parental ssDNA generated by uncoupling (Figure 1.7A).  Many DNA 
binding proteins can support the annealing of two complementary ssDNA 
molecules in vitro. But at a replication fork, ssDNA is bound by RPA, which must 
be removed to allow base pairing. DNA translocases like RAD54 can remove 
RPA to promote loading of RAD51 (a necessary step in recombination pathways). 
However, displacing RPA must also be coupled to re-annealing of the parental 
strands. 
Until recently, it was not clear whether an enzyme could catalyze this 
reaction at forks. Re-annealing of RPA-ssDNA is catalyzed by at least two 
closely related enzymes of the SNF2 family (discussed below), SMARCAL1 
(SWI/SNF, matrix associated, actin-dependent regulator of chromatin, A-like 1) 
and AH2 (annealing helicase 2), which have been deemed ‘annealing helicases’. 
These proteins may function in cells to re-anneal parental strands and ‘undo’ the 
effects of helicase and polymerase uncoupling.  Evidence provided in this thesis 
supports that the annealing helicase activities of SMARCAL1 are indeed required 
to limit ssDNA accumulation during replication stress, and deficiencies in 
annealing helicase activity cause fork collapse. Although SMARCAL1 is likely 
involved in later steps of reversal, it seems that its re-annealing activity is an 
essential step in promoting fork stability.  
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Figure 1.7. Fork reversal requires coordinated steps of re-annealing and 
unwinding. (A) The first step at a fork stalled by low dNTPs or HU is to remodel 
excess RPA-ssDNA generated by uncoupling. This requires strand annealing 
coupled to RPA removal. (B) The second step requires helicase activities to 
unwind nascent strands and this is coordinated with continued re-annealing of 
parental strands. The result is formation of a Holliday junction. 
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Assuming the DNA lesion or other replication inhibitor has been removed, 
fork re-annealing to the site of the block could result in recoupling of replisome 
activities and fork progression would resume.  However, if the block to replication 
persists fork reversal likely continues.  Step two (Figure 1.7B) requires the 
unwinding of nascent-parental duplexes.  SMARCAL1 and AH2 may cooperate 
with DNA helicases at this step to promote reannealing of the nascent strands as 
they are unwound. The helicases involved at this step are likely the Werner 
syndrome helicase (WRN) and Bloom syndrome helicase (BLM). Both can 
promote fork reversal on model replication fork substrates in vitro (34,35). And, in 
cells WRN and BLM are required for fork progression and fork restart following 
replication stress (36,37).  
The fork reversal presented here is specific to forks where the functional 
uncoupling of helicase and polymerase activity has generated long stretches of 
RPA-ssDNA. However, fork reversal is not thought to be limited to these 
structures and can likely initiate at step two in the absence of excessive ssDNA.   
 
Restarting from reversed forks 
How does fork reversal promote replication restart? In some instances, 
fork reversal facilitates lesion repair or bypass. For example, certain DNA lesions 
may only be recognized by DNA repair machinery in the dsDNA context. Fork 
reversal may be a mechanism to promote repair of DNA lesions (Figure 1.8A). 
Fork reversal may also promote bypass of the lesion.  In this model, the nascent 
strand from the lesion-free strand is used as an alternate template for the 
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replication past the lesion (Figure 1.8B).  A necessary step in both pathways is 
the resolution of remodeled substrates to restore an active replication fork. The 
DNA ends formed by nascent strand re-annealing may be prone to nuclease 
activities.  Degradation of nascent strands could restore the fork structure (Figure 
1.8C). Alternatively, the reversed fork could be ‘reversed’. This would require 
branch migration of the Holliday junction (Figure 1.8D). Among others, 
SMARCAL1, WRN, and BLM promote branch migration on Holliday junctions in 
vitro. However, in this scenario their annealing and unwinding activities would 
necessarily be in the reverse direction. Recent in vitro evidence suggests that 
some helicases have a directional preference for translocation on reversed fork 
substrates (38). Fork reversal enzymes may exhibit similar directionality in cells 
allowing the opportunity to reverse fork remodeling. 
 
Recombination-dependent restart 
If fork reversal does not lead to lesion bypass, another mechanism for 
restart of stalled forks involves the components of homologous recombination 
and is referred to as recombination-dependent restart (RDR). The Holliday 
junction formed by fork reversal can be processed via two proposed mechanisms 
(Figure 1.9)(32,39,40).  First, the double-stranded DNA end resulting from fork 
reversal can recombine with the homologous sequences in the parental strands 
to form a displacement loop (D-loop) and subsequently another Holliday junction 
(Figure 1.9, left). As long as the original block is removed, cleavage of both 
Holliday junctions by endonucleases would generate a new fork structure
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Figure 1.8. Fork reversal promotes repair or bypass of DNA lesions. (A) 
DNA repair proteins recognize specific lesions only in the context of dsDNA. Fork 
reversal returns the lesion to the parental duplex and may facilitate repair. (B) 
Another option following fork reversal is to use the lesion-free strand as a 
template for DNA synthesis. When the fork is restored as in (D), replication past 
the lesion can resume. (C,D) A necessary step in restart after fork reversal is 
resolution of the reversed fork. (C) Nascent-strand ends are subject to nuclease 
activity and may be degraded to restore the fork structure. (D) Branch migration 
of the Holliday junction can restore the fork without degrading DNA.  
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Figure 1.9. Recombination-mediated restart. The Holliday junction formed by 
fork reversal is a substrate for recombination enzymes. There are two options for 
processing the fork via RDR. (Left) The dsDNA end formed by nascent strand 
annealing can recombine with the parental duplex. The free 3’ end of the leading 
strand invades the duplex and displaces the homologous parental strand, 
forming a D-loop. This forms a second Holliday junction. The 4-way junction is a 
substrate for endonucleases and cleavage occurs at both junctions. This 
removes the connection between the sister duplexes and results in crossover 
between nascent and parental DNA. (right) Alternatively a cleavage event 
happens at the initial Holliday junction. This generates a free arm in the top 
duplex that can invade the bottom duplex and form a D-loop and Holliday 
junction. This is cleaved and resolved as described above. Both result in a fork 
structure from which replication can resume. Figure adapted from (40). 
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on which replisome components could be reassembled and replication restarted.  
Second, endonucleases may cleave at the stalled fork prior to recombination 
from the dsDNA end. The outcome is the same, the dsDNA end resulting from 
cleavage forms a D-loop with the homologous duplex, and additional cleavage of 
the Holliday junction generates the fork structure (Figure 1.9, right).  
  
Reassembling the replisome 
Fork remodeling requires the disassembly of replisome components. So, 
to resume replication replisome components must be reassembled. PCNA can 
reload polymerase on 3’ ends of DNA, which would be available after reversing 
fork remodeling. However, it is unclear how the MCM helicase would be 
recoupled. This remains a speculative step in the process.  Determining whether 
or not MCM helicase activity can be recoupled to stalled forks would be a major 
discovery and clarify the overarching mystery in the field of whether fork reversal 
is an artifact or an active pathway of fork restart. Despite the uncertainties in 
mechanisms of fork reversal and restart, the number of enzymes required for 
replication fork stability in cells indicates some requirement for extensive fork 
processing.  
 
Fork rescue 
When considering replication fork restart pathways in eukaryotes, one 
needs to appreciate that eukaryotic DNA replication initiates from many origins. If 
a replication fork stalls, DNA replication can be rescued from the progression of a 
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nearby fork (Figure 1.10A).  Also, only a subset of origins are fired each round of 
replication.  After prolonged exposure to HU, most stalled forks collapse and 
replication reinitiates from new origin firing (31).  This evidence implies that 
excess origins function as an alternative for restarting forks and completing 
replication  (Figure 1.10B).  This pathway may be preferred over restart pathways 
like RDR, which involves cleavage events that risk inappropriate recombination.  
However, in certain genomic locations origins are scarce and there may be no 
potential for fork rescue (41).  Stalled forks under these conditions may require 
fork restart mechanisms like RDR. Indeed, studies of mammalian fork restart 
indicate that replication inhibitors activate recombination pathways (42,43). 
Evidence demonstrating the genetic requirements of fork remodeling 
enzymes in replication fork restart pathways primarily comes from single 
molecule analysis of replication dynamics (44). In these studies, fork restart was 
analyzed in cells following exposure to HU for various amounts of time. Because 
every replication fork is stalled in the presence of HU, HU-stalled forks mimic 
stalled forks that cannot be rescued by origin firing or nearby forks. By measuring 
the resumption of DNA synthesis at individual forks after the HU is removed, we 
have made interpretations about the enzymatic activities required to maintain 
viable forks during prolonged fork blocks. Prolonged fork stalling is likely rare in 
cells, and most forks directly restart without significant fork remodeling. However, 
defects in replication fork remodeling enzymes are associated with human 
syndromes and cancer suggesting that prolonged fork stalling is a challenge to 
genome stability however infrequent it may be (45-47).   
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Figure 1.10. Replication fork rescue. (A) Stalled forks have the potential to be 
rescued by the progression of neighboring forks. This rescues the requirement 
for the stalled fork to restart and complete replication. The DNA lesion can be 
repaired post-replication. (B) Excess origins are licensed each round of 
replication. After prolonged stalling, new origins can fire new replication forks to 
rescue stalled forks as in (A). 
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Fork restart and repair pathways rely on the activities of DNA helicases, 
DNA translocases, recombinases, and nucleases.  Further characterizing the 
function of these enzymes and how they cooperate at stalled forks will help 
elucidate the molecular mechanisms that promote fork restart and genome 
stability during DNA replication.     
 
The SNF2 Family 
 
 
Members of the SNF2 family of ATPases typically function within multi-
protein complexes that remodel chromatin.  However, SNF2 proteins have 
chromatin independent functions and are more generally appreciated as DNA 
translocases.  Using the energy from ATP hydrolysis, they translocate along DNA 
rearranging nucleosomes or other DNA-interacting proteins to facilitate gene 
regulation, replication, recombination, and DNA repair.  
 
ATPase motor 
All SNF2 proteins contain seven motifs that are similar to those found in 
helicases.  These motifs are divided between two domains, referred to as 
ATPase_N and ATPase_C, and must be in close proximity to each other to 
hydrolyze ATP (48,49). The motor domain enables SNF2 proteins to convert the 
chemical energy from ATP hydrolysis into mechanical force for translocating 
along DNA substrates.  
 28 
Based on similarities in their helicase-like domains, SNF2 family members 
are grouped into 24 subfamilies (Figure 1.11A). The organization of their 
helicase-like domains likely confers the functional specificity of these enzymes on 
DNA substrates. SNF2 proteins contain additional sequences outside of this 
domain that further define the biological context in which the specific ATPase 
motor is needed.   
 
DNA remodeling activities 
The DNA remodeling activities of SNF2 proteins in the context of 
chromatin have been appreciated for decades.  SNF2 proteins translocate DNA 
with enough force to disrupt DNA-protein interactions, like those between DNA 
and nucleosomes. By doing so, they remodel the accessibility of DNA to 
transcription factors and DNA repair factors.  What has become obvious in recent 
years is that SNF2 proteins have very important chromatin-independent functions, 
especially at DNA replication forks. The yeast protein Rad5 can reverse model 
replication forks in vitro (50). In combination with its ubiquitin ligase activity, Rad5 
promotes template switching to bypass lesions at stalled replication forks. 
Helicase-like Transcription Factor (HLTF) is one of two mammalian proteins 
closely related to yeast Rad5, and promotes similar activities (51). The annealing 
helicases SMARCAL1 and AH2 use their ATP-driven motor to rewind RPA-
bound complementary ssDNA strands (52,53). This activity can promote fork 
reversal as well (54).  
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Defects in SNF2 proteins cause genome maintenance syndromes 
Importantly, mutations in SNF2 genes cause human disease.  ATR-X (a-
thalassemia/mental redardation, X-linked) syndrome (MIM 301040) is caused by 
mutations in ATRX. Patients with ATR-X syndrome exhibit severe developmental 
delay, mental retardation, and abnormal hemoglobin. ATRX interacts with the 
histone variant macroH2A and may regulate its distribution in the genome.  
Deposition of macroH2a demarks transcriptionally silenced chromatin. Therefore, 
deregulated macroH2A distribution especially at specific loci may contribute to 
the phenotypes of ATRX syndrome (55).    
Defects in Excision repair cross-complementing rodent repair deficiency, 
complementation group 6 (ERCC6), gene function cause Cockayne syndrome B 
(MIM 133540).  ERRC6 is essential for transcription-coupled excision repair, a 
process that removes bulky DNA lesions that stall transcription (56). Cockayne 
syndrome patients exhibit progressive multisystem degeneration, premature 
aging, and extreme UV sensitivity.  
HLTF is frequently inactivated in human colon cancers (57). Evidence 
from Hltf-deficient mice suggests that loss of function promotes transformation by 
inducing genomic instability in the colon.  HLTF can catalyze the removal of 
proteins from DNA and may do so at replication forks to maintain genome 
stability. The diseased states resulting from alterations in ATR-X, ERRC6, and 
HLTF functions emphasize the importance of SNF2 family activities in genome 
maintenance. 
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SMARCAL1 
SMARCAL1 defines a distant subfamily of SNF2 proteins (Figure 1.11A). 
This subfamily includes two subtypes: SMARCAL1 and AH2. SMARCAL1 and 
AH2 have highly similar ATPase motors but are flanked by completely different 
accessory domains.  The SMARCAL1 subtypes include at least one HARP 
(HepA-related protein) domain N-terminal to the ATPase domain.  Human 
SMARCAL1 is 954 amino acids and its defined domains consist of two HARP 
domains, HARP1 and HARP2, the highly conserved ATPase domain, and an 
RPA binding domain, which we defined in Chapter IV (Figure 1.11B).  Evidence 
presented in this thesis and elsewhere (58-61) identified the RPA binding domain 
as an essential domain for SMARCAL1 function in cells. The HARP domains are 
required for the annealing helicase activity of SMARCAL1 and chimeric proteins 
with HARP1/2 fused to other ATPase motors can support annealing helicase 
activity in vitro and in cells (62). Furthermore, HARP2 is as part of a minimal 
catalytic core that can accomplish all in vitro activities defined for full-length 
SMARCAL1 (54).  
Like other SNF2 proteins, SMARCAL1 ATPase activity is stimulated by 
DNA binding. When SMARCAL1 was initially cloned and characterized (63), it 
was classified as a ssDNA stimulated ATPase. Further characterization of 
SMARCAL1 DNA binding has defined a much broader list of SMARCAL1 DNA 
substrates (54). SMARCAL1 binds a number of DNA substrates with a general 
requirement for ssDNA-dsDNA transitions (Figure 1.12). However, SMARCAL1 
also binds complex substrates like 3-way and 4-way junctions that do not have
 31 
 
 
 
 
 
 
 
Figure 1.11. SMARCAL1 is defines a distant subfamily of SNF2 proteins. (A) 
Borrowed from (64)This tree is a representation of the subfamilies defined based 
on full-length alignments of the ATPase domains. SMARCAL1 is distantly related 
to other subfamilies in the SNF2 superfamily. SMARCAL1 family members have 
at least one HARP domain N-terminal to the ATPase domain. Depicted in (B) 
human SMARCAL1 has a defined RPA binding domain (RBD), two HARP 
domains, and a highly conserved ATPase domain, which consists of the 
ATPase_N and ATPase_C domains.  
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Figure 1.12. DNA substrates that stimulate SMARCAL1 ATPase activity.  
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any intended ssDNA regions.  Importantly, SMARCAL1 also reverses model 
replication fork substrates, indicating that the enzymatic capabilities of 
SMARCAL1 reach farther than re-annealing RPA-ssDNA (54).  
Loss of function mutations in SMARCAL1 cause Schimke immuno-
osseous dysplasia (SIOD) (65).  SIOD clinical phenotypes include growth 
retardation, renal failure, recurrent infections, cerebral ischemia, and skin 
pigmentation beginning in early childhood.  Disease severity varies with some 
patients experiencing in utero onset and death within 5 years, while others have 
a later onset of symptoms and live until their early twenties.  We provide 
evidence that the phenotypes of SIOD are due in part to defects in SMARCAL1 
annealing helicase activities at stalled replication forks. Thus, SIOD represents 
another genome maintenance syndrome.  
The cellular processes that require annealing helicase activity were largely 
unknown until the identification of SMARCAL1 as a replication stress response 
protein.  We identified SMARCAL1 in a functional genomic screen for genome 
maintenance genes (66).  The details of this screen will be presented in Chapter 
III.  After identifying SMARCAL1 as a genome maintenance protein, I further 
discovered that the annealing helicase activities of SMARCAL1 promote genome 
integrity specifically at DNA replication forks (Chapter IV) (58).  SMARCAL1 is a 
substrate for the DDR kinases ATR, ATM, and DNA-PK.  In Chapters V and VI, I 
present evidence demonstrating that DDR-dependent and independent 
phosphorylation regulates SMARCAL1 replication stress response activities. 
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Antibodies 
Antibodies were obtained as follows: KAP1 pS824 (Bethyl Laboratories, 
A300-767A) and SMARCAL1 (Bethyl Laboratories, A301-616A), $H2AX (Upstate 
Biotechnology, 05-636, clone JBW301), HA.11 (Covance, MMS-101P, clone 
16B12), PCNA-PC10 (Santa Cruz Biotechnology, sc-56) and FLAG/OctA-Probe 
D-8 (Santa Cruz Biotechnology, sc-807), cyclin A Ab-7 (Thermo-Scientific, RB-
1548-PO) and RPA/p34 Ab-1 (Thermo-Scientific, MS-691-PO, clone 9H8), BrdU 
(Becton Dickenson, 555627, clone 3D4), FLAG M2 (Sigma, F3165, clone M2). 
Additionally, custom SMARCAL1 antibodies targeting the N or C-terminus of 
SMARCAL1 and two different phosphopeptides were produced by Covance and 
Open Biosystems. See Table 2.1 for a comprehensive list of SMARCAL1 
antibodies and the conditions for various applications.  
 
ATPase assay 
The ATPase assay was performed using purified protein from three 
different conditions: (1) Flag-SMARCAL1 and Flag-SMARCAL1-%32 were 
purified from baculovirus-infected insect cells essentially as previously described 
(52) with the following modifications. Cells were lysed in 20mM Tris pH 7.5, 
150mM NaCl, 0.1mM EDTA, 1mM DTT 0.2mM PMSF, 1µg/ml leupeptin, 1µg/ml
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aprotinin, and 0.1% triton.  A final CM-sepharose step was added after elution of 
protein from the Flag-beads. 
(2) HEK-293T cells were transfected at the 10cm dish scale with pLPCX-
Flag-SMARCAL1 plasmids using Lipofectamine 2000 (Invitrogen). The day after 
transfection cells were passaged to one, 15cm dish.  Seventy-two hours after 
transfection, the cells were lysed in NETN buffer (150mM NaCl, 1mM EDTA, 
20mM Tris, and 0.5% Igepal) for 30 min on ice. After high-speed centrifugation, 
the cleared lysates were incubated with 30µL of EZview Red ANTI-Flag-M2 
Affinity Gel beads (Sigma, F2426) for 3 h at 4°C. The beads were washed three 
times in NETN and twice in SMARCAL1 buffer (20 mM HEPES at pH 7.6, 20% 
glycerol, 0.1 M KCl, 1.5 mM MgCl2, 0.2 mM EDTA, 1 mM DTT, 0.2 mM PMSF, 
0.01% IGEPAL CA-630). The bound proteins were eluted in 75µL of SMARCAL1 
buffer containing 0.3 mg/ mL Flag peptide on ice for 1 hour. Eluted protein was 
aliquoted and stored at -80°C.  
(3) Endogenous SMARCAL1 was purified from 18- and 9-15 cm dishes for 
16hr HU and NT conditions, respectively.  80mg and 40mg of lysate was input 
into 909-IPs on protein A magnetic dynabeads to purify the HU and NT protein.  
Following the IP, beads were washed three times with NETN buffer and two 
times with SMARCAL1 buffer then eluted with 909 peptide 1:5 in 50!L of 
SMARCAL1 buffer for 1hr at RT.  Following elution 1!L of purified protein was 
used in each reaction in triplicate.  
The ATPase assay was performed as follows. The day before the ATPase 
reaction, chromatography buffer (1M Formic acid, 0.5M LiCl) was prepared and 
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added to the chromatography tank to pre-equilibrate.  The buffer does not need 
to be prepared fresh each time. The fork DNA substrate (15µM final 
concentration) was prepared by mixing 3µL of top (100µM) and 3µL of bottom-
fork (100µM) DNA primers to 12µL of H2O and 2µL of NaCl (0.5M) for a final 
volume of 20µL.  The primers were annealed using the RB anneal program. 
Conditions for each 10µL ATPase reaction were as follows: 0.24µL of ATP, [$-
32P] (Perkin Elmer, BLU502Z250UC, 10mCi/mL), 1µL of cold ATP (1µM), 1µL of 
diluted fork DNA (50nM or 12.5nM for 5 and 1.25nM final concentration) or H2O 
for 0nM DNA, 1µL of 50nM SMARCAL1, and 6.76µL of ATPase buffer (20mM 
HEPES pH 7.6, 0.1M KCl, 5mM MgCl2, 3% glycerol, 0.25mg/mL BSA, 0.05mM 
EDTA, 0.5mM DTT, 0.01% Igepal). Master mixes for 0, 1.25, and 5nM DNA 
conditions were prepared for all samples with the exception of adding 
SMARCAL1. After adding hot ATP to the reaction mix, 9µL was aliquoted to 
individual sample tubes on ice.  After adding 1µL of purified SMARCAL1 to all 
tubes, tubes were transferred from ice to the heat block set at 30°C for a reaction 
time of 30 min.  To stop the reaction, samples were transferred back to ice. An 
aliquot (1µL) of each reaction was spotted on PEI cellulose plates (Selecto 
Scientific, 05-719-854) and allowed to dry for at least 5 minutes. The plates were 
subjected to thin-layer chromatography for 45 min. The plates were dried and 
quantitated using a phosphorimager. The results are presented as the ratio of 
ATP hydrolyzed to total ATP during the reaction. ATPase assays were performed 
a minimum of three times each, and graphs depict means and standard deviation 
error bars. Fork DNA sequence used: 
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       Top-5’-CCAGTGAATTGTTGCTCGGTACCTGCTAAC-3’ 
        Bot-fork-5’-GACATTTGATACCGAGCAACAATTCACTGG-3’  
 
Cell culture and transfections 
HEK293T and U2OS cells were cultured in DMEM + 7.5%FBS. SIOD 
patient fibroblasts (SD31) were cultured in DMEM + 15%FBS.  Transfections 
were performed by Lipofectamine 2000 (Invitrogen), Fugene6, or FugeneHD 
(Roche). siRNA transfections were performed with HiPerfect (Qiagen) using 
siRNAs purchased from Qiagen or Dharmacon.  Sequences for Qiagen siRNA 
used in this thesis were as follows:  
SMARCAL1_1: CAGCTTTGACCTTCTTAGCAA 
SMARCAL1_3: TTGAGTTATGAGTTAGGTCAA  
SMARCAL1_5: TTGATTGGGTACAATGCGCAA   
 
A Dharmacon ON-TARGET plus siRNA was used for silencing 
SMARCAL1 when not otherwise specified. The siRNA-resistant SMARCAL1 
mutants used for complementation experiments contain 10 wobble base pair 
mutations in the S6-targeting sequence. Sequence of the S6 or SMARCAL1_6 
siRNA: GCUUUGACCUUCUUAGCAA.   
Standard siRNA transfections were performed either at a 10cm or 6-well 
scale in a reverse-transfection format.  For transfections in 10cm dishes, 2.4µL of 
siRNA (20µM) were added to 960µL of Opti-Mem media and 40µL of HiPerfect 
reagent. This transfection mix was incubated for 10 min at room temperature and 
then added to 2.3x106 U2OS cells in 8mLs of media. For the 6-well format, 1.2µL 
of siRNA (20µM) were added to 400µL of Opti-Mem media and 12µL of HiPerfect.  
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After 10 min, transfection mixes were added to 3x105 U2OS cells in 2mL of 
media. Assays were typically performed 48-72 hours following transfection.  
 
Chromatin fractionation   
Chromatin fractionation was performed as described previously (67). 
 
DDR activation assay 
Cells were transfected with Fugene HD at 12-well scale. 0.5µL HD + 45µL 
Opti-Mem + 250ng of pLEGFP-SMARCAL1 DNA were incubated for 15 minutes 
at RT and then resuspended in in 1mL of media containing 150,000 cells.  24 
hours later cells were seeded into 96 well CellCarrier plates (Perkin Elmer, 
6005550) that are compatible with Opera imaging.  At least 2 samples in the 
group were counted to estimate cell number and plate 8000 cells per well.  48hrs 
post tranfection cells were washed once with 100µL of PBS and fixed for 10 min 
with 100µL of 3%-paraformaldehyde and 2% sucrose solution. All washes were 
100!L of PBS dispensed by a 96 well plate dispenser and discarded by dumping 
the plate and tapping the excess on a blue pad. The IF protocol consisted of the 
following: after fixation, 3 PBS washes; add 100µL of a triton-X-100 solution 
(20mM HEPES, 50mM NaCl, 3mM MgCl2, 10.269g of sucrose, 0.5% Triton X-
100) for 10min at 4°C; 4 PBS washes; block with 5% BSA-PBS in 100µL; 1 PBS 
wash; aspirate PBS with multi-channel aspirator and add primary antibody 
(mouse anti-$H2AX, 1:10,000 diluted in 1%BSA-PBS) 50µL per well with a multi-
channel pipette; after a 30 min incubation at 30°C + humidity, 3 PBS washes; 
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aspirate PBS and add secondary (Cy5 goat anti mouse; Invitrogen A10524; 
diluted 1:500 in 1% BSA-PBS) for 20 min at RT in the dark; 3 PBS washes; add 
100µL of DAPI diluted in PBS for 3 min in dark; 3 PBS washes. Leave cells in 
100µL PBS for imaging. Images were collected by the Opera on the same day as 
staining.  
 Opera acquisition was set up as follows using the Opera Filter Selection 
Tool: Camera 1: 540/75; Camera 2: N/A; Camera 3: 690/50; Camera 4: select all; 
Detection Dichro: empty; Primary Dichro: 405/488/640. Select Camera 3 and 4 
for exposure 1 (Cy5 and DAPI) and select Camera 1 for exposure 2 (GFP). 
Samples were visualized with the 20X water objective and approximately 12 
subfields were imaged in each well.  Samples were seeded into 3 wells each 
time for experimental replicates. Analysis: Columbus analysis software was used 
to define nuclei using detection method B, and then calculate mean intensity per 
nucleus for GFP and H2AX. See Chapter V text for a more detailed description of 
further data analysis.  
 
Immunofluorescence  
With the exception of the quantitative DDR activation assay, 
immunofluorescent images were obtained with a Zeiss Axioplan microscope 
equipped with a Zeiss camera. In Chapter IV, the percent of cells staining with 
both cyclin A and $H2AX predicted by chance was calculated as follows: (% of 
cyclin A+ & $H2AX+ cells) ÷ (% cyclin A+ cells & % $H2AX+ cells). A staining 
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protocol similar to that described for the DDR activation assay was used for all 
immunofluorescence on coverslips. 
 
Lysis conditions 
 NETN buffer: 150mM NaCl, 1mM EDTA, 20mM Tris, and 0.5% Igepal.  
This buffer supplemented with 1mM PMSF, 5µg/mL aprotinin, 5µg/mL leupeptin, 
1mM NaF, 1mM Na2VO4, 1mM DTT, and 50mM B-glycerophosphate was used 
for all methods with a cell lysis step.  For HEK293T cells, cells were collected by 
scraping and washed twice with PBS.  In many cases, cell pellets were not lysed 
immediately but stored after collection at -80°C.  Cells were lysed for 30 minutes 
on ice.  
 
Mass spectrometry 
Endogenous SMARCAL1 was purified from HEK293T following 16hr HU, 
separated by SDS-PAGE and coomassie blue stained.  The SMARCAL1 band 
was excised from the gel and mailed to Dr. Jun Qin at Baylor College of Medicine 
for analysis.  Samples were run on two machines, LTQ and Orbi. (Dr. Qin 
emailed a powerpoint file with spectra on October 2, 2009) 
 
Phosphopeptide analysis 
For endogenous maps, HEK293T cells were plated in 10cm dishes the 
day before labeling. 1.5 x 107 cells were plated in each of 2-10cm dishes for 
untreated; 2.5 x 107 cells were plated in each of 2-10cm dishes for HU samples.  
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2mM HU was added for 16hrs before cells were washed twice with equilibrated 
phosphate-free DMEM (Cellgro, DMEM, 1X with 4.5g/L glucose and sodium 
pyruvate without L-glutamine and phosphate, 17-206-Cl, 6x100mL).  Cells were 
incubated in 5 mLs of equilibrated phosphate-free DMEM containing 10% 
dialyzed FBS (Gibco, 26400-036) with or without HU for 30 minutes.   During this 
time, a betashield box was also placed in the incubator to equilibrate.   To label 
cells, 32P-orthophosphoric acid (Perkin Elmer, Phosphorous-32 radionuclide, 
25mCi or 10mCi, NEX053025MC or NEX053010MC) was added to the media for 
a final concentration of 0.5mCi/mL for 30 minutes. Cells were washed once with 
PBS and 700µL of trypsin added to each plate for 5 minutes.  700µL of media 
was added to trypsinized cells, cells were transferred to a 1.5mL screw cap 
microcentrifuge tube and pelleted at 1000 rpm for 5 minutes.     Pellets were 
washed once with PBS and combined into a single tube and pelleted.   Cells 
were lysed in 1mL of NETN lysis buffer containing 1mM PMSF, 5µg/mL aprotinin, 
5µg/mL leupeptin, 1mM NaF, 1mM Na2VO4, 1mM DTT, and 50mM B-
glycerophosphate for 30 minutes on ice and then cleared at 4oC for 20 minutes at 
16.1xg.    
During the clearing step, Protein A dynabeads were prepared for 
immunoprecipitation.  Per sample, 50!L of the resuspended bead mixture was 
washed one time with lysis buffer and then incubated with 2µL of the 909 
antibody in 500!L of lysis buffer for 10 minutes, rotating at room temperature.  
Beads were always prepared as a mix for all samples and divided equally into 
tubes following antibody binding.  After the pre-binding, beads were washed once 
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in lysis buffer then resuspended in buffer again to divide the beads into two tubes.  
1mL of lysate was added to the 909-beads and rotated at room temperature for 
30 minutes behind the shield.  After the IP, beads were washed 3 times with 
NETN buffer and once with NETN containing 500mM LiCl. 30µL of 2X sample 
buffer was added to beads and boiled for 10 minutes.   909-IPs were separated 
by SDS-PAGE on an 8% acrylamide gel for 1 hour at 120V and transferred to 
methanol-activated PVDF at 0.2 Amps for 6 hours.    
Usually the following day, PVDF membranes were exposed to film for 1 
hour to visualize proteins with 32P incorporated.   Film was aligned to the 
membrane, and a syringe was used to perforate the membrane around 
radiolabeled SMARCAL1.   Membrane was cut and transferred to a 1.5mL 
centrifuge tube.   1mL of 100% methanol was added to the membrane for 1 
minute and then removed.   Membranes were washed with 1mL of 0.05M of 
ammonium bicarbonate containing 0.1% Tween-20 once and then incubated in 
1mL of the solution for 30 minutes at 37oC.   Membranes were washed onced 
with 1mL of 0.05M ammonium bicarbonate without Tween-20.  30µL of 0.05M 
ammonium bicarbonate was added to cover the membrane, and 10µL of 
sequencing grade trypsin (resuspended at 1mg/mL in trypsin buffer, Promega, 
V5111, 100µg) was added.  Proteins were digested at 37oC for 3 hours, and 
another 10µL of trypsin was added for an additional 3 hours.   400µL of milliQ 
water was added to digested proteins and dried in a speed vacuum over night 
(no heat).   
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The next day, 400µL of milliQ water was added to dried samples, vortexed 
well, and then dried in a speed vacuum for 3 hours or until completely 
dry.   Digested proteins were then resuspended in 400µL of pH 1.9 
electrophoresis buffer (2.5% formic acid, 7.8% glacial acetic acid), vortexed well, 
transferred to a new tube, and lyophilized again.  After lyophilizing, centrifuge 
tubes were placed with caps open in a dry scintillation vial and 32P was counted 
in a scintillation counter.   Peptides were resuspended in pH 1.9 buffer to 
equalize counts/volume.   Usually 500 counts were then spotted onto cellulose 
coated glass thin layer chromatography plates according the standard protocol 
(68). Plates were electrophoresed at 1000V for 30 minutes on a Hunter Box in 
pH 1.9 buffer and then completely dried in the fume hood for several 
hours.   Plates were then transferred to a chromatography tank containing 
phosphochromatography buffer (7.5% glacial acetic acid, 25% pyridine, 37.5% n-
Butanol) for 16hrs.   Plates were dried and then exposed to film for 4 days (42). 
This time can be adjusted if fewer counts are spotted.  
 The only difference for GFP-SMARCAL1 maps is that cells are transfected 
two days before labeling.  The transfection protocol was as follows: 60µL of 
LF2000+1.5mL of Opti-mem was incubated for 5 min at RT then mixed with 
900ng of pLL5.0-GFP-GW-SMARCAL1 DNA +23µg of salmon sperm DNA in 
1.5mL of Opti-mem.  20 min later LF2000-DNA complexes were resuspended 8 
mL of DMEM containing 2x107 cells and plated in 10cm dishes.  24 hours later 
cells were passaged to 2 10-cm dishes and in HU conditions, HU was added for 
16hrs before labeling, approximately 48hrs after transfection.  
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Phospho-shift assay 
 HEK293T cells were transfected with Lipofectamine 2000 at a 6-well scale.  
LF2000 complexes were prepared as follows: 5!L of LF2000 was added to 
125µL Opti-Mem and incubated for 5 minutes before adding it to 125µL of Opti-
Mem containing 100ng of SMARCAL1 in the pLL5.0-GFP-GW vector and 2µg of 
sheered salmon sperm DNA. Complexes were incubated for 20 minutes.  During 
this time cells were prepared at a density of 9x105 per mL.  LF2000-DNA 
complexes were resuspended in 2mL of cells and plated in 6-well dishes. The 
day after transfection cells were split from 1:2 into 2 wells.  2mM HU was added 
to one of the wells for 16-18hrs. Cells were harvested and lysed in 60µL of NETN 
buffer plus additives for 30 minutes.  After clearing protein concentrations were 
measured and 2X sample buffer added. Samples were boiled for 10 minutes and 
then separate on 6% acrylamide SDS-PAGE for 2 hours at 100V.  Gels were 
transferred onto nitrocellulose for 6hrs at 0.2A.  Standard 909-immunoblotting 
conditions were used with the exception of supplementing the milk-TBST with 
NaF (1:1000).  
 
 
Protein interactions 
The two-hybrid screen was performed by Hybrigenics using their 
ULTImate Y2H methodology. Immunopurifications of endogenous SMARCAL1 
complexes from nuclear extracts was performed with the 909 antibody.  
Associated proteins were identified by tandem-mass spectrometry by the 
Vanderbilt Mass Spectrometry Center.  Flag-HA dual epitope purifications were 
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performed according to published protocols (69) using 293T cells stably 
expressing Flag-HA-SMARCAL1.  
 
Replication stress agent sensitivity assays 
Cells transfected with siRNAs using HiPerfect (Qiagen) were treated with 
drug (HU, 3mM; APH,15µM; CPT, 150nM)  for 24 hours, washed, and then 
allowed to recover for 24 hours.  Cell viability was measured using the WST-1 
reagent (Roche).  All statistical tests were performed on the log of the ratio of 
treated/untreated measurements using a two-tailed unpaired t-test. 
 
 
Vectors  
The details of all vector constructs are available upon request.  The 
pLEGFP-C1 vector was used to drive levels of GFP-SMARCAL1 expression 
sufficient to cause DNA damage.  pLL5.0-GFP-GW was used for attenuated 
expression levels that did not induce DNA damage. siRNA-resistant mutants and 
phospho-mutants were generated using site-directed mutagenesis and primers 
and diagnosis are listed in Table 2.2.   
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Table 2.2.  Primers for SMARCAL1 mutagenisis and sequencing.  
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CHAPTER III 
 
A cDNA OVEREXPRESSION SCREEN FOR IDENTIFYING DEREGULATED 
GENOME MAINTENANCE ACTIVITIES1 
 
Introduction 
 
ATR and other DDR pathways are not only activated by endogenous and 
exogenous sources of DNA damage (such as radiation and reactive oxygen 
species), but also respond to tumorigenic gene function defects that promote 
genome instability (70).  The overexpression or activation of oncogenes and 
inactivation of some tumor suppressors induce DDR activation in pre-malignant 
lesions, presumably due to aberrant cell division cycles and replication stress 
(71-75). These findings suggest a model whereby the ATM/ATR-mediated DDR 
serves as a barrier to constrain tumor development by limiting cellular 
proliferation, inducing apoptosis, and promoting DNA repair (70). 
Several oncogenes and tumor suppressors that induce DDR activation 
when deregulated have been identified; however, the heterogeneity of cancer 
suggests there are many others that challenge genome integrity and promote 
tumorigenesis. To better understand the variety of biological processes required 
for genome maintenance and determine the extent to which deregulation of these 
                                            
1 This Chapter includes excerpts from reference 66. Lovejoy, C.A., Xu, X., 
Bansbach, C.E., Glick, G.G., Zhao, R., Ye, F., Sirbu, B.M., Titus, L.C., Shyr, Y. 
and Cortez, D. (2009) Functional genomic screens identify CINP as a genome 
maintenance protein. Proc Natl Acad Sci USA, 106, 19304-19309. 
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pathways could also activate the DDR, Courtney Lovejoy and I completed a 
functional genomic screen for genes that when silenced or overexpressed cause 
activation of the DDR.  Using the screen methodology developed by Courtney, I 
identified genes that activate the DDR when overexpressed. 
 
Results 
 
A three step methodology was used to identify genes that when 
overexpressed cause activation of the DDR in the absence of any added 
genotoxic agents (Figure 3.1A).  First, pools of three cDNAs were co-transfected 
into HeLa cells with a GFP expression vector to identify successfully transfected 
cells. A total of 5,796 cDNAs expressed from the pCMV-SPORT6 vector were 
analyzed. Two days after transfection, fixed cells were monitored for DDR 
activation resulting from gene overexpression by immunofluorescence staining 
using a phospho-peptide-specific antibody to the ATM substrate KAP1 (KRAB 
domain associated protein 1) (76). Secondly, the vectors from cDNA pools that 
caused KAP1 phosphorylation were deconvoluted and the KAP1 phosphorylation 
assay was repeated. Finally, individually positive cDNA vectors were transfected 
into a distinct cell type (U2OS) and DDR activation was monitored by 
immunofluorescence analysis of $H2AX. 
A total of 97 genes were identified that caused DDR activation when 
overexpressed in both HeLa and U2OS cells (Figure 3.1B and Appendix A). 
Gene products with biological functions linked to gene expression, cell cycle 
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Figure 3.1.  A cDNA overexpression screen identifies genes that cause DDR 
activation. (A) Schematic of the cDNA overexpression screen. (B) The average 
of the $H2AX count from each of the 97 positive cDNAs is graphed and 
compared to the control empty vector. 
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regulation, nucleic acid metabolism, and cancer were strongly over-represented 
when compared to the biological functions present within the cDNA screening 
library (Figure 3.2).  Some of these genes have been linked to cancer (Table 
3.1), and represent candidates for the oncogenes that promote replication stress 
and DDR activation in pre-malignant lesions.  
Among the genes linked to cancer are several Ets family transcription 
factors that act as oncogenes in Ewing sarcoma, prostate cancer and myeloid 
leukemia (77).  We confirmed that their overexpression activates the DDR even 
in untransformed epithelial cells (Figure 3.3) 
In some cases both overexpression and silencing of a gene caused DDR 
activation.  For example, we identified SMARCAL1 and members of the H2AFY 
histone family in both the siRNA and cDNA overexpression screens.  We also 
found that PLK1 overexpression activated the DDR, while silencing PLK1 was 
previously reported to cause DNA damage (78,79).   
To further understand the functional relationships between the genes 
identified in the cDNA overexpression screen, we performed an extensive 
bioinformatics analysis using published literature and functional annotation 
programs.  This analysis placed many of the genes into four major functional 
groups: the ATM/ATR related DNA damage response, mitosis, chromatin 
regulation, and RNA metabolism (Figure 3.4). In order to visualize the combined 
efforts of our genome maintenance screens, both RNAi and cDNA 
overexpression genes are depicted within the four groups.  
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Figure 3.2.  Biological classifications of genes reproducibly activating the 
DDR after overexpression. Classifications were assigned using (A) PANTHER 
or (B) Ingenuity pathways. 
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Figure 3.3.  Activation of the DDR by overexpression of ets family.  DDR 
activation by overexpression of ets family members was monitored in U2OS cells 
(A) or hTERT-immortilized retinal epithelial cells (B). Error bars are standard 
deviation (n=3). 
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In some cases the functional relationships can be understood 
mechanistically based on previously published research. For example, DDB1 
was identified as a genome maintenance gene in the RNAi screen and CDT1 
was identified in the overexpression screen (Figure 3.4C). DDB1 regulates 
replication origin firing by promoting the ubiquitin-dependent degradation of 
CDT1. Previous publications demonstrated that an accumulation of CDT1 in 
DDB1-silenced cells causes re-replication, and consequently, DDR activation 
(80,81). Another functional relationship that is apparent in the connectivity 
diagrams involves three mitotic protein kinases: CHK1, PLK1, and WEE1 (Figure 
3.4B). Aberrant mitotic regulation caused by either too much PLK1 activity or too 
little CHK1 or WEE1 activity may cause premature entry into mitosis and an 
accumulation of DNA damage (82). 
 
Discussion 
 
As expected, many of the genes identified are suspected or known 
oncogenes (Table 3.1). The cDNA overexpression screen found several 
oncogenes that induce genetic instability when overexpressed, including PLK1 
which causes chromosomal instability due to its function in centrosome and 
mitotic control (83). Another interesting example is the DEK oncogene. DEK 
regulates chromatin and DNA topology, and was originally identified in a 
translocation in acute mylogenous leukemia (84). DEK overexpression also 
suppresses the phenotypic defects of an ataxia-telangiectasia cell line defective
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Figure 3.4.  Network modeling of gene products identified in the RNAi and 
cDNA genome maintenance screens. In each network, the genome 
maintenance genes identified in the RNAi screen are colored in blue and genes 
identified in the cDNA overexpression screen are colored in yellow.  A solid line 
between two gene products indicates a protein-protein interaction; an arrow 
indicates that one gene product acts on the gene product to which the arrow is 
drawn (for example, a kinase-substrate relationship). Cellular activities containing 
more than one gene product, such as the anaphase promoting complex (APC/C), 
are diagramed as rounded rectangles.  Uncolored circles were not identified in 
the screens but were added to the network to establish connections.  
Transcriptional relationships are not diagrammed.  The predominant pathways 
identified include (a) DNA damage response (b) mitotic control (c) chromatin 
regulation, and (d) RNA metabolism.  
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Table 3.1.  Genes identified in the cDNA overexpression screen that are 
published oncogenes. 
 
 
 
 
 
 
 
 
 
  
 57 
in ATM activity (85). This suppression is cell-line specific and unique to a 
relatively mild ATM mutation (deletion of amino acids 2427 and 2428). Thus, 
DEK overexpression may cause chromatin changes that increase the activity of 
the mutant ATM protein, leading to partial suppression of the DNA damage-
sensitivity phenotype.  
Several Ets family transcription factors also caused DDR activation when 
overexpressed. Since these proteins are frequently overexpressed and/or 
amplified in human tumors (77), they may contribute to tumorigenesis by 
promoting genome instability (70). This is also true for other known or putative 
oncogenes identified in the overexpression screen. In some cases, gene 
overexpression may directly perturb genome maintenance activities such as DNA 
repair. For example, HOXB7 is linked to DNA repair through interactions with 
PARP and DNA-PK proteins (86) and its overexpression is linked to melanoma. 
Overexpression of the DNA repair proteins DCLRE1A and MLH1 may cause 
DNA damage via dominant negative effects since these proteins function as part 
of protein complexes. 
 Other major categories of genes identified in the screen include 
regulators of mitosis (PLK1) and several chromatin regulatory proteins (DEK, 
H3F3A, H1F0, H2AFY2). In some cases the effect on genome maintenance may 
be indirect through transcriptional changes.  In other cases, the chromatin 
regulation may directly affect DNA repair.  Chromatin regulation and DNA repair 
were also prominent categories of genes found in an S. cerevisiae screen that 
used increased spontaneous Rad52 foci as an assay (87). 
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 We also identified several proteins that are phosphorylated by ATM or 
ATR in response to DNA damage but with unknown functions including 
PLEKHO2, SCFD1, MED13L, COPZ1, RBBP5, and PPP1R12C (88). Our data 
confirm their placement in a DDR pathway, and further analyses will be required 
to understand their specific genome maintenance activity.  
 Finally, for some genes identified it is unclear why deregulation would lead 
to DDR activation.  For example, a large number of RNA binding proteins not 
previously linked to DNA metabolism was found (Figure 3.10D).  In some of 
these cases, the effect may be indirect or could be because of induction of 
apoptosis.  We excluded obvious apoptotic cells in our analysis.  We did identify 
CIDEC, CASP10, and CRADD that participate in apoptotic pathways.  Thus, in 
some cases the $H2AX staining could be a result of the initiation of early stages 
of an apoptotic program.   
In conclusion, our RNAi and cDNA overexpression screening 
methodologies have proven successful in identifying new genome maintenance 
activities.  In Appendix B, I provide an extensive review of other functional 
genomic approaches to identify and characterize genome maintenance pathways.  
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CHAPTER IV 
 
 
SMARCAL1 FUNCTIONS AT STALLED REPLICATION FORKS TO MAINTAIN 
GENOME INTEGRITY2  
 
 
Introduction 
 
 
Genome maintenance requires the coordinated activities of cell cycle, 
DNA repair, and DNA replication proteins. Defects in any of these activities can 
cause genome instability and disease including developmental disorders, 
premature aging, and cancer predisposition (89-92).  The ataxia-telangiectasia 
mutated (ATM), ATM and Rad3-related (ATR), and DNA-dependent protein 
kinase (DNA-PK) are apical protein kinases activated by DNA damage or 
replication stress that function to coordinate cell cycle transitions with DNA 
metabolism including DNA repair and replication (93,94).  These kinases are 
activated in premalignant lesions presumably due to replication stress caused by 
activated oncogenes or inactivation of tumor suppressors (71,73). 
Accurate replication of the genome and continuous surveillance of its 
integrity are essential for cell survival and the avoidance of diseases such as 
cancer. The genome is constantly exposed to environmental and endogenous 
genotoxic insults that challenge DNA replication. The replication stress response 
                                            
2 The majority of this chapter has previously been published in reference 58.
 Bansbach, C.E., Bétous, R., Lovejoy, C.A., Glick, G.G. and Cortez, D. 
(2009) The annealing helicase SMARCAL1 maintains genome integrity at stalled 
replication forks. Genes Dev, 23, 2405-2414.. 
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is a subset of the DNA damage response that acts during every cell division 
cycle to deal with these challenges and promotes the faithful duplication of the 
genome. The accumulation of single-stranded DNA at stalled replication forks as 
a consequence of polymerase and helicase uncoupling is an important signal to 
activate replication stress response pathways including the ATR checkpoint (95).  
The heterotrimeric single-stranded DNA binding protein replication protein A 
(RPA) is a mediator of multiple protein-protein interactions at stalled replication 
forks that promote signaling and repair (13,94,96). 
 All nucleic acid metabolism including replication happens in the context of 
chromatin. Chromatin regulation is an integral part of the DNA damage and 
replication stress responses. Perhaps the best understood example is 
phosphorylation of histone H2AX by the ATM/ATR kinases (97). This histone 
modification regulates the recruitment of both checkpoint and repair proteins to 
DSBs. In addition, everything from the location of replication origins to the 
elongation rate of replication forks is influenced by chromatin structure (98). 
The SNF2 family of ATPases act in the context of chromatin to regulate 
transcription, replication, repair, and recombination. Sequence analysis has 
defined 24 SNF2 subfamilies (64). Many of these proteins act as chromatin 
remodelers to alter DNA-protein interactions.  In yeast, the activities of SNF2 
family members are important for replication initiation and replication through 
heterochromatin (99-101). They are also directly involved in responding to 
replication stress. For example, mutations in the yeast Ino80 complex cause 
hypersensitivity to replication stress agents such as hydroxyurea (HU). 
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Furthermore, this complex accumulates at stalled replication forks and is 
essential to restart replication (102).  
Defects in SNF2 genes cause many human diseases including Schimke 
immunoosseous dysplasia (SIOD) due to loss of function mutations in the SNF2 
protein SMARCAL1 (also called HARP and DNA-dependent ATPase A) (65). 
SIOD is a multi-system disorder characterized by renal failure, growth defects, 
immune deficiencies and other complex phenotypes.   
In vitro, SMARCAL1 is a DNA-dependent ATPase that binds and is 
stimulated by DNA containing fork structures (103).  SMARCAL1 has not been 
shown to remodel chromatin; however, it was recently demonstrated to be an 
ATP-dependent annealing helicase in vitro (52).  SMARCAL1 reanneals single-
stranded DNA bubbles in plasmid DNA that were stabilized by RPA. Prior to the 
evidence presented in this Chapter, the cellular context for where and when this 
activity might be important had not been previously described. 
We identified SMARCAL1 in two functional genetic screens for genome 
maintenance activities in human cells (66).  These screens, introduced in 
Chapter III, utilized markers of activated DNA damage response pathways to find 
genes whose deregulation either by RNAi or overexpression cause spontaneous 
DNA damage in the absence of any genotoxic agents.  SMARCAL1 was 
identified in both screens.  Subsequent experiments have defined SMARCAL1 as 
a replication stress response protein that acts to maintain genome integrity at 
stalled replication forks.   
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Results 
 
Changes in SMARCAL1 expression cause activation of the DNA damage 
response in cells undergoing DNA replication 
  
In the RNAi screen cells were transfected with one RNAi molecule per well 
in 96-well plates. Initially, DNA damage response activation resulting from RNAi-
mediated gene silencing in HeLa cells was assayed by immunofluorescence 
staining using a phospho-peptide-specific antibody to the ATM substrate KAP1. 
The damage-induced phosphorylation of this transcriptional co-repressor is 
necessary for ATM-mediated chromatin relaxation following DNA double-strand 
break (DSB) formation (76). To confirm the DNA damage response activation 
phenotype and ensure it was neither cell type nor marker specific, four individual 
siRNA oligonucleotides for each candidate gene were transfected into a second 
cell type (U2OS), and DNA damage response activation was monitored by 
examining H2AX S139 phosphorylation ($H2AX). The ATM/ATR family of kinases 
phosphorylate $H2AX at sites of DSBs resulting in the formation of discrete, 
nuclear foci (104,105). 
A cDNA overexpression screen was completed using a similar 
methodology using cDNAs expressed from a CMV promoter.  In this case, small 
pools of cDNA expression vectors were co-transfected with a GFP vector to mark 
successfully transfected cells and DDR activation was monitored with antibodies 
to phosphorylated KAP1.  Positive pools were then deconvoluted and tested in 
both HeLa and U2OS cells using both the KAP1 and $H2AX markers.  
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SMARCAL1 was identified in both the RNAi and cDNA overexpression 
screens. In the RNAi screen, three of four siRNAs targeting SMARCAL1 caused 
substantial activation of the DNA damage response in the absence of any added 
genotoxic agents (Figure 4.1A,B).  We confirmed the siRNAs successfully 
silenced SMARCAL1 expression and the amount of H2AX phosphorylation 
correlated with the level of knockdown (Figure 4.1C).  
SMARCAL1 silencing and overexpression cause distinct $H2AX 
phenotypes. $H2AX localizes to foci in SMARCAL1-silenced cells but exhibits 
pan-nuclear staining in cells overexpressing SMARCAL1 (Figure 4.1B). $H2AX 
foci are thought to represent sites of DSBs and the foci induced in SMARCAL1-
silenced cells did co-localize with other markers of DSBs including Rad51 (data 
not shown).  The cause of the pan-nuclear $H2AX staining is unclear, but we also 
observed this staining pattern in a large percentage of cells transfected with 
RNAi to silence the single-stranded DNA binding protein RPA.  However, we 
were unable to detect a significant increase in Rad51 foci formation or evidence 
of DSBs using Comet assays in the overexpression context raising the possibility 
that the DNA damage response activation is not associated with DSBs in this 
case.  Neither of the staining patterns was associated with apoptotic nuclei and 
both patterns were due to chromatin-associated $H2AX (data not shown). Neither 
overexpression nor siRNA silencing of SMARCAL1 caused a discernable change 
in cell proliferation rates but we did observe a slight increase in the percentage of 
cells in the G2/M phase of the cell cycle (Figure 4.2). 
 64 
  
 
 
 
 
Figure 4.1.  Deregulation of SMARCAL1 expression causes activation of the 
DNA damage response. (A) U2OS cells were transfected with siRNA targeting 
SMARCAL1 or expression vectors encoding either SMARCAL1 or GFP-
SMARCAL1.  Three days after transfection, cells were stained with antibodies to 
$H2AX and appropriate secondary antibodies.  The percentage of cells with 
$H2AX staining was scored. Error bars are standard deviation (n"3). (*, P<0.05) 
(B) Representative images of $H2AX staining. (C) Immunoblots of U2OS cell 
lysates with antibodies to SMARCAL1 or CHK1 after transfection with the 
indicated SMARCAL1 siRNAs. (NT, non-targeting). 
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Figure 4.2.  Overexpression and silencing of SMARCAL1 do not affect cell 
proliferation. Cell cycle profiles of cells transfected with SMARCAL1 cDNA or 
siRNA. HeLa cells were transfected with control or SMARCAL1 expression 
vectors, or with non-targeting or SMARCAL1 siRNA. Three days after 
transfection, the cells were labeled with BrdU, stained with fluorescein-
conjugated anti-BrdU antibodies and propidium iodide, and processed by flow 
cytometry. 
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Approximately 20% of the SMARCAL1 overexpressing cells exhibited the 
pan-nuclear $H2AX-staining pattern. These cells were exclusively in S-phase 
since they incorporated BrdU and were cyclin A-positive (Figure 4.3A,B). RNAi 
silencing of SMARCAL1 also caused DNA damage predominantly in replicating 
cells.  Co-staining SMARCAL1-silenced cells with antibodies to both $H2AX and 
cyclin A demonstrated that 60% of the $H2AX+ cells stained strongly for cyclin A 
(Figure 4.3C).  This is 1.75-fold higher than predicted by chance and similar to 
what is observed when the replication checkpoint protein CHK1 is silenced 
(Figure 4.3D).  In contrast, there is no preference for $H2AX staining in any 
phase of the cell cycle after ionizing irradiation, which causes DNA breaks 
irrespective of cell cycle position. We also did not observe DNA damage 
response activation in G0-arrested, SMARCAL1-depleted cells (data not shown).  
Thus, the DNA damage response activation caused by both overexpression or 
silencing of SMARCAL1 is associated with cells undergoing DNA replication. 
 
SMARCAL1 localizes to stalled replication forks via an interaction with RPA34 
 Adding an N-terminal green fluorescent protein (GFP) tag to SMARCAL1 
did not alter the $H2AX phenotype caused by overexpression (Figure 4.1A) but 
did allow us to correlate the $H2AX with both SMARCAL1 expression levels and 
localization. GFP-SMARCAL1 accumulated in nuclear foci in 20% of the GFP-
SMARCAL1 over-expressing cells (Figure 4.4A). The GFP-SMARCAL1 
overexpression foci perfectly correlated with the pan-nuclear $H2AX phenotype. 
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Figure 4.3. DNA damage response activation caused by SMARCAL1 
deregulation occurs in S phase cells.  (A and B) U2OS cells were transfected 
with a SMARCAL1 overexpression vector then fixed and stained with the 
indicated antibodies and appropriate fluorophore-conjugated secondary 
antibodies.  In (A) the cells were pulsed with BrdU for 20 minutes prior to staining. 
(C and D) U2OS cells transfected with siRNA targeting CHK1 or SMARCAL1_06 
siRNA were stained with antibodies to $H2AX and cyclin A.  Cells were scored as 
positive for one or both proteins by immunofluorescence imaging.  Untransfected 
cells were also irradiated with 5Gy of ionizing radiation for comparison. 
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Figure 4.4.  Overexpressed GFP-SMARCAL1 accumulates at replication 
centers.  U2OS cells were transfected with the pLEGFP-SMARCAL1 expression 
vector then fixed and stained. Staining in (B) is as follows: (1-4 = SMARCAL1 
(green) and BrdU (red); 5-8 = SMARCAL1 (green) and RPA (red); 9-12 = 
SMARCAL1 (green) and PCNA (red)). 3, 7, and 11 are merged images; 4, 8, 12 
were stained with DAPI. 
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Cells in which GFP-SMARCAL1 did not accumulate into foci did not have 
detectable $H2AX staining. 
The focal localization pattern and its restriction to S-phase cells suggested 
SMARCAL1 might be localized to replication factories.  Indeed, labeling 
replication factories with BrdU, RPA, or PCNA demonstrated co-localization of 
SMARCAL1 foci with sites of DNA replication (Figure 4.4B).  Treating cells with 
HU induced a marked increase in the percentage of cells containing SMARCAL1 
foci (Figure 4.5A) Importantly, we also found that endogenous SMARCAL1 
localizes to stalled replication forks (marked by the ATR-interacting protein 
ATRIP) following treatment with HU or ultraviolet (UV) radiation (Figure 4.5B,C). 
The percentage of cells containing SMARCAL1 foci increased with the time of 
HU-exposure (Figure 4.5D).  Endogenous SMARCAL1 foci were rarely observed 
in undamaged cells. These localization data place SMARCAL1 at sites of 
replication stress. We also observed SMARCAL1 foci in response to ionizing 
radiation treatment. These foci appeared several hours after irradiation in only 
the S/G2 phase cells that contain cyclin A (data not shown).  This pattern is 
consistent with a requirement for end-resection at a DSB. 
To identify SMARCAL1-interacting proteins we performed both 
immunopurifications combined with mass-spectrometry and a two-hybrid screen.  
Immunopurifying endogenous SMARCAL1 complexes with antibodies to the C-
terminus of SMARCAL1 or using a tandem-epitope approach combined with 
mass spectrometry identified peptides from all three subunits of the single-
stranded DNA binding protein replication protein A (RPA) (Figure 4.6A).  The 
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Figure 4.5.  Endogenous SMARCAL1 localizes to stalled replication forks.  
In (A) the cells containing SMARCAL1 localized to foci were scored after addition 
of 2mM HU. (B,C) Localization of endogenous SMARCAL1 was examined by 
indirect immunofluorescence with affinity purified anti-SMARCAL1 antibody in HU, 
UV radiation-treated (1hr after 50J/m2), or (Unt.) untreated U2OS cells.  These 
cells also stably express HA-ATRIP, which permitted analysis of co-localization 
using anti-HA monoclonal antibody. Specificity of the SMARCAL1 antibody was 
confirmed in SMARCAL1-silenced cells. Cells were pre-extracted with 0.5% triton 
X-100 solution for 10min prior to fixation so only chromatin bound-SMARCAL1 is 
observed. (C) The percentage of cells containing endogenous SMARCAL1 in foci 
was scored in cells treated with 2mM HU for the indicated times. Error bars in all 
graphs are standard deviation (n=3). 
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two-hybrid screen using a full-length SMARCAL1 protein bait identified ten 
interacting fragments of the 32kDa subunit of RPA.  The minimal interacting 
region contained RPA32 amino acids 156-267 corresponding to the winged-helix 
protein-interaction domain (32C) (Figure 4.6B).  This region of RPA32 binds to 
several DNA repair proteins including UNG2, XPA, and RAD52 (106).  Co-
immunoprecipitation of endogenous proteins confirmed the SMARCAL1-RPA 
interaction and indicated it is stimulated by replication stress (Figure 4.6C,D).  
While a C-terminal antibody to SMARCAL1 efficiently co-
immunoprecipitates all three RPA subunits (Figure 4.5A) an antibody raised to 
the N-terminus of SMARCAL1 fails to co-immunoprecipitate RPA (data not 
shown) suggesting it may compete for the same binding surface as RPA.  
Sequence analysis of this SMARCAL1 region identified a highly evolutionarily 
conserved sequence (amino acids 1-32) that has similarity to the Timeless-
Interacting Protein (TIPIN) (Figure 4.7A). Notably, this region of TIPIN was 
previously demonstrated to bind RPA32 (107)  suggesting it might be the RPA32-
interacting surface on SMARCAL1.  Indeed, deletion of the first 32 amino acids of 
SMARCAL1 severely impairs its ability to interact with RPA (Figure 4.7B).  
Furthermore, this SMARCAL1-#N32 protein fails to localize to intranuclear foci 
either in the absence or presence of HU (Figure 4.8C).     
To determine whether this N-terminal region of SMARCAL1 is also 
sufficient to bind RPA32 and localize SMARCAL1 to stalled forks, we fused it to 
GFP.  A GFP protein containing only the first 32 amino acids of SMARCAL1 
(GFP-SMARCAL1 1-32) bound poorly to RPA and localized to foci in only a small 
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Figure 4.6.  Immunopurifications and two-hybrid screen identify RPA as an 
interacting partner of SMARCAL1. (A) Endogenous SMARCAL1 or Flag-HA-
SMARCAL1 was immunopurified from nuclear cell extracts and the resulting 
protein complexes were analyzed by mass spectrometry.  The table indicates the 
number of peptides identified for each RPA protein subunit.  IgG is a control 
immunoprecipitation; Sm = Flag-HA-SMARCAL1; Ctrl=Flag-HA empty vector 
cells.  Where indicated, the cells were treated with 1mM HU for 16 hours prior to 
the purification.  (B) A schematic diagram of RPA subunits.  The lines under 
RPA32 indicate the sizes (with amino acid numbers) of the different RPA32 
protein fragments identified in the unbiased two hybrid screen using full-length 
SMARCAL1 as a bait.  (C,D) HeLa cell nuclear extracts were used for 
immunoprecipitation with anti-SMARCAL1 or pre-immune antibodies. In (C), the 
lysates were treated with benzonase nuclease (Benz.) as indicated to ensure the 
interaction is not dependent on DNA.  Nuclear extracts from untreated or cells 
treated with HU for 8 hours were used for immunoprecipitation in (D).  
Immunoprecipitated proteins were separated by SDS-PAGE and immunoblotted 
with RPA or SMARCAL1 antibodies. Data for panels A, C, and D were produced 
by Remy Betous.  
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Figure 4.7. The N-terminal region of SMARCAL1 is necessary for RPA 
binding and localization to stalled replication forks. (A) Sequence alignment 
of human-, mouse-, and Xenopus SMARCAL1 with human TIPIN.  (B) HEK293 
cells were transfected with wild-type GFP-SMARCAL1 (WT) or GFP-SMARCAL1 
lacking the first thirty-two amino acids (%32).  Cells transfected with an empty 
vector (VEC) were also prepared as a control.  Anti-GFP or anti-RPA 
immunoprecipitated proteins were separated by SDS-PAGE and blotted with 
anti-GFP or anti-RPA2 antibodies.  (C) U2OS cells were transfected with GFP-
SMARCAL1-WT or -%32 vectors and treated with 2mM HU for 6 hours.  
Approximately 30% of the wild-type SMARCAL1 expressing cells had 
SMARCAL1 foci while we never observed the SMARCAL1-%32 protein in foci.  
Representative images are shown. Data for panel B was produced by David 
Cortez. 
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percentage of HU-treated cells (Figures 4.8A,B).  However, fusion of a slightly 
longer portion of the SMARCAL1 N-terminus (amino acids 1-115) to GFP created 
a protein that binds to RPA and localizes to stalled replication forks as efficiently 
as full-length SMARCAL1 (Figure 4.8A-C).  In these experiments we used a 
GFP-expression vector (pLL5.0-GFP-GW) with attenuated expression levels to 
avoid spontaneously activating the DNA damage response in the absence of HU 
that is observed with wild-type GFP-SMARCAL1 expressed at higher levels.  
Thus, the N-terminus of SMARCAL1 encodes a binding surface for RPA32 that is 
both necessary and sufficient to localize SMARCAL1 to stalled replication forks.   
 
An SIOD-associated patient mutation and an RPA-binding mutant are both 
defective in the cellular functions of SMARCAL1 
 
To determine whether the spontaneous DNA damage response activation 
observed after high levels of SMARCAL1 overexpression is due to too much 
enzymatic activity we examined whether an SIOD-associated patient mutation 
(R764Q) in SMARCAL1 that perturbs its ATPase and annealing helicase 
activities alters the ability of overexpressed SMARCAL1 to cause DNA damage.  
We also tested the ability of SMARCAL1 lacking its RPA binding domain to 
cause DNA damage response activation to determine whether localization to 
replication factories and/or RPA binding is essential. GFP-SMARCAL1-R764Q is 
deficient in activating the DNA damage response when overexpressed in cells 
compared to wild-type SMARCAL1 (Figure 4.9A) Similarly, the GFP-SMARCAL1 
#N32 protein completely fails to activate the DNA damage response although it 
is expressed at equal levels as wild-type SMARCAL1 (Figure 4.9A,B). The SIOD 
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Figure 4.8.  Amino acids 1-115 of SMARCAL1 are sufficient to bind RPA and 
localize to stalled replication forks.  (A) GFP-SMARCAL1 containing only the 
first 32 or 115 amino acids of SMARCAL1 was transfected into cells, 
immunoprecipitated and immunoblotted.  (B) The indicated expression vectors 
(pLL5.0-GFP-GW backbone for attenuated expression levels) were transfected 
into HeLa cells.  The cells were treated for 7h with 1mM HU or left untreated and 
the percentage of cells containing foci of the indicated proteins was scored.  
Error bars are standard deviation (n=3).  (C) Representative images of the 
localization of SMARCAL1-1-115 and wild-type SMARCAL1. David Cortez 
performed all experiments for this figure. 
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mutant SMARCAL1 protein can be recruited to stalled replication forks as 
efficiently as wild-type SMARCAL1 in HU-treated cells (Figure 4.9C).  In contrast, 
as noted previously, the SMARCAL1-#N32 protein does not localize to foci.  
These data indicate that both the RPA binding and enzymatic activities of 
SMARCAL1 are necessary to cause replication-associated DNA damage 
response activation. Overexpression of SMARCAL1 likely deregulates its activity 
perhaps allowing aberrant access to replication forks and causing problems 
during DNA replication.  
We next asked whether the SIOD patient mutation or the RPA-binding 
mutation would impair the function of endogenous SMARCAL1 in cells.  
Specifically, we tested the ability of wild-type and mutant SMARCAL1 proteins to 
functionally complement the spontaneous appearance of $H2AX foci in 
SMARCAL1-silenced cells.  U2OS cells co-transfected with siRNA-resistant 
pLL5.0-GFP-GW-SMARCAL1 cDNAs and either non-targeting siRNA as a 
control or SMARCAL1 siRNA were stained with antibodies to $H2AX.  GFP-
positive cells were scored for $H2AX foci.  As expected, transfection of the GFP 
empty vector by itself did not prevent the appearance of $H2AX foci in 
SMARCAL1-silenced cells (Figure 4.9D).  Expression of wild-type GFP-
SMARCAL1 completely suppressed this defect.  However, neither expression of 
the R764Q SIOD mutant nor the #N RPA-binding mutant SMARCAL1 protein 
was capable of preventing the appearance of $H2AX foci when endogenous 
SMARCAL1 was silenced (Figure 4.9D).  Thus, RPA-binding is essential for the
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Figure 4.9.  RPA binding and annealing helicase activities of SMARCAL1 
are required for its cellular functions. (A) HeLa cells were transfected with 
expression vectors (pLEGFP backbone for high levels of expression) encoding 
GFP-tagged wild-type SMARCAL1 (WT), the annealing helicase deficient SIOD 
patient mutant protein R764Q, or SMARCAL1-%32.  The amount of DNA damage 
response activation was scored by monitoring KAP1 phosphorylation. (B) 
Expression levels of the GFP-SMARCAL1 proteins were determined by 
immunoblotting. The loading control was either ATM or RPA32. (C) The 
percentage of HU-treated cells in which GFP-SMARCAL1 wild-type or mutant 
proteins localized to intra-nuclear foci was scored.  Cells were treated with HU for 
8 hours. (D) U2OS cells were co-transfected with the indicated pLL5.0-GFP-GW 
plasmids that encode siRNA-resistant SMARCAL1 cDNAs and siRNA targeting 
SMARCAL1. GFP-positive cells were scored for $H2AX staining. (GFP, GFP 
empty vector; NT, non-targeting siRNA control). Error bars in all panels are 
standard deviation (n=6). 
 78 
function of SMARCAL1 in vivo.  These data also link the SIOD phenotype caused 
by the R764Q mutation directly to a genome maintenance defect.   
The ability of SMARCAL1 to bind to RPA raises the question of whether 
this binding only serves to regulate the localization of SMARCAL1 or if it also is 
important for the annealing helicase activity previously described for SMARCAL1 
(52).  The annealing helicase assay utilizes the ability of RPA to bind to 
supercoiled plasmid DNA and form bubbles by melting the DNA strands.  When 
SMARCAL1 is added, the DNA strands are re-annealed in an ATP-dependent 
reaction, thereby displacing RPA.  We tested SMARCAL1- #N32 to determine if 
this RPA-binding mutant maintains its ATPase and annealing helicase activities. 
We found no difference between wild-type and mutant SMARCAL1 in either 
assay (Figure 4.10).  Fork DNA stimulates the ATPase activity of SMARCAL1- 
#N32 equivalently to wild-type SMARCAL1 (Figure 4.10B).   Furthermore, it acts 
as an annealing helicase as efficiently as wild-type SMARCAL1 (Figure 4.10C,D).  
The small differences observed at some concentrations were not reproducible. 
Thus, RPA binding primarily serves to regulate the localization of SMARCAL1, 
which is critical for SMARCAL1 function in cells but not essential for its enzymatic 
activity.  
 
SMARCAL1 is regulated by the DNA damage response 
 In the course of studying SMARCAL1, we noticed that it often migrates as 
multiple bands on SDS-PAGE gels.  Closer examination indicated that 
SMARCAL1 exhibits a phosphorylation-dependent gel-mobility shift when cells
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Figure 4.10. The SMARCAL1 RPA binding domain is not necessary for 
ATPase or annealing helicase activities in vitro.  (A) Coomassie stained gel of 
the Flag-SMARCAL1 and Flag-SMARCAL1-D32 purified from baculovirus-
infected insect cells. (B) ATPase activity of the wild-type and D32 SMARCAL1 
proteins was measured in the presence of the indicated concentrations of fork 
DNA.  Error bars are standard deviation (n=3).  (C and D) Annealing helicase 
activities of wild-type and D32 SMARCAL1 proteins.  The concentration of 
SMARCAL1 protein in (C) is 300nM.  Remy Betous performed all experiments for 
this figure.  
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are treated with replication stress and DNA damaging agents including HU, IR, 
and UV-radiation (Figure 4.11A,B).   
 SMARCAL1 contains several consensus motifs (SQ/TQ) for 
phosphorylation by the DNA damage and replication stress-activated ATM/ATR 
family of kinases.  To determine whether these kinases can phosphorylate 
SMARCAL1 we used in vitro kinase assays.  Purified wild-type ATM and ATR but 
not kinase-dead proteins efficiently phosphorylated SMARCAL1 in vitro (Figure 
4.12A). Purified DNA-PK also phosphorylated SMARCAL1 in a DNA-stimulated 
reaction (Figure 4.12B).   
 To determine which of these kinases may be responsible for the 
phosphorylation of SMARCAL1 in cells, each was depleted using siRNA. 
However, we failed to detect any difference in the HU-dependent phosphorylation 
of SMARCAL1 when individual kinases were silenced (Figure 4.13A).  We then 
examined combinations of specific kinase inhibitors and RNAi.  Specific ATM and 
DNA-PK inhibitors had no appreciable effect on SMARCAL1 phosphorylation 
after HU even when used together (Figure 4.13B, compare lanes 2 and 5).  The 
inhibitors also had only a minimal effect after IR (Figure 4.13B, compare lanes 6 
and 9).  Silencing ATR by itself also had minimal effects after HU treatment, but it 
did reduce phosphorylation after IR (Figure 4.13B, compare lanes 6 and 16). 
Silencing ATR and treating cells with the specific ATM and DNA-PK inhibitors 
significantly reduced the phosphorylation of SMARCAL1 both after HU and IR 
treatment (Figure 4.13B, compare lanes 5 and 15, 9 and 19). The residual 
phosphorylation of SMARCAL1 under these circumstances in which all three
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Figure 4.11. SMARCAL1 is phosphorylated in response to replication stress 
or DNA damage.  (A) Cell lysates from cells treated with 1mM HU, 10Gy of IR, 
or 50J/m2 of UV-radiation, were separated by SDS-PAGE and immunoblotted.  
The time points represent the duration of the HU treatment or the length of time 
the cells were allowed to recover following the radiation exposure. (Unt, 
untreated).  (B) Cell lysates from untreated or HU-treated cells were incubated in 
the presence of lambda phosphatase and the phosphatase inhibitor sodium 
vanadate as indicated for 30 or 60 minutes prior to separation by SDS-PAGE and 
immunoblotting.  David Cortez performed all experiments for this figure. 
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Figure 4.12.  ATM, ATR, and DNA-PK phosphorylate SMARCAL1 in vitro. (A 
and B) Flag-ATM or Flag-ATR wild-type (WT) or kinase dead (KD) proteins or 
wild-type Flag-DNA-PKcs were immunopurified from transfected cells.  Wild-type 
DNA-PK was also purchased from Promega (B, right panel). The kinases were 
incubated with purified SMARCAL1 in the presence of $-32P-ATP.  Sonicated 
salmon sperm DNA was added to the DNA-PK reactions as indicated.  Reactions 
were separated by SDS-PAGE and subjected to autoradiography (32P).  The 
levels of SMARCAL1, ATM, ATR, and DNA-PKcs proteins in each reaction were 
visualized by coomassie staining.  David Cortez performed all experiments for 
this figure. 
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Figure 4.13.  ATM, ATR, and DNA-PK phosphorylate SMARCAL1 in cells.  
(A) 293T cells transfected with the indicated siRNAs (NT, non-targeting) were 
treated with HU for 6 or 20h.  Lysates were separated by SDS-PAGE and 
immunoblotted with antibodies to SMARCAL1, ATR, or ATM. (B) 293T cells were 
transfected with either non-targeting (NT) or ATR siRNA.  Cells were also treated 
with specific ATM (KU55933, 10µM) (108) or DNA-PK (KU57788, 1µM) (109) 
inhibitors as indicated and exposed to 1mM HU or 10Gy of IR. Cell lysates were 
separated by SDS-PAGE and immunoblotted for SMARCAL1 or ATR.  David 
Cortez performed all experiments for this figure. 
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kinases are inhibited may be due to incomplete silencing of ATR, inhibition of 
ATM or DNA-PK, or potentially the involvement of additional kinases.   
 This type of phosphorylation pattern is common to many substrates of the 
ATM/ATR family of kinases such as RPA32 that are phosphorylated by multiple 
family members. SMARCAL1 is likely phosphorylated on several sites since the 
banding pattern on SDS-PAGE gels is complex.  To identify sites of 
phosphorylation, we immunopurified SMARCAL1 from HU-treated cells and 
subjected it to mass spectrometric analysis. Several phosphorylation sites were 
observed including S173 that lies in a good consensus sequence for the 
ATM/ATR family (SQE) (see appendix for full list and spectra).  Our data indicate 
that SMARCAL1 functions downstream of the ATM/ATR/DNA-PK kinases in 
response to replication stress.  I present further analysis of SMARCAL1 damage-
dependent phosphorylation in Chapter V.  
 
Loss of SMARCAL1 function causes persistent RPA phosphorylation, RPA 
loading onto chromatin and hypersensitivity to replication stress agents. 
  
The localization of SMARCAL1 to stalled replication forks, appearance of 
$H2AX foci in S-phase of SMARCAL1-silenced cells, phosphorylation by the 
ATM/ATR/DNA-PK kinases, and its ability to act as an annealing helicase in vitro 
suggests that SMARCAL1 may have a critical function to anneal DNA strands at 
stalled replication forks.  If this were true, we would expect that SMARCAL1-
deficient cells should accumulate more RPA bound to single-stranded DNA than 
control cells.  Consistent with this hypothesis, more RPA is loaded onto 
chromatin in SMARCAL1-deficient cells than control cells and this difference is 
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even more pronounced after exposure to HU (Figure 4.14A).  SMARCAL1 is also 
loaded onto chromatin under these conditions. RPA loaded at stalled replication 
forks is rapidly phosphorylated by the ATM/ATR family of kinases (96). 
SMARCAL1-silenced cells treated with HU exhibited hyper-phosphorylation of 
RPA that also persisted after the HU was removed (Figure 4.15B).  These data 
are consistent with a model in which the annealing helicase activity of 
SMARCAL1 functions to reduce the amount of single-stranded DNA available for 
RPA binding at stalled forks.   
 If SMARCAL1 activity is important for the proper nucleic acid metabolism 
at sites of replication stress, then cells lacking SMARCAL1 should be 
hypersensitive to replication stress agents.  Indeed, silencing SMARCAL1 
causes a marked hypersensitivity to HU, the DNA polymerase inhibitor 
aphidicolin, and the topoisomerase I inhibitor camptothecin (Figure 4.15A-C).  
Thus, SMARCAL1 activity is important to maintain viability when cells are 
challenged with drugs that induce uncoupling of helicase and polymerases at 
replication forks. 
 
Discussion 
 
The SIOD disease is caused by loss of function mutations in SMARCAL1 
(65).  This disease has a complex phenotype affecting multiple organs and 
tissues. There is also variability in phenotypic severity among patients. These 
characteristics have made it difficult to propose a unifying model for the 
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Figure 4.14.  SMARCAL1-deficient cells exhibit increased RPA-loading onto 
chromatin and persistent RPA phosphorylation after replication stress.  (A) 
The chromatin fraction of cells transfected with non-targeting (NT) or SMARCAL1 
(S6) siRNA was isolated and immunoblotted with the indicated antibodies.  
Quantitation of the amount of RPA versus ORC2 in the chromatin fraction was 
performed with an Odyssey instrument (arbitrary units).  (B) Cells transfected 
with non-targeting or SMARCAL1 siRNA were treated with HU for 5h (HU) then 
the HU was removed and the cells were allowed to recover for 4h (+4h). Total 
cell lysates were prepared and immunoblotted with the indicated antibodies.  (Unt, 
untreated).  
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Figure 4.15.  SMARCAL1-deficient cells are hypersensitive to replication 
stress agents.  (A) Cells transfected with the indicated siRNA were split into four 
plates, two of which were treated with 2mM HU for 24hrs. The HU was removed 
and replaced with standard growth media for an additional 24h before cell 
viability was quantitated using the WST-1 cell proliferation reagent (Roche).  
Reported values are the mean and standard deviation of three experiments. All 
four SMARCAL1 siRNAs yielded significant hypersensitivity to HU with p values 
ranging from 0.02 to 10-4.  (B and C) Cells transfected with the indicated siRNAs 
were treated with 5mM aphidicolin or 150nM camptothecin and cell viability 
compared to untreated controls.  P value of non-targeting compared to 
SMARCAL1-silenced for both aphidicolin (n-=12) and camptothecin (n=24) 
treatments are less than 10-5. 
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molecular functions of SMARCAL1 that would explain the disease. Our 
mechanistic analysis of SMARCAL1 suggests at least part of the underlying 
molecular cause of SIOD is a defect in cellular responses to replication stress. 
SMARCAL1 is a member of the SNF2 family of ATPases that function in a 
variety of chromatin-associated processes including transcription, replication, and 
DNA repair (64). These proteins often alter DNA-protein interactions as a 
consequence of hydrolyzing ATP. A single SMARCAL1 protein is found in 
humans and it is evolutionarily conserved in invertebrates including C. elegans 
and D. melanogaster. However, yeast orthologues have not been identified.   
A major advance in understanding SMARCAL1 activity was made with the 
identification of its annealing helicase activity in vitro (52).  While many helicases 
can act to reverse a fork under some in vitro conditions, SMARCAL1 is the only 
protein identified thus far that primarily acts to anneal two DNA strands without 
exhibiting any helicase activity.  The context of where and when this activity is 
important in the cell has not been defined. 
We have now defined SMARCAL1 as a replication stress response protein 
that acts at stalled replication forks to limit replication-associated DNA damage.  
SMARCAL1 contains an RPA32 interacting domain at its N-terminus similar to a 
domain in the replication stress response protein TIPIN (107).  This domain is 
both necessary and sufficient to localize SMARCAL1 to stalled forks. RPA 
binding is required for the genome maintenance activity of SMARCAL1 during 
DNA replication, but it is not required for its annealing helicase activity in vitro.  
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Like many replication stress response proteins, SMARCAL1 is 
phosphorylated by the ATM/ATR/DNA-PK family of protein kinases. SMARCAL1 
contains multiple consensus sequences for phosphorylation and its complex gel 
mobility pattern indicates that several may be phosphorylated. Our mass 
spectrometry analysis indicates one of these is S173.  The ATM/ATR/DNA-PK 
kinases have somewhat overlapping and redundant activities on SMARCAL1 in 
response to replication stress since all three kinases must be inhibited to observe 
a significant reduction in phosphorylation after HU.  This is not unusual for 
substrates of these kinases since HU can activate all three kinases and there is 
significant cross-talk between them.  
Both silencing and overexpression of SMARCAL1 causes activation of the 
DNA damage response kinases in replicating cells. Activation of the DNA 
damage response upon overexpression of SMARCAL1 is strictly limited to S-
phase cells.  The pattern of $H2AX staining in these SMARCAL1 overexpressing 
cells is unusual in that it is pan-nuclear and never localized in discrete foci. This 
pattern has previously been noted in cells in which ATR is activated in the 
absence of DNA damage (110,111). However, we have found no evidence that 
SMARCAL1 functions as a direct regulator of ATR activation. We have also 
observed this pan-nuclear pattern when RPA is depleted from cells with RNAi.  
However, in this circumstance a significant portion of cells in the population also 
exhibit focal $H2AX staining. As yet, the molecular basis of the SMARCAL1 
overexpression-associated pan-nuclear $H2AX staining is unclear, but our data 
does indicate that it is dependent on both the ATPase and RPA binding activities 
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of SMARCAL1. Multiple proteins bind to the same region of RPA32 as 
SMARCAL1 (106).  A competition between interacting proteins is likely to prevent 
SMARCAL1 from gaining access to the limited amount of RPA at normal 
elongating forks.  However, when SMARCAL1 is overexpressed, it may out-
compete other proteins, gain access to normal replication forks, and then use its 
enzymatic activity to reanneal DNA strands inappropriately. RPA silencing may 
phenocopy SMARCAL1 overexpression in some cells when RPA levels are 
insufficient to stabilize the ssDNA at elongating forks. 
 Silencing SMARCAL1 increases both the amount of RPA bound to 
chromatin and its phosphorylation following a challenge with HU.  RPA 
phosphorylation also persists after removing HU from the growth media in 
SMARCAL1-silenced cells. These results are consistent with the idea that 
SMARCAL1 acts as an annealing helicase at stalled forks to limit the amount of 
single-stranded DNA that accumulates. Since the DNA at a replication forks is 
not bound into nucleosomes, it may have an increased propensity to form 
bubbles or flaps that would be substrates for the annealing helicase activity of 
SMARCAL1. DNA polymerase and helicase activities are uncoupled at 
replication forks in response to DNA lesions or agents like HU that interfere with 
DNA synthesis (95). Uncoupling causes the formation of regions of single-
stranded DNA that is rapidly coated with the single-stranded DNA binding protein 
RPA. We envision at least four possible substrates for the annealing helicase 
activity of SMARCAL1 at a stalled fork (Figure 4.16). (a) The uncoupled 
replication fork itself could be a substrate, although this may require dissociation 
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Figure 4.16. Model of possible substrates for SMARCAL1 annealing 
helicase activity at stalled replication forks. (see text for details) 
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of the MCM helicase complex for SMARCAL1 to obtain access. (b or c) Single-
stranded bubbles may form in the DNA at the stalled fork since it is not stabilized 
into nucleosome structures. The positive supercoiling ahead of the fork would 
likely inhibit bubble formation at position (c). However, the pre-catanenes behind 
the fork may not prevent ssDNA bubbles from forming especially in genomic 
sequences that are AT rich or prone to secondary structure formation. (d) 
SMARCAL1 may anneal DNA flaps that could form when replicative polymerases 
dissociate from the DNA. Flaps could form on either the leading strand or lagging 
strand at the 5’ or 3’ end of an Okazaki fragment. If SMARCAL1 prevents flap 
formation, then it may act to inhibit a process of fork-reversal (112,113), which is 
energetically favorable but thought to be inhibited by the tethering of the nascent 
strand ends to their parental templates by the replisome during normal replication 
(114). Finally, it is possible that SMARCAL1 acts at replication origins to limit 
replication origin firing.  Of course, these potential activities are not mutually 
exclusive. 
SMARCAL1 deficiency causes the appearance of DSB markers at 
replication factories, increased RPA loading and phosphorylation in response to 
replication stress, and decreased viability after treatment of cells with agents that 
stall replication forks.  Cells expressing only an SIOD-associated mutant 
SMARCAL1 protein accumulate $H2AX foci even in the absence of a replication 
stress agent.  While it is difficult to link these effects directly to the symptoms in 
SIOD patients, these data suggest that loss of SMARCAL1 function in patients 
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may cause DNA replication-associated genome instability that contributes to the 
pleiotropic phenotypes of this disease. 
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Chapter V 
 
CHARACTERIZATION OF DDR-REGULATED SMARCAL1 
PHOSPHORYLATION 
 
Introduction 
 
The DDR kinases ATR, ATM, and DNA-PK phosphorylate hundreds of 
overlapping substrates at serine and threonine residues that are followed by 
glutamine (S/TQs). The substrates identified thus far, mostly by massive 
proteomic efforts (88,115,116), function in diverse cellular pathways. How DDR-
dependent phosphorylation regulates these pathways remains vastly 
uncharacterized.   
During DNA replication, DDR kinases are important for responding to DNA 
damage. ATR activation is especially important during S phase to coordinate 
DNA replication with cell cycle transitions (94,117).  ATR signaling promotes fork 
stability, preventing the accumulation of aberrant fork structures and DNA 
damage during replication (29).  In the absence of fork stabilizing activities, DSBs 
regularly form at collapsed replication forks and activate ATM and DNA-PK to 
promote fork repair (44).  It is not clear how ATR signaling stabilizes forks but the 
most likely targets are proteins that function directly at stalled replication forks. 
Investigating the functional consequences of DDR-dependent phosphorylation for 
this particular group of proteins is critical for understanding the mechanisms that 
promote replication fork stability.   
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SMARCAL1 is a substrate of the DDR kinases ATM, ATR, and DNA-PK 
and is phosphorylated by all three kinases in cells after DNA damage.  
SMARCAL1 travels with at least some replication forks in untreated cells and 
accumulates at stalled replication forks when cells are treated with replication 
inhibitors (54,58).  Importantly, SMARCAL1 deficiencies cause fork restart 
defects after replication stress, sensitivity to replication stress agents, and 
aberrant fork structures that result in DNA double-strand breaks (DSB) (54,58,59).  
Recent biochemical evidence suggests that SMARCAL1 can catalyze fork 
regression and remodel a variety of fork-like structures; activities that can both 
potentially promote replication restart and prevent replication-associated DNA 
double strand breaks in vivo (54).      
The functional consequences of SMARCAL1 phosphorylation are 
unknown.  We hypothesized that SMARCAL1 is targeted by DDR kinases to 
promote replication fork stability. We determined that SMARCAL1 is 
phosphorylated at three major sites following DNA damage. Importantly, 
SMARCAL1 localization to stalled forks and subsequent DNA binding are 
required for phosphorylation. DNA binding stimulates SMARCAL1 ATPase 
activity and SMARCAL1 fork remodeling activities. Our data suggest that DDR-
dependent phosphorylation regulates activated SMARCAL1 at replication forks. 
Furthermore, we provide functional evidence to support that phosphorylation in 
the ATPase hinge domain of SMARCAL1 limits the activities of SMARCAL1 at 
stalled replication forks.  
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Results 
 
DDR-regulated phosphorylation of SMARCAL1 requires DNA binding at stalled 
replication forks 
 
SMARCAL1 exhibits a phosphorylation-dependent gel mobility shift when 
cells are treated with the replication stress agent hydroxyurea (HU).  Though less 
complex than the endogenous SMARCAL1 shift, we were able to detect an HU-
induced phospho-shift of GFP-SMARCAL1 when we use conditions that express 
low levels of protein (Figure 5.1A).  SMARCAL1 localizes to HU-stalled 
replication forks through an interaction with RPA.  To determine whether 
SMARCAL1 was phosphorylated directly at stalled forks, we examined the 
phospho-shift of the %N mutant, which cannot bind RPA or localize to stalled 
replication forks (58).  The %N mutant does not exhibit a detectable phospho-shift 
(Figure 5.1B, lane 6) suggesting that DDR-regulated phosphorylation depends on 
SMARCAL1 localization to forks.  
The RPA interaction likely functions to concentrate SMARCAL1 near its in 
vivo substrates, replication fork structures.  We expect that once localized 
SMARCAL1 binds DNA to promote fork restart. SMARCAL1 has two HARP 
domains that are critical for SMARCAL1 activities in cells (62).  We recently 
defined the HARP domains as DNA binding domains in SMARCAL1, with 
HARP2 being essential for DNA binding (54). We analyzed the shift pattern of 
HARP mutants. Mutants lacking the entire HARP1 domain or containing two 
point mutations in conserved HARP residues (%H1 and H1-WF) exhibit a 
decreased shift (Figure 5.1B, lanes 8,10).  Similar mutants of HARP2 (%H2 and  
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Figure 5.1. The SMARCAL1 DDR-regulated phospho-shift depends on 
localization and DNA binding. (A) HEK293T cells were transfected with 
expression vectors (pLL5.0-GFP-GW backbone for low expression) encoding 
GFP-tagged wild-type SMARCAL1. Cell lysates from transfected cells treated 
with 2mM HU for 16hr were separated by SDS-PAGE and immunoblotted with 
SMARCAL1 antibodies. The arrow marks the GFP-SMARCAL1 protein, which is 
larger and runs above endogenous SMARCAL1, lower band. (NT) No treatment. 
(B) Using the same conditions as in (A) cells were transfected with various GFP-
SMARCAL1 mutants. Image was cropped to show only GFP-SMARCAL1 bands. 
Odd lanes (NT), even lanes (HU). 
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H2-WF) resemble the %N mutant and exhibit no HU-induced shift (Figure 5.1B, 
lanes 12,14).  
These observations correlate well with our HARP DNA binding studies.  
HARP1 mutants retain some DNA binding while HARP2 mutants are deficient in 
DNA binding (54).  Since the HARP2 mutants are also inactive ATPases, it is 
possible that SMARCAL1 ATPase function affects whether or not SMARCAL1 is 
a substrate for DDR kinases.  However, the ATPase-dead mutant R764Q, which 
retains DNA binding activity, shifts similar to WT protein (Figure 5.1B, compare 
lanes 2 and 4).  Importantly, all mutants except %N co-localize with RPA foci at 
stalled replication forks (Figure 5.2).  Together these results suggest that 
SMARCAL1 DDR-regulated phosphorylation is dependent on localization to 
stalled replication forks and subsequent DNA binding. Consistent with our results, 
Postow and colleagues observed an increase in the caffeine-sensitive 
phosphorylation of frog SMARCAL1 when it was bound to DNA (118).  This also 
implies that DDR-dependent regulation of SMARCAL1 is conserved.   
 
Identifying DDR-regulated phosphorylation sites in SMARCAL1 by 
phosphopeptide mapping 
 
Identifying phosphorylation sites in SMARCAL1 is important for 
establishing the functional significance of SMARCAL1 phospho-regulation 
following DNA binding at stalled replication forks.  We initially analyzed 
SMARCAL1 purified from HU-treated cells by mass spectrometry (see Table 6.1 
for results).  We detected phosphorylation on two DDR kinase consensus sites,
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Figure 5.2.  HARP mutants co-localize with stalled replication forks. U2OS 
cells were transfected with pLL5.0-GFP-SMARCAL1 vectors, either WT or 
mutant.  Two days later cells were treated with HU for 5 h, then fixed and stained 
with RPA2 antibodies and DAPI. 
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S173 and S652.  We had no indication from this analysis to what extent 
SMARCAL1 was phosphorylated in response to damage.  Our phospho-shift 
studies suggest that SMARCAL1 is likely phosphorylated on multiple sites since 
the banding pattern on SDS-PAGE gels is complex. 
To better characterize the full extent to which SMARCAL1 is 
phosphorylated after DNA damage, we examined SMARCAL1 phosphopeptides 
obtained from 32P-orthophosphate metabolically labeled cells. Phosphopeptide 
maps of SMARCAL1 show differences in phosphorylation before and after 16hrs 
in HU (Figure 5.3A).  When comparing the no treatment and 16hr HU map, we 
note the appearance of phosphopeptide-a, -d, and-e, along with increases in -b 
and -c.  Phosphopeptide-1 and -2 represent major sites of phosphorylation in 
SMARCAL1 during conditions of normal cell growth.  As discussed below, DDR-
regulated phosphorylation is likely responsible for the change in mobility 
observed for phosphopeptide-1 and -2 (denoted by larger circle) in the HU map.   
Because we are interested in identifying DDR-regulated phosphorylation, 
we determined whether any of the HU-specific phosphopeptides were sensitive 
to DDR kinase inhibition.  Cells were exposed to HU for 16hrs.  DMSO or DDRi 
(a mix of individual specific inhibitors for ATM, ATR, and DNA-PK) was added to 
cells during the 32P metabolic labeling step.  Inhibition of all three DDR kinases 
led to the loss of phosphopeptide-a and -d and somewhat restored the mobility of 
phosphopeptides-1 and -2 (Figure 5.3B). Phosphopeptide-e was not detectable 
in the control so we could not determine the DDR dependence of its 
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Figure 5.3. HU-induced phosphorylation of SMARCAL1 depends on DDR 
kinases.  (A,B) HEK293T cells were treated with HU for 16hr and then 
metabolically labeled in the presence of HU with 32Pi for 30min. SMARCAL1 
immunoprecipitations were prepared, separated by SDS-PAGE, and transferred 
to PVDF membranes.  SMARCAL1 bands incorporating 32P were excised from 
membranes and trypsin-digested to isolate phosphopeptides. Equal counts of 32P 
were spotted on chromatography plates and subjected to two-dimensional thin 
layer chromatography analysis.  (A) Phosphopeptides that change between no 
treatment and 16hr HU treatment are labeled [1,2, a, b, c, d, e].  A change in the 
mobility of 1 and 2 is marked with a red circle.  (B) DMSO or a mixture of kinase 
inhibitors for ATR, ATM, and DNA-PK (DDRi) was added for 30min prior to 
labeling and was present during the labeling for (+HU) and (+HU +DDRi) 
respectively. (x) marks spots on the film caused by condensation and do not 
represent phosphopeptides. 
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phosphorylation. These results demonstrate that the majority of HU-induced 
phosphopeptides that we can detect by mapping depend on DDR kinase activity. 
 
 
Mapping SMARCAL1 mutants to identify DDR-regulated phosphopeptides 
 
We next determined whether phosphopeptide maps of transiently 
expressed GFP-SMARCAL1 protein were similar to endogenous SMARCAL1 
maps.  One concern with transient expression of exogenous protein is that the 
overexpressed protein will not be regulated similarly.  To address this issue, we 
used transfection conditions that resulted in very low levels of GFP-SMARCAL1 
expression. These conditions were optimized for analyzing the phospho-shift of 
GFP-SMARCAL1 mutants (Figure 5.1).  Even though the phospho-shift for GFP-
SMARCAL1 is not as robust as the endogenous protein shift, we observed a 
similar pattern of phosphopeptides in GFP-SMARCAL1 phosphopeptide maps 
indicating the GFP protein is regulated similarly (Figure 5.4).  We assigned the 
same phosphopeptides (1,2; a-d) with exception of phosphopeptide-e that was 
not detectable. We also note the appearance of phosphopeptide-3, which is likely 
related to the mobility change of phosphopeptide-1 and -2 observed in the 
endogenous HU-map.  
Overexpression of SMARCAL1 activates a DNA damage response (58).  
We attribute the increases of phosphopeptide-a, -b, and -c in the untreated GFP-
SMARCAL1 maps to low levels of DDR activation due to SMARCAL1 
overexpression. We observe an increase in these phosphopeptides after HU- 
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Figure 5.4. GFP-SMARCAL1 is regulated similarly to endogenous 
SMARCAL1.  HEK293T cells were transfected with expression vectors (pLL5.0-
GFP-GW backbone for low expression) encoding GFP-tagged wild-type 
SMARCAL1. The day after transfection cells were passaged and HU was added 
for 16hrs. Cells were metabolically labeled and peptides processed as in (Figure 
5.3). GFP-SMARCAL1 was purified using SMARCAL1 antibodies. Samples were 
separate on a lower percentage SDS-PAGE to resolve the GFP-SMARCAL1 
band from the endogenous SMARCAL1 band. GFP-SMARCAL1 bands were 
excised instead of endogenous SMARCAL1.  DDR-regulated phosphopeptides 
are marked [1-3, a-d]. 
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treatment indicating that more molecules of SMARCAL1 are phosphorylated at 
these sites following robust activation of the DDR.  Similar to the endogenous HU 
map, phosphopeptide-d appears following HU treatment.  The altered mobility of 
GFP-SMARCAL1 phosphopeptide-1 and -2 is less drastic following HU.  Instead, 
we observe the appearance of phosphopeptide-3 in the GFP-SMARCAL1 HU 
map. The interpretation of this phosphopeptide pattern is discussed below.   
Since we were able to identify DDR-induced phosphopeptides in GFP-
SMARCAL1, we used GFP-SMARCAL1 phospho-mutants to elucidate the 
identity of specific phosphorylation sites.  SMARCAL1 contains 10 S/TQ DDR 
kinase consensus sites.  Initially, we mutated 6 of these sites (S115, S173, S350, 
S652, T742, S919) to alanine.  The phospho-shift of this 6A mutant is 
considerably reduced compared to WT (Figure 5.5A). This mutant retains the 
ability to localize to stalled forks, so the 6 alanine mutations do not affect RPA 
binding (Figure 5.5B). Consistent with the reduction in phosphorylation by 
phospho-shift analysis, the 6A phosphopeptide map reveals loss of the most 
abundant DDR-regulated phosphopeptides. Phosphopeptide-3 and -d are absent 
along with substantial decreases in -b and -c (Figure 5.6A, compare panels 1 and 
2). To determine the identity of phosphopeptide-3, -b, -c, and -d we analyzed 
single mutants for each site in the 6A mutant. A single S173A mutant resulted in 
the loss of phosphopeptide-d and the decrease in -b, and -c (Figure 5.6A, panel 
3). Phosphopeptide-3 was absent in the S919A map (Figure 5.6A, panel 4). 
S115A, S350A, T742A, and S652A maps showed no detectable changes in 
phosphopeptides compared to WT (Figure 5.6B and C).
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Figure 5.5.  A 6A phospho-mutant reduces SMARCAL1 phosphorylation but 
does not affect localization to stalled forks.  (A) HEK293T cells were 
transfected with pLL5.0-GFP-WT or 6A mutants and analyzed for phosphoshift 
after 16hr in 2mM HU. (B) U2OS cells were transfected with the same expression 
vectors. Two days later, cells were treated with HU for 5 h, then fixed and stained 
with RPA2 antibodies and DAPI.     
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Figure 5.6.  S173 and S919 are major DDR-regulated phosphorylation sites 
in SMARCAL1. All maps were prepared as in Figure 5.4 from cells treated with 
HU for 16hrs. DDR-regulated peptides are marked. 
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S173 is a major site of DDR-regulated phosphorylation 
We further investigated why the S173A mutant affected three 
phosphopeptides. Trypsin cleavage occurs at specific sites in a peptide 
sequence, preferentially at Arg and Lys that are not followed by Pro. Using the 
ExPASy peptide cutter tool we generated a list of SMARCAL1 tryptic peptides.  
The S173 peptide generated by this tool (Figure 5.7A, peptide (ii)) has the 
potential to be inefficiently cleaved. Phosphorylation near trypsin cleavage sites 
has been demonstrated to reduce the efficiency of cleavage (Benore-Parsons 
1989). Additionally, trypsin cleavage is inefficient at Arg followed by Asp. Based 
on these characteristics of trypsin cleavage and the sequence surrounding tryptic 
peptide (ii), two additional phosphopeptides containing S173 could result from 
inefficient trypsin cleavages at the N- and C-terminal ends (Figure 5.7A, peptide 
(i) and (iii)).  These peptides vary in size, charge, and hydrophobicity and would 
have distinct mobilities in both dimensions of separation. Although we can 
speculate on which products correlate with phosphopeptide-b, -c, and -d, the 
important observation is that S173 is present in each phosphopeptide and 
represents the major site of DDR-regulated phosphorylation.  
In our mass spectrometry investigations it was unclear whether S172 or 
S173 was the phosphorylated residue. We did identify a peptide that was clearly 
phosphorylated at S173, but did not rule out the possibility that S172 could be 
phosphorylated as well. Additionally, a phosphopeptide containing both S172 and 
S181 phosphorylations was identified among 494 other unique phosphopeptides 
in a massive mass spectrometry study that profiled phosphorylation events in 
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Figure 5.7.  Phosphopeptide-b,-c, and -d are tryptic products of a S173-
containing phosphopeptide.  (A) Possible tryptic cleavage products 
surrounding the S173 peptide. Serines in red denote sites of phosphorylation 
(S172, S173, and S181 from left to right). (i) Phosphorylation of S172 or S173 
may cause inefficient cleavage at the K in bold. This cleavage product adds a 
number of hydrophobic residues (underlined). (ii) Represents the fully cleaved 
tryptic product. (iii) Inefficient cleavage can occur at Rs followed by D. (B) Maps 
were prepared as in Figure 5.4 from cells treated with HU for 16hrs. 
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human skin fibroblasts (119). An alternative interpretation of the S173A mutant 
map is that S173 is required for DDR-regulated phosphorylation of S172. The 
loss of phosphopeptide signal could bedue to loss of S172 phosphorylation 
instead of S173 directly.  To address this discrepancy, we mapped the S172A 
mutant. The S172A map exhibits some reduction in phosphopeptide-b and -c 
signal compared to WT, but overall does not appreciably inhibit S173 
phosphopeptides (Figure 5.7B).  We conclude that phosphorylation of S173 
accounts for the majority of the damage-inducibility of phosphopeptide-b, -c, and 
-d. 
 
The S919 peptide is phosphorylated at a minimum of three sites 
Our map of the S919A mutant revealed that phosphopeptide-3 contains 
phosphorylated S919 (Figure 5.6A, panel 4).  S919 is located on a large tryptic 
peptide containing 14 potential sites of phosphorylation (Figure 5.8A).  Peptides 
migrate in the electrophoresis step according to size and charge.  
Phosphopeptide-1, -2, and -3 migrate very little from the origin in the horizontal 
direction suggesting these peptides are large and negatively charged.  Also, the 
mobility pattern of phosphopeptides 1-3 resembles the diagonal pattern 
associated with a single peptide containing multiple phosphorylation states (120).  
In the organic chromatography buffer, peptides migrate further based on 
hydrophobicity. The addition of phosphate (decreasing hydrophobicity) retards 
the mobility of phosphopeptides in the chromatography dimension, resulting in a 
downward diagonal with increasing phosphates.  We therefore assigned 
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Figure 5.8.  Phosphopeptides 1-3 represent different phosphorylation 
states of a single peptide. (A) Tryptic peptide containing S919 (underlined). 
Amino acids in red represent possible sites of phosphorylation. (B) Images are 
cropped from maps of GFP-WT protein, purified from either untreated cells (NT) 
or HU treated cells (HU).  +1, +2, +3 mark the addition of phosphates on a single 
peptide.  The addition of phosphates retards the mobility of the peptide as 
indicated by the arrow. Peptides move in the electrophoresis phase based on 
size and charge, more positively charged peptides moving farther right.  Peptides 
move up in the chromatography phase based on hydrophobicity.  
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phosphopeptide -1, -2, and -3 as +1, +2, and +3 phosphates on a single peptide 
respectively (Figure 5.8B).  The appearance of phosphopeptide-3 reflects the 
damage-induced phosphorylation of S919 on phosphopeptide-2. Further 
mutational analysis is required to determine what additional sites are 
phosphorylated in this large peptide.  We speculate that these peptides likely 
contain DNA-damage independent phosphorylation sites since phosphopeptide-1 
and -2 are dominant in the endogenous map of SMARCAL purified from 
untreated cells (Figure 5.3A). 
 
A phospho-specific antibody identifies S652 as a DDR-regulated phosphorylation 
site 
 
We identified S652 phosphorylation by mass spectrometry. However, we 
were not able to detect loss of any phosphopeptides in S652A phosphopeptide 
maps (Figure 5.6C). To characterize phosphorylation of S652 further, we 
generated a phospho-specific antibody to a peptide phosphorylated at S652.    
The pS652 antibody recognizes FLAG-SMARCAL1 on immunoblots following 
immunoprecipitation (Figure 5.9).  The antibody most strongly recognizes WT 
protein purified from cells treated with HU (Figure 5.9A, lane 5), and the HU-
induced signal is phosphatase sensitive.  The detection of WT protein purified 
from untreated cells and of S652A protein purified from HU treated cells is 
relatively similar (compare lanes 1 and 3).  This suggests that the antibody 
weakly detects a non-pS652 epitope in addition to pS652.  The recognition of this 
epitope is partly sensitive to phosphatase but does not change in response to 
DNA damage.  Although this antibody is not entirely specific to pS652, we were 
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Figure 5.9. A phospho-specific S652 antibody detects DDRi-sensitive 
increases in S652 phosphorylation in response to HU. HEK293T cells were 
transfected with FLAG expression vectors containing WT or S652A SMARCAL1. 
FLAG immuno-preciptations using FLAG-beads were prepared, separated by 
SDS-PAGE, and transferred to membranes for immunoblotting with pS652 and 
FLAG antibodies. (A) Following FLAG purifications, beads were incubated in the 
presence of l-phosphatase to remove phosphates for 30min before separating by 
SDS-PAGE. (B) Cells were treated with HU for 6hrs with the addition of either 
DMSO (HU), ATR inhibitor (ATRi, vertex, 5!M), or DDRi. Intensity of pS652 and 
FLAG signal were determined by Odyssey quantitation and relative pS652 
intensity was calculated by normalizing the pS652 intensity according to protein 
levels for each sample, i.e. FLAG intensity. The corrected pS652 intensity was 
then used to calculate the pS652 intensity relative to the NT sample.  
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confident that the bulk of signal detected in SMARCAL1 following HU is due to 
phosphorylation at S652. We next determined whether S652 phosphorylation 
depends on DDR kinases.  Using the ATR inhibitor (ATRi) was not sufficient to 
reduce pS652 in SMARCAL1 purified from HU-treated cells (Figure 5.9B).  
However, inhibition of all three kinases with DDRi completely reduced pS652 to 
untreated levels. Thus, S652 is another DDR-regulated phosphorylation site in 
SMARCAL1.   
 
 
A S652 phospho-mimetic mutant has decreased ATPase activity 
From our mass spectrometry and phosphopeptide mapping studies, we 
conclude that the majority of SMARCAL1 DDR-regulated phosphorylation occurs 
at 3-SQ consensus sites: S173, S652, and S919.  To determine the functional 
consequences of phosphorylation at these sites we generated mutants that 
mimicked constitutive phosphorylation (S to D) to analyze alongside of the (S to 
A) mutants we used in our mapping experiments.  We first confirmed that all 
phosphorylation mutants localize to stalled replication forks (Figure 5.10).  All 
mutants are capable of co-localizing with RPA at stalled replication forks.  
High levels of SMARCAL1 cause replication-associated DNA damage 
response activation, primarily in the form of pan-nuclear H2AX phosphorylation 
(pan-$H2AX).  Both RPA binding and enzymatic activities of SMARCAL are 
required to efficiently induce pan-$H2AX (58).  The negative effects of 
SMARCAL1 overexpression suggest that regulating SMARCAL1 activity at 
replication forks is necessary for genome maintenance. Left unchecked, 
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Figure 5.10.  Phospho-mutants localize to stalled replication forks. U2OS 
cells were transfected with pLL5.0-GFP-SMARCAL1 vectors, either WT or 
mutant.  Two days later cells were treated with HU for 5 h, then fixed and stained 
with RPA2 antibodies and DAPI. 
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SMARCAL1 annealing activity could potentially reverse every active replication 
fork.  Since we determined that the phospho-mutants do not affect RPA-
dependent localization, we hypothesized that another possible function of DDR-
regulated phosphorylation could be to limit SMARCAL1 enzymatic activity at 
stalled replication forks. We purified phospho-mutants from cells and tested the 
fork-stimulated ATPase activity of each (Figure 5.11).  S173A/D and S919A/D 
mutants hydrolyzed ATP similar to WT (Figure 5.11A and B).  However, the 
S652D mutant exhibited a significant decrease in fork-stimulated ATPase activity 
(Figure 5.11C). The S652A mutant retained WT activity suggesting that the 
serine itself is not critical for ATP hydrolysis.  
The fork-stimulated ATPase assay measures the ability of SMARCAL1 to 
bind a simple forked-DNA molecule and hydrolyze ATP.  In cells, the substrate at 
a stalled replication fork is more complex and any remodeling that SMARCAL1 
promotes would require removing other DNA-binding proteins at the fork.  Thus, 
remodeling replication forks in cells likely requires more efficient enzymatic 
activity than would be required in vitro.  The pan-$H2AX caused by SMARCAL1 
overexpression reflects high levels of SMARCAL1 annealing helicase activity at 
replication forks. We reasoned that we could measure the activity of phospho-
mutants in cells by determining the efficiency of pan-$H2AX induction.  If S652 is 
important for regulating SMARCAL1 activity at replication forks we expect that a 
constitutively limited SMARCAL1 (i.e. S652D) will also be limited in causing pan-
$H2AX when overexpressed.  
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Figure 5.11.  The S652D mutant has decreased ATPase activity in vitro. 
Protein was purified from HEK293T cells that were transiently overexpressing 
FLAG-SMARCAL1. ATPase activity of the WT and phospho-mutants was 
measured in the presence of the indicated concentrations of fork DNA.  Error 
bars are standard deviation (n=3). Quantification of FLAG-SMARCAL1 by WB 
represents an average of protein input across replicates. (C) (***) P values for 
1.25nM DNA and 5nM DNA were P<0.0001 and P=0.0002 respectively. Two-
tailed unpaired t-test. 
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We developed our previous qualitative overexpression assay (used in 
Figure 4.9) to be highly quantitative using the Opera Imaging platform and 
Columbus software.  SMARCAL1 expression levels largely determine the 
phenotype in this assay. Our new methodology allows us to compare hundreds 
of individual nuclei across all samples based on their GFP-SMARCAL1 
intensities. To determine percent DDR activation, we first defined an upper and 
lower cutoff for GFP-SMARCAL1 intensity.  The R764Q mutant can activate the 
DDR but requires much higher levels than WT. Before analyzing the entire data 
set, we sorted nuclei from WT and R764Q control samples based on $H2AX 
intensity and determined the average GFP intensities for nuclei that had DDR 
activation ($H2AX intensity >1000) (Figure 5.12A).  This initial analysis 
demonstrates that the average GFP-R764Q expression levels required for DDR 
activation are higher than for GFP-WT.  Additionally, there were not considerable 
differences in the number of nuclei imaged, so the decreased number of nuclei 
observed is a consequence of R764Q decreased activity. We set the upper GFP 
intensity limit at the average intensity for GFP-WT cells with DDR activation.    
For this analysis we analyzed nuclei with GFP intensities between 500 
and 2500. Percent DDR activation is calculated from the percent of these nuclei 
with pan-nuclear $H2AX.  When we apply these cutoffs across all samples, we 
observe significant decreases in the abilities of the R764Q mutant and S652D 
mutant to induce DDR activation (Figure 5.12B).  Similar to our in vitro results, 
the S652D mutant retains some enzymatic activity but exhibits reduced activity 
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Figure 5.12. A quantitative assay for DDR activation following SMARCAL1 
over-expression demonstrates that the S652D mutant is less active in cells. 
U2OS were transfected with high expressing GFP-SMARCAL1 vectors. Cells 
were plated into 96-well plates for imaging by the Opera, 3 wells per sample.  
48hrs after transfection cells were fixed and stained for $H2AX and appropriate 
secondary. DAPI was added for detecting nuclei. 12 subfields were analyzed per 
well. Images collected were analyzed for mean $H2AX intensity and mean GFP 
intensity per nuclei by the Columbus analysis software. (A) The GFP intensities 
for individual nuclei (n=49 and n=29) that had mean $H2AX intensities greater 
than 1000. Data is from one well and was used to set a GFP cutoff. Bar 
represents average intensity. (B) Percent pan-$H2AX for S652 phospho-mutants 
using the cutoff defined in (A). (***) P=0.0007. (*) P=0.0231. Two-tailed unpaired 
t-test. 
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when compared to WT.  Again, the S652A mutant does not exhibit any significant 
differences in activity.  
 
 
Endogenous SMARCAL1 purified from HU-treated cells is less active 
 
Our S652 mutant studies suggest that DDR-regulated phosphorylation 
may be a mechanism for limiting SMARCAL1 enzymatic activity at replication 
forks. To test whether phosphorylated SMARCAL1 is indeed less active, we 
purified endogenous SMARCAL1 from untreated cells or cells treated with HU for 
16 hours and measured its ATPase activity.  We selected a dose and time for HU 
treatment in which we observed 100% of SMARCAL1 in the shifted form (Figure 
5.1A). We found that SMARCAL1 purified from HU treated cells is less active, 
exhibiting nearly a two-fold decrease in ATPase activity (Figure 5.13).  This 
indicates that SMARCAL1 is less active following long exposures to replication 
stress.  Although the role of phosphorylation in this observation is circumstantial, 
our evidence for S652 phosphorylation suggests that this decrease in activity is 
mostly due to the DDR-dependent phosphorylation of S652.   
 
 
Discussion 
 
 
 
We set out to identify DDR-regulated phosphorylation sites in SMARCAL1 
and found that the majority of DDR-dependent phosphorylation events occur at 
S173, S652, and S919. The identities of two additional DDR-regulated 
phosphopeptides have yet to be determined.  Importantly, we discovered that 
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Figure 5.13. Endogenous SMARCAL1 purified from HU-treated cells 
exhibits decreased ATPase activity. Endogenous SMARCAL1 was purified 
from HEK293T cells that were untreated (NT) or treated with HU for 16hrs.  
ATPase activity of SMARCAL1 from NT and HU conditions was measured in the 
presence of 5nM fork DNA.  Error bars are standard deviation (n=3). 
Quantification of SMARCAL1 by WB represents an average of protein input 
across replicates. Purified protein for WB was treated with phosphatase before 
input to collapse the shifted band for more accurate quantification (***) P=0.0007. 
Two-tailed unpaired t-test. 
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DDR-regulated phosphorylation has functional consequences. Evidence from a 
SMARCAL1 mutant mimicking constitutive phosphorylation at S652 suggests 
that S652 may be targeted by DDR kinases to limit SMARCAL1 enzymatic 
activity at stalled forks.  
 
Unidentified phosphopeptides 
The 6A phospho-mutant led to the identification of two major DDR 
regulated phosphorylation sites in SMARCAL1.  We failed to identify 
phosphopeptide-a, which decreased after cells were treated with DDR kinase 
inhibitors and was detectable in GFP-SMARCAL1 maps (Figure 5.3B and 5.4).   
To determine whether phosphopeptide-a contained one of the remaining 4 S/TQs 
in SMARCAL1, we generated and mapped single mutants for each (S55A, 
S236A, S407A, T592A). However, none of these mutations led to the 
disappearance of any additional phosphopeptides (Figure 5.14). 
Phosphopeptide-a may be phosphorylated by DDR kinases at a non-consensus 
serine or threonine.  Alternatively, it contains a site that is phosphorylated by 
another kinase whose activity is dependent on DDR kinase activity.  
Phosphopeptide-e was an HU-induced peptide not detectable in the GFP-
SMARCAL1 maps (Figure 5.4).  We identified S652 phosphorylation by mass 
spectrometry and confirmed it as a DDR-regulated site using a pS652 antibody.  
However, we were not able to detect loss of any phosphopeptides in S652A 
phosphopeptide maps (Figure 5.6C). It is possible that phosphopetide-e is a 
peptide containing p-S652. To validate the identity of phosphopeptide-e, we have 
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Figure 5.14. Mutating the 4 remaining S/TQ sites in SMARCAL1 does not 
affect DDR-regulated phosphopeptides.  Maps were prepared as in Figure 5.4. 
from cells treated with HU for 16hrs. 
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synthesized the tryptic peptide and plan to phosphorylate it in vitro with DDR 
kinases in the presence of gamma-32P-ATP. Phosphorylated S652 peptides will 
be spotted on plates with SMARCAL1 phosphopeptides purified from HU-treated 
cells to determine if the two phosphopeptides overlap.   
 
A model for limiting SMARCAL1 activity at stalled replication forks. 
  S652 resides in a highly conserved hinge domain located between the 
ATPase_N and ATPase_C domains of SMARCAL1 (Figure 5.15A). Based on a 
crystal structure of the SNF2 protein SsoRad54 bound to DNA, these domains 
likely undergo rotational changes that position them in a conformation required 
for ATP binding and hydrolysis (121-123). This conformational change involves a 
180° rotation of the ATPase_C domain to reposition necessary active site motifs 
from an “open-” inactive orientation, to a “closed-” active orientation (Figure 
5.15B). Nucleotide binding is thought to initiate the switch from open to closed 
(124). The hinge domain likely provides flexibility for the conformational change 
that occurs between the ATPase_N and ATPase_C domains.  In support of this 
model, a mutation in the hinge of the yeast SNF2 protein Mot1 abolishes ATPase 
activity (122).  The authors propose that this mutation impairs the flexibility of the 
linker and inhibits the transition from the open to closed conformation. We 
hypothesize that alterations affecting flexibility of the hinge domain result in loss 
of SMARCAL1 enzymatic functions.  Thus, phosphorylation of S652 has the 
potential to disrupt critical structural components of the enzymatic core and 
render SMARCAL1 a less active enzyme.   
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Figure 5.15. A conserved hinge domain in SMARCAL1 and other SNF2 
family members provides the flexibility for rotation of ATPase_N and 
ATPase_C domains.  (A) A hinge domain is located between the ATPase_N 
and ATPase_C domains and is highly conserved in various species of 
SMARCAL1. The hinge domain of yMot1 is almost identical to SMARCAL1. 
Arrow marks the site of the R1507K mutation in yMot1 that abolishes ATPase 
activity. (B) Model for the conformational change that positions active site motifs 
(light blue spheres) to the closed-active state. Arrow shows direction of 180° 
rotation (adapted from (122)). 
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Figure 5.16. A model for limiting SMARCAL1 activity at stalled replication 
forks. 1. In the presence of replication stress, SMARCAL1 accumulates at 
stalled replication forks via its N-terminal RPA binding domain (RBD).  (2) 
Localization to forks concentrates SMARCAL1 near its DNA substrates and 
subsequently SMARCAL1 binds the fork DNA.  (3) DNA binding promotes ATP 
binding and transition from the open-inactive state to the closed-active state. ATP 
hydrolysis drives SMARCAL1 translocation on the DNA to reanneal the parental 
strands, displacing RPA. The conformational change exposes S652 to DDR 
kinases like ATR, which is activated by stalled replication forks.  Phosphorylation 
of S652 in the hinge domain hinders ATPase domain flexibility thereby inhibiting 
the next enzymatic cycle of ATP binding and hydrolysis.  Presumably this 
inactivated molecule dissociates and a new molecule of SMARCAL1 can bind. 
This mechanism provides the opportunity for SMARCAL1 to catalyze necessary 
fork remodeling activities, but with limited processivity.  
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We propose the following model for how DDR-dependent phosphorylation 
of S652 regulates SMARCAL1 activities (Figure 5.16).  In the presence of 
replication stress, SMARCAL1 accumulates at stalled replication forks via an 
interaction with RPA.  Localization to forks concentrates SMARCAL1 near its 
DNA substrates and subsequently SMARCAL1 binds DNA.  DNA binding 
promotes ATP binding and transition from the open-inactive state to the closed-
active state. This conformational change facilitated by the SMARCAL1 hinge 
domain exposes S652 to DDR kinases like ATR, which is activated by stalled 
replication forks.  Phosphorylation of S652 in the hinge domain hinders ATPase 
domain flexibility thereby inhibiting the next enzymatic cycle of ATP binding and 
hydrolysis.  This mechanism provides the opportunity for SMARCAL1 to catalyze 
necessary fork remodeling activities, but with limited processivity.  
Other enzymes function to remodel replication forks. For example, WRN 
and BLM are DNA helicases required for fork restart following replication stress 
(36,37).  WRN and BLM are also substrates for DDR kinases (125-127).  The 
DDR-dependent phosphorylation of replication fork remodeling enzymes may 
serve to coordinate the cooperation of these enzymes at forks.  The fork 
remodeling that promotes fork restart requires unwinding and rewinding of DNA 
at multiple steps.  Little is know about the exchange of these factors on their DNA 
substrates in cells. Our studies of SMARCAL1 phospho-regulation indicate that 
phosphorylation could be a mechanism to regulate their processivity and 
influence their residence times on fork substrates. Characterizing the functional 
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significance of DDR-dependent phosphorylation events on fork remodeling 
enzymes is critical for understanding the dynamics of fork stabilization and restart.  
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Chapter VI 
 
PHOSPHORYLATION REGULATES AN AUTO-INHIBITORY DOMAIN IN 
SMARCAL1 
 
Introduction 
 
SMARCAL1 is phosphorylated at multiple sites during normal and 
replication-stressed conditions.  We identified a total of 7 sites as phospho-sites 
by mass spectrometry (Table 6.1).  The SMARCAL1 sample used for this study 
was purified from cells after 16 hours in HU with the intention of identifying sites 
that contributed to the DDR-dependent regulation of SMARCAL1. Indeed, we 
identified S173 and S652 and determined that they are both phosphorylated by 
DDR kinases following replication stress (Chapter V).  We also identified a 
cluster of SP sites in the N-terminus of SMARCAL1 (S112, S123, S129, and 
S198).  SP is a consensus for cyclin dependent kinases, which are activated cell 
cycle dependent manner (128). We aligned the protein sequences of this region 
between the RPA binding domain and the first HARP domain of human, mouse, 
xenopus, and zebrafish SMARCAL1 to determine the conservation of these sites 
(Figure 6.1A). We find there is little sequence conservation, but there are number 
of SP sites in this region in all species.  The cluster of phosphorylation sites in 
this region may have potential to regulate cell cycle specific activities of 
SMARCAL1.
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Table 6.1. Sites identified by mass spectrometry 
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Figure 6.1. Conservation of SMARCAL1 phospho-sites.  Alignments of 
human, mouse, xenopus and zebrafish SMARCAL1 were performed using 
ClustalW.  (A) Alignment for the N terminus of SMARCAL1 spanning aa96-223. 
Arrows indicate S112, S123, S129, S173, and S198. (B) Alignment for the C-
terminus of SMARCAL1 spanning aa858-952. Arrow indicates S889. 
 
 
 
S112 S123 S129 
S173 
S198 
S889 
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We also identified S889.  The SMARCAL1 C-terminus is more conserved 
than the N-terminal region defined above. Likewise, we find that S889 is well 
conserved across SMARCAL1 species (Figure 6.1B). Because of its strong 
conservation, we expected that this site might have a conserved function in 
regulating SMARCAL1 activities.  We initially investigated S889 phosphorylation 
to determine its contribution to DDR-dependent regulation of SMARCAL1.  
Instead, we discovered that S889 phosphorylation regulates an auto-inhibitory 
domain in the C-terminus. Our results indicate that phosphorylation of S889 is 
critical for priming SMARCAL1 activation at stalled replication forks.  
 
Results 
 
S889 phosphorylation regulates SMARCAL1 enzymatic activity 
 S889 is located C-terminal to the core enzymatic domain of SMARCAL1.  
A fragment of SMARCAL1 consisting of amino acids 317-870 is a functional 
annealing helicase in vitro (54).  Therefore, we did not expect S889 to be 
required for SMARCAL1 enzymatic activities. We purified FLAG-SMARCAL1 
phospho-mutants (S889A and S889D) from cells and tested whether these 
mutants retained fork-stimulated ATPase activity. Surprisingly, the S889A mutant 
is significantly less active than WT at both concentrations of fork DNA tested 
(Figure 6.2A).  The opposite effect was observed for the phospho-mimetic mutant.  
S889D activity was significantly higher than WT when stimulated by 1.25nM fork-
DNA. To further confirm our results, we measured ATP hydrolysis at various
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Figure 6.2. S889 mutants have altered ATPase activity. Protein was purified 
from HEK293T cells that were transiently overexpressing FLAG-SMARCAL1. (A) 
ATPase activity of the WT and phospho-mutants was measured in the presence 
of the indicated concentrations of fork DNA.  (B) ATPase activity was measured 
at the indicated concentrations of FLAG-SMARCAL1 in the presence of 1.25nM 
fork DNA. Error bars are standard deviation (n=3). Quantification of FLAG-
SMARCAL1 by WB represents an average of protein input across replicates. For 
(A), (*)P=0.0186, (**)P=0.0018, (***)P=0.0003. For (B), (**)P=0.0031, 
(***)P<0.0001. Two-tailed unpaired t-test calculated between WT and mutant in 
each condition. 
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concentrations of SMARCAL1 in the presence of 1.25nM fork DNA.  At very low 
concentrations the S889D mutant was still able to hydrolyze more ATP than WT 
(Figure 6.2B).  This trend was true for all SMARCAL1 concentrations tested.  The 
S889A mutant was consistently less active.  
 We next asked whether this change in activity in vitro translated into a 
change in activity in cells.  We first confirmed that mutating S889 does not 
compromise localization to stalled replication forks. Both mutants co-localize with 
$H2AX foci after HU treatment (Figure 6.3A).  We then measured the ability of 
S889A and S889D to activate a DDR when overexpressed.  Using the 
quantitative assay described in Chapter 5 (Figure 5.12), we determined that in 
cells the activity of the S889A mutant resembles the ATPase-dead mutant 
R764Q (Figure 6.3B). And consistent with in vitro observations, the S889D was 
overactive compared to WT.  
 
Phosphorylation of S889 affects DDR-dependent phosphorylation 
 In the course of studying S889 mutants, we noticed that the S889D mutant 
usually migrates as two bands on SDS-PAGE gels (Figure 6.2).  Since S889D is 
an overactive form of SMARCAL1 and activates a DDR more readily than WT 
when overexpressed, we reasoned that this shifted form could be due to DDR-
regulated phosphorylation.  To confirm that this shift was due to phosphorylation 
we purified protein from cells overexpressing FLAG-SMARCAL1 and treated it 
with phosphatase.  The phosphatase treatment collapsed S889D into a single 
band (Figure 6.4A).  Due to high expression levels, we observed a mild shift of
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Figure 6.3.  S889 phosphorylation is required for SMARCAL1 activity in 
cells. (A) U2OS cells were transfected with lower expressing pLL5.0-GFP-
SMARCAL1 vectors. The day after transfection cells were seeded onto 
coverslips. The next day cells were treated with HU for 5 h, then fixed and 
stained with $H2AX antibodies and mounted on slides with ProLongGold +DAPI. 
(B) Higher expressing pLEGFP-SMARCAL1 vectors were transfected into U2OS. 
The day after transfection, cells were seeded into 96 well plates. The next day 
cells were fixed in 96 well plates and stained with $H2AX antibodies and DAPI.  
Cells were imaged using the Opera and individual nuclei were measured for 
mean GFP intensity and mean $H2AX intensity using the Columbus analysis 
software. Data represents the percent of cells (500<GFP<2500) with mean 
$H2AX >1000.  Error bars are standard deviation (n=7 wells, 3 biological 
replicates). (***) P=0.008. (**)P =0.0027; (*)P =0.0409. Two-tailed unpaired t-test 
calculated between WT and mutant.  
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WT protein that was also reduced by phosphatase treatment.  This further 
supports that a mutant mimicking constitutive phosphorylation of S889 is 
hyperactive.  
When we transfect lower expressing vectors of GFP-SMARCAL1 we 
generally observe a phospho-shift only in HU-treated cells.  In these conditions, 
we see a striking difference in the shift pattern of WT and S889D proteins.  The 
S889D mutant is super-shifted even in the untreated samples (Figure 6.4B).  The 
phospho-shift increases with the addition of HU.  This may indicate that the 
S889D is not only more active, but is also a better substrate for phosphorylation 
by DDR kinases. Importantly, we observe the opposite effect for S889A. We 
reproducibly observe a reduced shift of the S889A protein; however, it shifts 
slightly more than the %N mutant indicating DDR phosphorylation is not 
completely abrogated. This distinguishes the S889A mutant from the R764Q 
mutant, which is also inactive but phospho-shifts similar to WT.   
 
 
Phosphorylation of S889 regulates an auto-inhibitory domain in the C-terminus of 
SMARCAL1  
 
The S889A mutant exhibits reduced activity compared to WT in all assays 
tested thus far.  The phospho-shift result suggests that S889A more closely 
resembles a DNA binding mutant. However, S889 is not located in a region of 
SMARCAL1 that would obviously contact DNA and promote enzymatic function. 
If S889 did participate in some step of catalysis we would expect a truncation of 
resembles a DNA binding mutant. However, S889 is not located in a region
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Figure 6.4. S889D mutant is hyper-phosphorylated. Samples were prepared, 
separated by SDS-PAGE, transferred to nitrocellulose and immunoblotted with 
SMARCAL1 antibodies.  (A) FLAG-SMARCAL1 was overexpressed in HEK293T 
cells and purified from cell lysates.  Following immunopurification, protein was 
incubated in the presence of '-phosphatase 1X buffer (-/+) enzyme for 45min at 
30°C. (B) HEK293T cells were transfected with the lower expressing pLL5.0-
GFP-SMARCAL1 and treated two days later with 2mM HU for 16hrs.  
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of SMARCAL1 that would obviously contact DNA and promote enzymatic 
function. If S889 did participate in some step of catalysis we would expect a 
truncation of the C-terminal portion containing S889 to result in decreased 
activity as well.  We generated a C-terminal truncation mutant that removed 
amino acids 861-954 (%C). This region is not essential for SMARCAL1 annealing 
helicase activity, but we wanted to confirm the activity of a %C mutant alongside 
S889 mutants in the ATPase assay.  We repeated the fork-stimulated ATPase 
assay with all mutants.  The %C mutant shows increased activity similar to the 
S889D mutant (Figure 6.5A).  Remarkably, removing the C-terminus containing 
S889 has the same affect on ATPase activity as mimicking phosphorylation at 
S889.  
When we analyzed the localization of the %C mutant in cells, we found that 
the majority of the protein is cytoplasmic.  Since we use protein purified from 
human cells in our ATPase assays we wanted to confirm that localization of the 
%C mutant did not impact our result.  We added an NLS and confirmed that this 
protein localizes to the nucleus (NLS-%C).  We then compared the activities of 
the %C and NLS-%C mutant.  When localized properly a %C mutant is still 
significantly more active than WT protein (Figure 6.5D). We also note that the 
NLS-%C mutant exhibits a slight phospho-shift compared to %C.  This further 
supports that the NLS-%C localizes properly and causes DDR activation similar to 
S889D. The %C data confirms that S889 is not directly involved in the enzymatic 
functions of SMARCAL1. Furthermore, it indicates that the C-terminus contains
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Figure 6.5. The C-terminus of SMARCAL1 contains an auto-inhibitory 
domain.  (A,D) Protein was purified from HEK293T cells that were transiently 
overexpressing FLAG-SMARCAL1. ATPase activity was measured in the 
presence of 1.25nM fork DNA. (A) R764Q was not included in all replicates so 
data is not shown. (B,C) U2OS cells were transfected with lower expressing 
pLL5.0-GFP SMARCAL1 vectors. The day after transfection cells were seeded 
onto coverslips. The next day cells were treated with HU for 5 h, then fixed and 
stained with $H2AX antibodies and mounted on slides with ProLongGold +DAPI 
Error bars are standard deviation (n=3). Quantification of FLAG-SMARCAL1 by 
WB represents an average of protein input across replicates. For (A) 
(***)P=0.0005, (**)P=0.0049, (*)P=0.031. For (D), (*) p=0.043; (**) p=0.0031. All 
two-tailed unpaired t-test comparing WT and mutants. 
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an auto-inhibitory domain that must be relieved for SMARCAL1 to function 
efficiently.  
 
S889 is phosphorylated in undamaged cells 
We mapped phosphopeptides of the S889A mutant to identify the pS889 
peptide and determine whether it changed after HU. We were able to detect the 
loss of phosphopeptide-f in S889A maps (Figure 6.6). Phosphopeptide-f 
consistently migrated underneath an unknown phosphopeptide (marked with an 
asterisk) and above the S173 phosphopeptide-b.  Because of the HU-induced 
streak pattern of phosphopeptide-b we were unable to determine conclusively if 
the pS889 peptide changed in response to HU. 
In order to characterize the regulation of S889 phosphorylation, we 
generated a phospho-specific antibody to a pS889 peptide.  We determined that 
this antibody recognized WT protein purified from untreated cells (Figure 6.7A). 
The antibody had some affinity for S889D, but did not recognize the S889A 
mutant. The detection of WT protein was also phosphatase sensitive (Figure 
6.7B).  We conclude that this antibody specifically recognizes phosphorylated 
S889 in SMARCAL1. The pS889 antibody was then used to determine whether 
S889 phosphorylation was induced following replication stress. Although this 
evidence is still preliminary, we found that the pS889 antibody signal is reduced 
when FLAG-SMARCAL1 is purified from cells treated with HU (Figure 6.7C). 
These data suggest that SMARCAL1 is phosphorylated at S889 during normal 
conditions and then removed during times of replication stress.   
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Figure 6.6.  Phosphopeptide mapping of the S889A mutant identifies a 
pS889 containing peptide. HEK293T cells were transfected with expression 
vectors (pLL5.0-GFP-GW backbone for low expression) encoding GFP-tagged 
WT and S889A SMARCAL1. The day after transfection cells were passaged and 
HU was added for 16hrs where indicated. Cells were metabolically labeled and 
peptides processed as in (Figure 5.4). Phosphopeptide-f reproducibly migrates 
above the S173 phosphopeptide-b and below the unknown phosphopeptide 
marked with an asterisk.   
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Figure 6.7. S889 is phosphorylated in undamaged cells.  (A,B) HEK293T 
cells were transfected with FLAG-SMARCAL1 vectors and two days later protein 
was purified from cell lysates.  After FLAG-purification, protein was eluted from 
FLAG antibodies with FLAG peptide (300µg/mL). (B) Eluted protein was 
incubated with l-phosphatase buffer (-/+) enzyme for 45min at 30°C. Samples 
were separated by SDS-PAGE, transferred to nitrocellulose and immunoblotted 
with pS889. Where indicated (FLAG-SMARCAL1), FLAG antibodies were used 
to detect SMARCAL1. In other cases, pS889 blots were stripped and reprobed 
with SMARCAL1 antibodies. (C) Cells were synchronized by thymidine for 16hrs 
and released for 1.5h before harvesting (NT) or adding HU for 4 hours. (C) Cells 
were transfected as in (A). (*) Denotes SMARCAL1 band. The non-specific 
bands in (C) appear when samples are processed on FLAG beads rather than 
eluting (as in A and B) 
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Discussion 
 
 Deregulated SMARCAL1 activity at replication forks is associated with 
genome instability indicating that fine-tuning the amount of SMARCAL1 activity at 
replication forks is critical for genome maintenance. We have determined that the 
C-terminus of SMARCAL1 contains an auto-Inhibitory Domain, or CID, that is 
regulated by S889 phosphorylation.  The phenotypes of S889 phospho-mutants 
reflect defects in CID regulation.  A mutant that cannot be phosphorylated is 
constitutively inhibited, while a phospho-mimetic mutant or %CID mutant is 
constitutively uninhibited. Our data suggest that phospho-regulation of CID 
function is important for regulating SMARCAL1 activation at stalled replication 
forks.   
 
Regulation of S889 phosphorylation 
 Our results indicate that SMARCAL1 is maintained in a CID-resistant state 
by constitutive phosphorylation of S889.  The kinase that phosphorylates S889 is 
unknown.  The sequence surrounding S889 does not fit any described kinase 
consensus.  We did identify a potential protein interaction with the protein kinase 
homeodomain-interacting protein kinase 3 isoform 2 (HIPK3) in a yeast-2-hybrid 
screen for SMARCAL1 interacting proteins.  HIPK3 is implicated in regulating 
RNA processing pathways.  The pS889 antibody can be used to screen available 
kinase inhibitors and narrow the list of possible kinases that phosphorylate S889. 
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Importantly, preliminary data indicates that S889 phosphorylation may 
decrease in cells following treatment with HU.  In Chapter V we determined that 
an inactivating phosphorylation in the hinge domain of SMARCAL1 is an 
important function of DDR-dependent S652 phosphorylation.  Removal of S889 
phosphorylation at stalled replication forks would further promote limiting 
SMARCAL1 activity.  This would relieve inhibition of the CID.  The interplay 
between S652 and S889 phosphorylation warrants further investigations. 
 
S889 phosphorylation primes SMARCAL1 for activation 
Unique domains or subdomains are often attached to the amino- or 
carboxy- terminus of the ATPase motor in SNF2 and the related SF2 helicase 
proteins.  In some cases, these domains have been demonstrated to inhibit the 
ATPase motor by either blocking initial nucleic acid binding site or influencing 
ATPase domain orientation (129).  The CID of SMARCAL1 could function 
similarly.  For domains that block nucleic acid binding, removal of the inhibitory 
domain usually removes the nucleic-acid requirement for ATPase activity (130). 
We do not observe significant increase in fork-DNA independent activation of the 
%C mutant.  Therefore, we favor a model in which the CID affects the orientation 
of the ATPase domain. 
For the SF2 helicase DDX19, an N-terminal helix of DDX19 wedges itself 
between the two ATPase domains and prevents the closed conformation of the 
ATPase domains (131).  We propose a similar mechanism for the CID of 
SMARCAL1 (Figure 6.8).  The CID makes important contacts with the ATPase 
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Figure 6.8. Phosphorylation of S889 relieves an auto-inhibitory domain in 
SMARCAL1. An unknown kinase phosphorylates S889 to relieve the inhibitory 
conformation of the CID.  Following replication stress, phosphorylated S889 is 
removed potentially by a DDR phosphatase. This would return the CID to the 
inhibitory conformation. 
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motor in order to inhibit ATP hydrolysis.  Phosphorylation of S889 alters the 
conformation of the CID and relieves inhibition.  
Structural information about how the C-terminus contacts the catalytic 
core of SMARCAL1 will be necessary to understand how phosphorylation at 
S889 may regulate this domain.  Alternatively, S889 could regulate an interaction 
with an inhibitory protein.  It is possible that this protein is present in our ATPase 
reactions since we purify SMARCAL1 from human cells.  This alternative would 
suggest that S889 regulates a protein-protein interaction in the CID. Whether or 
not the CID directly contacts the ATPase motor or binds another protein to 
facilitate inhibition can be determined, but the predicted functional outcomes are 
the same.  
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CHAPTER VII 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
Further characterization of genome maintenance genes 
 
Our genome maintenance screens identified 171 genes with potential 
functions in genome maintenance pathways.  Using published literature and 
functional annotation programs we placed many of the genes into four major 
functional groups: the ATM/ATR-related DNA damage response, mitosis, 
chromatin regulation, and RNA metabolism.  However, in most cases direct 
evidence for gene function in these pathways is lacking.  We investigated the 
biological functions of three proteins identified in our screens, DDB1, CINP and 
SMARCAL1.  As validation for our screen methodology, we found that all three 
promote genome integrity (58,66,81). 
A dataset including over 100 uncharacterized gene products awaits further 
validation.  As functional genomic screens continue to develop as tools for 
discovery, primary-screening methodologies will grow in complexity and yield 
more specific information about gene function.  Only three years after completing 
our genome maintenance screen, our methodologies have advanced far beyond 
the initial limitations of an entirely manual immunofluorescence screen.   A post-
doctoral fellow in our laboratory, Dr. Gina Kavanaugh, has recently completed a 
genome-wide RNAi screen, nearly fully-automated, in which she measured four 
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different indicators of replication stress and DNA damage. I expect that cross-
referencing this data set with our previous data set will yield new mechanistic 
information for how these genes function in genome maintenance pathways.   
Developing hypotheses for loss of function phenotypes in the RNAi screen 
is somewhat easier than interpreting overexpression phenotypes.  However, 
identification of sixteen oncogenes in the overexpression screen emphasizes the 
capacity of this methodology to identify novel oncogenes.  We expect that other 
genes identified in the screen are oncogenic and drive abnormal cell division 
cycles that challenge genome integrity and promote cancer progression. To test 
this hypothesis, we need to determine whether these gene alterations are 
sufficient to drive cancer in vivo.   
Overexpression of Hox genes has been associated with a subset of 
human myeloid leukemias (132). Importantly, Hox gene overexpression can drive 
transformation of mouse hemopoietic cells, providing direct evidence for Hox 
involvement in leukemic transformation (133,134).  The methodology used in 
these studies could also be used to validate genes we identified in our 
overexpression screen.  The basic experimental scheme involves (i) cloning 
cDNAs into high expressing retroviral vectors, (ii) viral transduction of mouse 
primary bone marrow cells, (iii) reconstituting bone marrow depleted mice with 
infected bone marrow cells, and (iv) assessing leukemic growth in vivo.   
Enhancing our understanding of the cellular response to DNA damage will 
help us better understand cancer development and progression.  Our knowledge 
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of genome maintenance pathways and how cancer cells manipulate these 
pathways will also help refine how we classify and treat the disease.  
 
SMARCAL1 
 
My thesis work led to the identification of the SNF2 protein SMARCAL1 as 
a genome maintenance protein. My characterization of SMARCAL1 functions, 
along with evidence from other investigators (58-61), led to the discovery that 
SMARCAL1 annealing helicase activity promotes genome integrity specifically at 
stalled replication forks.  Since this initial discovery, SMARCAL1 activities have 
been further defined. SMARCAL1 travels with at least some replication forks in 
untreated cells and accumulates at stalled replication forks when cells are treated 
with replication inhibitors (54).  Biochemical evidence suggests that in addition to 
re-annealing RPA-ssDNA, SMARCAL1 can catalyze fork regression and remodel 
a variety of fork-like structures.  These activities can promote replication restart 
and prevent replication-associated DNA double strand breaks in vivo. Indeed, 
SMARCAL1 deficiencies cause fork restart defects after replication stress, 
sensitivity to replication stress agents, and aberrant fork structures that result in 
DSBs (54,58,59).  
In the second part of my thesis, I investigated the functional implications of 
SMARCAL1 phosphorylation by DDR kinases.  I identified a number of DDR-
dependent and DDR-independent sites.  My characterization of phospho-mutants 
provides evidence to support a model in which DDR-regulated phosphorylation 
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limits SMARCAL1 activity at stalled replication forks by modulating 
conformational changes required for ATP hydrolysis.    
 
SIOD: a genetic model for studying SMARCAL1 replication stress functions 
Defects in the activities of many replication fork-remodeling enzymes are 
associated with human syndromes (45,47,135). The requirement for fork 
remodeling in vivo has been elucidated from studies investigating the cellular 
defects of patients. Mutations in SMARCAL1 cause SIOD (65). In our 
characterization of SMARCAL1 genome maintenance functions, we established 
the first link between SIOD and a defect in the replication stress response. We 
showed that an R764Q mutant associated with the severest form of SIOD fails to 
complement the replication-associated DNA damage caused by silencing 
SMARCAL1 (58).  
 If the phenotypes of SIOD are, in part, due to defects in SMARCAL1 
function at stalled replication forks, we would expect to observe an increase in 
DNA damage in SIOD patient cells.  Indeed, fibroblasts derived from an SIOD 
patient exhibit elevated levels of $H2AX when compared to cells that have been 
complemented with functional SMARCAL1 (Figure 7.1A). An RPA binding-mutant 
(%N) and the R764Q SMARCAL1 mutant have no affect on the amount of $H2AX, 
indicating that the localization of annealing helicase activity is required for 
reducing DNA damage accumulation.  Additionally, we find that SIOD cells 
exhibit increased RPA phosphorylation following HU treatment (Figure 7.1B).  
These data support that SIOD cells are prone to accumulating DNA damage as
 150 
 
 
 
 
 
 
Figure 7.1. SIOD patient fibroblasts exhibit increased DNA damage 
signaling. (A) SIOD patient-derived human fibroblasts stably expressing vector 
only, WT, #N, or R764Q SMARCAL1 were cultured on coverslips and stained 
with antibodies to $H2AX and appropriate secondary antibodies. The percentage 
of cells with $H2AX staining was scored; error bars are standard deviation 300 
cells were counted with each cell type analyzed in triplicate. (B) Cells with an 
integrated empty vector (Vector) or vector expressing wild-type SMARCAL1 (WT) 
were left untreated (NT) or treated with 2 mM hydroxyurea (HU) for 5 h then 
released into normal growth media for 0 or 8 h as indicated. Total cell lysates 
were prepared and immunoblotted with antibodies to SMARCAL1, 
phosphorylated RPA2, or total RPA2. 
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they cycle and accumulate more phospho-RPA-ssDNA during replication stress.  
Furthermore, they suggest SMARCAL1 activities during replication stress are 
important for preventing SIOD. Complementation of these defects in SIOD 
fibroblasts will be a useful tool for determining the functional requirements for 
phosphorylation and CID regulation of SMARCAL1 at stalled replication forks.  
 
SIOD-associated mutations in the hinge domain 
Missense mutations associated with SIOD are particularly informative for 
determining important functional domains in SMARCAL1.  For example, R764 in 
SMARCAL1 is a conserved arginine that is predicted to make important contacts 
with ATP in the active site cleft of SNF2 and SF2 ATPases (121). The R764Q 
mutation associated with severe SIOD results in an ATPase-dead SMARCAL1, 
supporting the structural observation that this arginine is involved in ATP 
hydrolysis.  Some of the patient mutants that I think would be particularly 
interesting to characterize I have mapped on a model of SMARCAL1 domain 
structure for reference (Figure 7.2). Characterizing the functional defects of these 
mutants will lead to a better understanding of how SMARCAL1 is regulated to 
support genome integrity.  
A number of SIOD associated mutations (R644W, R645C, R645H, K647Q, 
and K647T) cluster in the hinge domain of SMARCAL1 suggesting this is a 
critical domain for SMARCAL1 function as well (65,136).  The hinge domain likely 
provides flexibility required for a critical conformational change that positions 
active site residues in the ATPase_N and ATPase_C domains for ATP
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Figure 7.2. SIOD patient mutations map to potential regulatory domains of 
SMARCAL1. Missense mutations in SMARCAL1 generally lead to SMARCAL1 
mutants that are expressed but lack necessary SMARCAL1 functions. These 
mutations may indicate critical regulatory domains for SMARCAL1 activities that 
maintain genome integrity and prevent SIOD. The mutations mapped here do not 
represent all SIOD patient mutations, only those that have implications for the 
potential regulatory domains I have identified in my thesis. (reference 
http://bioinf.uta.fi/SMARCAL1base/ for a complete list) 
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hydrolysis. As discussed below, I identified a S652D mutant that is less active 
likely due to inhibition of hinge domain function.  
I expect that the SIOD-associated mutations in the hinge domain also 
inhibit hinge flexibility and therefore inhibit SMARCAL1 enzymatic activity.   This 
is likely the cause of SIOD in these patients. It is possible that mutating R644, 
R645, K647, and K647 to alanines may preserve flexibility and ATPase function.  
In support of this hypothesis, the R645H mutation, which preserves the basic 
residue at 645 is associated with a mild form of SIOD.  Suggesting it may retain 
partial function. Demonstrating that the functional defect of these mutations can 
be rescued by mutating residues to more permissive amino acids will be 
important to validate the essential role of hinge domain flexibility in the activities 
of SMARCAL1 and other SNF2 enzymes.   
 
SIOD-associated mutation E848X is a !C mutant 
The E848X mutation has been identified in at least one allele of seven 
patients with SIOD (65,137). Five of the seven patients have severe SIOD. My 
results indicate that this truncated form would not localize to the nucleus 
efficiently. Although I was able to detect a portion of the %C protein localized to 
stalled replication forks, it is not clear whether this amount would be sufficient to 
support SMARCAL1 genome maintenance activities.  Based on in vitro activity 
for this mutant, the amount that does localize would be hyperactive.   Most likely 
the E848X mutant causes SIOD because this mutant lacks an NLS.  However, 
another more intriguing alternative may occur.  The E848X mutant may also be 
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hyperactive and the amount that is nuclear can disrupt normal replication fork 
processing activities. If this were true, it would be the first example where 
hyperactive SMARCAL1 can cause SIOD.  
Finally, a new SIOD-associated SMARCAL1 mutation has recently been 
identified in a patient seen here at Vanderbilt, S859P.  Because of the geometry 
of its side chain, proline can cause kinks in alpha helices. This mutation could 
induce a conformational change in the C-terminus of SMARCAL1.  The effects of 
this mutation on S889 phosphorylation or C-terminal auto-inhibition should be 
investigated.  Characterization of the S859P mutant may lead to a better 
understanding of how the C-terminus of SMARCAL1 regulates SMARCAL1 
activities.  
 
Defining SMARCAL1 interacting proteins 
SNF2 family members differ significantly in the protein sequence flanking 
the SNF2 domain (138). Protein domains outside the SNF2 domain often dictate 
the functional specificity of the protein. For example, protein-protein interactions 
in the N-terminus of the SNF2 protein INO80 direct localization of INO80 to sites 
of DNA DSBs where it functions to remodel nucleosomes and promote the 
recruitment of DNA processing factors (139).  I determined that SMARCAL1 
interacts with RPA through its N-terminus. The genome maintenance activities of 
SMARCAL1 in cells depend upon this interaction (58,59,61). 
Identifying additional SMARCAL1 interacting partners will be important to 
further elucidate SMARCAL1 functions at replication forks and potentially 
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uncover other cellular functions of SMARCAL1. We have investigated 
SMARCAL1 complexes purified from both HU-treated and untreated cells by 
mass spectrometry. Thus far, we observe no damage-inducible changes in 
SMARCAL1 complexes.  Additionally, many of the interactions seem to be 
dependent on RPA.  Indirect interactions through RPA do not exclude the 
possibility that forming these complexes in vivo is critical for SMARCAL1 function.  
It does however complicate the biochemistry and interpretation of results. 
Disrupting the SMARCAL1-RPA interaction abolishes SMARCAL1 replication 
stress function in cells.  
The conditions used for purifying complexes may have not been ideal for 
identifying more transient SMARCAL1 interactions.  Important interactions may 
be temporally regulated in the response to DNA damage.  Therefore, an analysis 
of SMARCAL1 complexes purified from synchronous cell populations exposed 
for different times in HU may yield new interacting partners.  
We also initiated a two-hybrid screen performed by Hybrigenics using their 
ULTImate Y2H methodology.  Using full-length SMARCAL1 as bait, we identified 
33-interacting clones, representing seven different proteins (FAM178A, HIPK3, 
KCTD13, PIAS2, RPA2, UBE2I, ZNF92). The identification of RPA2 subunits in 
this screen validates this methodology for identifying SMARCAL1 interacting 
proteins.  Interestingly, UBE2I and PIAS2 function together to sumoylate proteins.  
UBE2I is the only SUMO-E2 conjugating enzyme in mammals, while many 
different PIAS proteins direct substrate specificity for SUMO conjugation 
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(140,141). The identification of both in the Y2H screen suggests they may be 
biologically relevant for SMARCAL1 function.  
The interaction between SMARCAL1 and UBE2I or PIAS2 has not been 
validated, nor have I been able to detect SMARCAL1 sumoylation. However, 
SUMO modifications are very labile and are difficult to detect. SMARCAL1 
contains a sumoylation consensus site ((KxE) at K647 in the hinge region. 
Interestingly, S652 is positioned in a phospho-sumoyl switch motif ((KxExxS) 
that couples sequential phosphorylation and sumoylation (142). A SUMO 
regulatory network may be involved in the DDR-dependent regulation of 
SMARCAL1 at replication forks (Figure 7.3).  Presumably, addition of SUMO in 
the hinge region would enhance the inhibitory effect already induced by S652 
phosphorylation. If the interaction with UBE2I and PIAS2 can be confirmed, this 
would be sufficient rationale to investigate whether SMARCAL1 is a substrate for 
sumoylation in vitro. These studies would further define the mechanisms by 
which DDR kinases limit SMARCAL1 activity at stalled replication forks. 
 
Phospho-regulation of SMARCAL1 
We identified several CDK consensus sites in the N-terminus of 
SMARCAL1. CDK activity is important for regulating the cell cycle specific 
activities of other SNF2 proteins. CDK phosphorylation of the SNF2 protein, 
PICH (Plk1 interacting checkpoint helicase) is required to expose a Plk1 binding 
site in PICH and localize it to the centromere where it functions in the spindle 
checkpoint (143). The human SWI/SNF complex composed of Brg1 and Brm 
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Figure 7.3. Potential SUMO-regulatory network identified by yeast-2-hybrid 
screen.  A yeast-2-hybrid screen with full-length SMARCAL1 as bait identified 
fragments of UBE2I and PIAS2 as interacting clones. UBE2I and PIAS2 function 
together to conjugate SUMO to lysine on target proteins. Sumoylation is 
preferred at lysines within a certain consensus ((KxE). Sumoylation can also be 
directed by phosphorylation downstream of the lysine ((KxExxS) at a serine. 
SMARCAL1 contains this consensus in the hinge domain and S652 is located in 
the phospho-consensus site. Sumoylation may be another regulatory step in 
inactivating the hinge domain. 
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alters nucleosome structure in vitro and may regulate transcription via chromatin 
remodeling in cells (144).  BRG and BRM undergo phosphorylation when cells 
enter mitosis.  When purified from cells at different stages in the cell cycle, the 
phosphorylated complex from mitotic cells lacks nucleosome disrupting activity in 
vitro (145). Reversibly inactivating the SWI/SNF complex as cells traverse 
mitosis may be required for forming the tightly packed chromatin structure 
important for completing mitosis.   
The phosphorylation of S112, S123, S129, and S198 in the N-terminus of 
SMARCAL1 indicate the potential for cell-cycle dependent regulation of 
SMARCAL1. In fact, S198 phosphorylation was identified in a large-scale 
proteomic analysis of mitotic phosphorylation (146). Additionally, a peptide 
containing phosphorylated S172 and S181 was identified among 494 unique 
phosphopeptides that increased in samples from cells exposed to low doses of 
irradiation (119). Phosphopeptide mapping of SP-phospho-mutants will reveal to 
what extent these sites contribute to SMARCAL1 phospho-regulation. Maps of 
SMARCAL1 purified from synchronous populations of cells will indicate whether 
phosphorylation depends on cell cycle. 
We also uncovered at least two major sites of phosphorylation located on 
the same peptide as S919 that are phosphorylated in SMARCAL1 purified from 
normal growing conditions.  This suggests that DDR-independent phospho-
regulation of the C-terminus is also important for SMARCAL1 functions.  There 
are 14 potential sites in the S919 peptide and identifying which sites are 
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phosphorylated will be important to understand the functional requirements for 
DDR-independent and DDR-dependent phosphorylation in this region. 
 
A C-terminal auto-inhibitory domain is regulated by S889 phosphorylation 
SMARCAL1 is phosphorylated in the absence of DNA damage. S889 
phosphorylation was identified in our mass spectrometry analysis and I 
determined using p-S889 antibodies that this site is phosphorylated independent 
of DNA damage.  Functional characterization of S889 mutants in vitro and in cells 
suggests that S889 phosphorylation may regulate a C-terminal auto-inhibitory 
domain of SMARCAL1.    
The %C mutant in these studies truncates SMARCAL1 following aa860 
(Figure 7.4A).  Further defining this domain is important for studying its inhibitory 
function.  New mutants generated from scanning alanine mutagenesis or 
truncating various lengths from the C-terminus (Figure 7.4B) can be rapidly 
screened in the ATPase assay to determine the minimal domain required to 
inhibit SMARCAL1 activity. Also, our analysis indicates that the 860-end 
truncation also removes an NLS.  Defining the minimal inhibitory domain may 
circumvent this issue.  If the NLS is within the defined domain, then it will be 
important to use expression vectors that add a NLS.  An NLS vector was 
sufficient to localize %C to the nucleus.  
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Figure 7.4. Strategy for determining the minimal CID in the C-terminus of 
SMARCAL1. (A) The %C mutant truncates the C-terminus 861-954. (B) This 
domain contains a CID and also a NLS. A scanning alanine mutagenesis 
strategy can identify important residues in this region that contribute to CID 
function. Alternatively, smaller truncations can be made from the C-terminus..  
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Phosphorylation by DDR kinases 
I identified three damage-inducible phosphorylation sites in SMARCAL1: 
S173, S652, and S919.  As determined by phosphopeptide mapping, 
phosphorylation of S173 and S919 following HU is dependent on DDR kinases.  
Likewise, detection of S652 phosphorylation by p-S652 antibodies is reduced 
after DDR kinase inhibition.   ATR, ATM, and DNA-PK directly phosphorylate 
SMARCAL1 in vitro.  However, I did not determine whether S173, S652, or S919 
are directly targeted by these kinases.  Determining whether ATM, ATR, and 
DNA-PK directly phosphorylate these sites in vitro and whether there is any 
kinase specificity for each residue may shed light on the functional significance of 
these sites in cells.   
ATR is activated early at stalled replication forks while ATM and DNA-PK 
activation depend on fork collapse, or DSB formation.  If there is any selectivity 
for S173, S652, or S919, this may suggest DDR kinases regulate SMARCAL1 
activity at different stages in replication fork processing.  ATM/ATR selectivity has 
been observed for phosphorylation sites in the replication stress response 
helicase, WRN (126).  The model I propose for DDR-regulated phosphorylation 
assumes that phosphorylation at S173, S652, and S919 contribute to the same 
effect: limiting SMARCAL1 activity at stalled replication forks. I have inferred 
most of my model based on the observation that SMARCAL1 is less active when 
purified from cells treated with HU for 16hrs.  My findings could ultimately reflect 
the culmination of many steps of regulation at different times in the response to 
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HU-stalled forks that ultimately lead to less active SMARCAL1. However, the 
potential for positive regulatory effects of DDR phosphorylation is still possible.  
There is at least one additional DDR-dependent phosphorylation site in 
SMARCAL1 that does not fit the S/TQ consensus.  Phosphopeptide-a is reduced 
following DDR kinase inhibition but is not one of the ten S/TQs present in 
SMARCAL1.  This site may be a substrate for another kinase activated by ATM, 
ATR, or DNA-PK.  Alternatively, phosphopeptide-a could be one of the SP sites 
identified by mass spectrometry and increases with 16hrs in HU because this 
essentially synchronizes cells in S phase.  
 
Hypotheses for S173 and S919 phospho-regulation 
Whether or not S173 and S919 phosphorylation represent functionally 
important regulatory events is unclear. I determined that S173 and S919 do not 
affect SMARCAL1 ATPase activity in vitro. However, this interpretation is largely 
based on the assumption that the S173D and S919D mutants sufficiently mimic 
phosphorylation at these sites. Our evidence that the C-terminus contains a CID 
that is relieved by S889 phosphorylation suggests that the C-terminus undergoes 
conformational changes relevant to SMARCAL1 enzymatic activities. It is 
possible that DDR-dependent phosphorylation of S919 can also contribute to 
changes in the C-terminal domain structure.  
Alternatively, S919 phosphorylation could create a binding site for a 
regulatory protein. We observe a decrease in pS889 following HU-treatment. 
S919 phosphorylation may promote recruitment of a phosphatase that removes 
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S889 phosphorylation.  Removing pS889 would support the DDR-regulated 
inactivation of SMARCAL1, restoring the CID to an inhibitory conformation 
(Figure 7.5). The S919D mutant does not affect the ATPase of SMARCAL1 in 
vitro suggesting that this mutant does not affect pS889 status. Although the 
protein is purified from human cells, we overexpress FLAG-SMARCAL1 at very 
high levels and do not expect that the protein is regulated efficiently. It is not 
likely that a phosphatase would be present in high enough levels to remove all of 
pS889. The relationship between S919 and S889 phosphorylation should be 
investigated in conditions that express low levels of SMARCAL1.  
 It is less obvious how phosphorylation of SMARCAL1 in the N-terminus 
would regulate SMARCAL1 activities.  At least at the primary amino acid 
sequence level, S173 is closest to the first HARP domain in SMARCAL1. We 
have no evidence that it affects HARP function. S173 phosphorylation 
presumably occurs in a region that is phosphorylated at many other sites.  Maybe 
S173 phosphorylation promotes regulation of these sites following DNA damage. 
It is just as likely that S173 controls protein-protein interactions required for 
SMARCAL1 regulation.  We synthesized biotin-conjugated S173 peptides and 
phosphopeptides that can be used for streptavidin purification of proteins that 
specifically bind the S173 phosphopeptide in nuclear extracts.  The same should 
be done for S919 peptides.  This methodology bypasses the need for upstream 
regulatory events and will hopefully reveal some aspect of S173 and S919 
function. 
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Figure 7.5. Model for S919-dependent regulation of the CID. Phosphorylation 
of S919 in the C-terminus could regulate CID function. Activation of ATR at 
stalled replication forks leads to the phosphorylation of S919. Phospho-S919 
recruits a phosphatase (orange polygon) to S889 to remove phosphorylation. 
Following de-phosphorylation of S889 the CID returns to an inhibitory 
conformation leading to inactive SMARCAL1. 
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S652 phosphorylation regulates the SMARCAL1 hinge domain 
The hinge domain is a flexible linker that enables the ATPase_N and 
ATPase_C domains of SNF2 proteins to rotate into a closed-active conformation. 
The rotation of these domains is necessary for ATP hydrolysis and efficient DNA 
translocation.  Thus, changes in the flexibility of this hinge can affect the activities 
of SNF2 enzymes. The importance of this domain in SMARCAL1 is emphasized 
by the fact that a number of SIOD-associated mutations occur at hinge domain 
residues.  Introduction of a phospho-mimetic amino acid at S652 disrupts the 
ATPase activity of SMARCAL1 in vitro.  Since an alanine at this position has no 
affect on ATPase activity, we conclude that the serine itself is not required for 
activity; rather introducing a negatively charged side group or phosphate at this 
site in vivo most likely disrupts critical hinge domain functions. We observe 
damage-induced phosphorylation of S652 indicating that it is regulated in cells 
and may disrupt hinge function. However, evidence that S652 is the inactivating 
phosphorylation that contributes to the decreased activity of SMARCAL1 purified 
from HU-treated cells remains circumstantial.  Further studies are necessary to 
provide a direct link between DDR-regulated phosphorylation at S652 and the 
observed decrease in SMARCAL1 from HU treated cells.  
 
 
A comprehensive model for SMARCAL1 phospho-regulation at stalled replication 
forks 
 
SMARCAL1 acts as an annealing helicase at forks where the polymerase 
and helicase activities have been uncoupled due to DNA lesions or other 
perturbations.  This activity is important to prevent degeneration of the fork into a 
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MUS81-dependent double-strand break. The absence of this activity contributes 
to the human disease SIOD. Furthermore, too much SMARCAL1 activity is 
equally challenging to genome maintenance.  I have identified a number of 
phosphorylation events that would be excellent candidates for regulating 
SMARCAL1 activities at replication forks. I have summarized my interpretations 
and predictions for SMARCAL1 regulation during the replication stress response 
in a comprehensive model (Figure 7.6). Although many steps are quite 
speculative, the general theme is that phosphorylation provides an ‘on-off’ switch 
for SMARCAL1 activities at stalled replication forks.  
 The SMARCAL1-RPA interaction localizes annealing helicase activity to 
stalled replication forks.  This step in SMARCAL1 regulation is critical for its 
genome maintenance function. SMARCAL1 is likely recruited to forks in its ‘on’ 
conformation with pS889 relieving the CID.  Once localized, I favor the model 
that SMARCAL1 binds the parental fork DNA and re-anneals the parental strands 
to promote the first steps of fork reversal. After SMARCAL1 binds DNA and ATP, 
the rotation of the ATPase_N and ATPase_C domains drives ATP hydrolysis and 
subsequent translocation.  The HARP domains of SMARCAL1 are important for 
converting this force into strand annealing and RPA displacement.  
ATR is activated at stalled replication forks. During the translocation step, 
the hinge domain of SMARCAL1 is exposed to ATR kinase activity as a result of 
the conformational change upon DNA and ATP binding. Phosphorylation of S652 
reduces the flexibility of the hinge domain, inhibiting another round of ATP 
hydrolysis for this molecule of SMARCAL1.  The disruption of the hinge domain 
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Figure 7.6. A comprehensive model for SMARCAL1 phospho-regulation at 
stalled replication forks. 1. In normal conditions S889 phosphorylation is 
maintained, relieving the CID inhibitory conformation. In the presence of 
replication stress, SMARCAL1 accumulates at stalled replication forks in its 
active form via its N-terminal RPA binding domain (RBD). (2) Localization to forks 
concentrates SMARCAL1 near its DNA substrates and subsequently 
SMARCAL1 binds the parental fork DNA.  (3) DNA binding promotes ATP 
binding and transition from the open-inactive state to the closed-active state. ATP 
hydrolysis drives SMARCAL1 translocation on the DNA to re-anneal the parental 
strands while removing RPA. The conformational change exposes S652 to DDR 
kinases like ATR, which is activated at stalled replication forks.  Phosphorylation 
of S652 in the hinge domain hinders ATPase domain flexibility thereby inhibiting 
the next enzymatic cycle of ATP binding and hydrolysis. Additionally, S919 is 
phosphorylated by ATR and recruits a phosphatase to remove S889 
phosphorylation. This reactivates the CID and further inhibits SMARCAL1 activity 
at the fork. (4) The inactivated molecule dissociates and a new molecule of 
SMARCAL1 can bind. This mechanism provides the opportunity for SMARCAL1 
to catalyze necessary fork remodeling activities, but with limited processivity. 
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may also affect DNA binding and reduce the maintenance time of SMARCAL1 on 
its substrate.   
ATR most likely phosphorylates S919 in the C-terminal domain as well. 
Our evidence suggests that significant damage-induced phosphorylation does 
not occur prior to DNA binding. It is unclear whether S919 would depend on a 
DNA-dependent conformational change to be exposed to ATR kinase activity, 
considering the C-terminal inhibitory domain may already be in an open 
conformation.  The order of events is unclear, but if S919 did regulate the status 
of S889 phosphorylation I would expect a mechanism to be in place to prevent 
S919 phosphorylation until after SMARCAL1 translocates. If ATR phosphorylates 
S919 upon SMARCAL1 localization, SMARCAL1 would be turned ‘off’ before 
even binding DNA. S919 may also be masked until after DNA binding. Following 
translocation S919 is phosphorylated and activates the CID. The CID could 
further disrupt DNA binding and promote removal of SMARCAL1 from the fork 
DNA.   
Testing this model is anything but simple. A major challenge of projects 
related to phosphorylation is the difficulty in interpreting the phenotypes of 
phospho-mutants. Phospho-mimetic mutants may or may not mimic 
phosphorylation. For example, S173D and S919D may be active in vitro because 
they are not phospho-mimetic. Although we can make predictions based on the 
location of these sites in the primary sequence, we have little understanding of 
how the accessory domains of SMARCAL1 interact with each other or the 
ATPase motor. SMARCAL1 regulation is obviously complex and the accessory 
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domains seem to influence the ATPase domain more than expected. Further 
characterization of SMARCAL1 interacting proteins and even phospho-peptide 
interacting proteins will surely clarify more of the mechanisms of S173 and S919 
phosphorylation. As for S652, evidence strongly supports that phosphorylation in 
the hinge domain is inhibitory.  Structural information is necessary to validate this 
mechanism.   
 My thesis work has generated a number of testable models for 
SMARCAL1 regulation in normal and replication-stressed conditions. The 
overexpression phenotypes of SMARCAL1 demonstrate that SMARCAL1 
activities must be limited at replication forks. However, SMARCAL1 deficiencies 
indicate that SMARCAL1 activity is required to promote fork stability. The 
activities of SMARCAL1 must be unique enough to warrant recruitment of an 
enzyme that could potentially threaten genome stability if not regulated.   
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APPENDIX A 
 
RAW DATA FOR OVEREXPRESSION SCREEN  
 
 
 This appendix lists the 97 genes identified in the cDNA overexpression 
screen in the Appendix Table. The table includes the quantitation of $H2AX foci 
and calculated p values.  
  
 171 
 
Gene ID Gene Name Symbol Mean Std Dev adj. p value
N/A Control (empty vector) N/A 0.87 0.92 N/A
3005 H1 histone family, member 0 H1F0 2.33 1.51 0.016
7730 zinc finger protein 177 ZNF177 2.33 0.58 0.023
27237 Rho guanine exchange factor (GEF) 16 ARHGEF16 2.33 1.53 0.043
56033 BARX homeobox 1 BARX1 2.33 1.53 0.043
63979 fidgetin-like 1 FIGNL1 2.33 1.53 0.042
10399 guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1 GNB2L1 2.43 1.72 0.014
4292 mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) MLH1 2.67 1.03 0.001
10514 MYB binding protein (P160) 1a MYBBP1A 2.67 0.58 0.007
843 caspase 10, apoptosis-related cysteine peptidase CASP10 2.67 1.53 0.016
94 activin A receptor type II-like 1 ACVRL1 2.67 2.08 0.028
5709 proteasome (prosome, macropain) 26S subunit, non-ATPase, 3 PSMD3 2.75 1.50 0.007
373156 glutathione S-transferase kappa 1 GSTK1 2.75 2.22 0.020
26260 F-box protein 25 FBXO25 3.00 1.00 0.003
27166 PRELI domain containing 1 PRELID1 3.00 1.83 0.005
7913 DEK oncogene (DNA binding) DEK 3.00 3.00 0.030
6137 ribosomal protein L13 RPL13 3.29 3.50 0.023
3783 potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 KCNN4 3.33 0.58 7.43E-04
5307 paired-like homeodomain 1 PITX1 3.33 0.58 7.32E-04
64288 zinc finger protein 323 ZNF323 3.33 1.53 0.002
6128 ribosomal protein L6 RPL6 3.67 2.31 0.003
63924 cell death-inducing DFFA-like effector c CIDEC 3.67 2.52 0.003
10473 high mobility group nucleosomal binding domain 4 HMGN4 3.75 0.96 7.23E-05
4286 microphthalmia-associated transcription factor MITF 3.75 3.50 0.010
7026 nuclear receptor subfamily 2, group F, member 2 NR2F2 4.00 1.00 1.27E-04
7737 ring finger protein 113A RNF113A 4.33 1.53 1.14E-04
255252 leucine rich repeat containing 57 LRRC57 4.33 2.89 0.001
90441 zinc finger protein 622 ZNF622 4.33 3.21 0.002
5925 retinoblastoma 1 (including osteosarcoma) RB1 4.67 2.08 1.32E-04
128866 chromatin modifying protein 4B CHMP4B 4.67 2.89 6.40E-04
220202 atonal homolog 7 (Drosophila) ATOH1 4.67 3.21 0.001
2150 coagulation factor II (thrombin) receptor-like 1 F2RL1 4.75 3.40 0.001
7022 transcription factor AP-2 gamma (activating enhancer binding protein 2 gamma) TFAP2C 5.00 2.65 1.76E-04
8341 histone cluster 1, H2bn HIST1H2BN 5.22 2.22 2.07E-06
55957 lin-37 homolog (C. elegans) LIN37 5.33 1.15 3.20E-06
148327 cAMP responsive element binding protein 3-like 4 CREB3L4 5.33 1.15 3.27E-06
7704 zinc finger and BTB domain containing 16 ZBTB16 5.33 2.08 2.49E-05
9040 ubiquitin-conjugating enzyme E2M (UBC12 homolog, yeast) UBE2M 5.67 0.58 5.55E-07
58492 zinc finger protein 77 ZNF77 5.67 1.53 3.06E-06
6208 ribosomal protein S14 RPS14 5.67 4.37 8.47E-04
3217 homeobox B7 HOXB7 5.67 4.55 0.001
3020 H3 histone, family 3A H3F3A 5.83 3.06 0.002
65117 arginine/serine-rich coiled-coil 2 RSRC2 6.00 5.74 0.003
3428 interferon, gamma-inducible protein 16 IFI16 6.25 4.92 8.48E-04
8738 CASP2 and RIPK1 domain containing adaptor with death domain CRADD 6.25 5.44 0.002
210 aminolevulinate, delta-, dehydratase ALAD 6.33 0.58 1.04E-07
4200 malic enzyme 2, NAD(+)-dependent, mitochondrial ME2 6.33 3.51 6.48E-05
79576 NFKB activating protein NKAP 6.67 4.04 9.68E-05
2115 ets variant gene 1 ETV1 7.33 4.16 3.91E-05
3183 heterogeneous nuclear ribonucleoprotein C (C1/C2 HNRPC 7.33 4.93 1.44E-04
3280 hairy and enhancer of split 1, (Drosophila) HES1 7.33 4.93 1.46E-04
1747 distal-less homeobox 3 DLX3 8.33 3.06 5.92E-07
3202 homeobox A5 HOXA5 8.67 3.06 3.45E-07
23764 v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) MAFF 8.67 4.62 1.15E-05
83444 zinc finger, HIT type 4 ZNHIT4 8.67 7.37 8.40E-04
121599 Spi-C transcription factor (Spi-1/PU.1 related) SPIC 9.67 1.53 1.30E-09
971 CD72 molecule CD72 10.00 2.94 1.47E-08
5684 proteasome (prosome, macropain) subunit, alpha type, 3 PSMA3 10.00 3.61 1.80E-07
1746 distal-less homeobox 2 DLX2 10.33 0.58 7.35E-11
4332 myeloid cell nuclear differentiation antigen MNDA 10.50 5.80 9.28E-06
5347 polo-like kinase 1 (Drosophila) PLK1 10.67 2.31 2.54E-09
339488 transcription factor AP-2 epsilon (activating enhancer binding protein 2 epsilon) TFAP2E 10.67 2.52 4.12E-09
51564 histone deacetylase 7 HDAC7A 11.00 1.73 3.53E-10
126789 pseudouridylate synthase-like 1 PUSL1 11.00 4.97 8.84E-07
4998 origin recognition complex, subunit 1-like (yeast) ORC1L 12.33 0.58 5.39E-12
2114 v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) ETS2 12.33 2.52 5.51E-10
27345 potassium large conductance calcium-activated channel, subfamily M, beta member 4 KCNMB4 13.00 3.00 9.49E-10
55506 H2A histone family, member Y2 H2AFY2 13.33 2.08 1.88E-11
9324 high mobility group nucleosomal binding domain 3 HMGN3 13.67 1.53 7.92E-12
4152 methyl-CpG binding domain protein 1 MBD1 14.00 4.00 4.20E-09
55621 TRM1 tRNA methyltransferase 1 homolog (S. cerevisiae) TRMT1 15.00 4.36 3.81E-09
6625 small nuclear ribonucleoprotein 70kDa polypeptide (RNP antigen) SNRP70 16.33 3.79 3.15E-10
2119 ets variant gene 5 (ets-related molecule) ETV5 18.00 7.00 5.47E-08
5494 protein phosphatase 1A (formerly 2C), magnesium-dependent, alpha isoform PPM1A 19.33 2.89 2.23E-12
50485 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a-like 1 SMARCAL1 19.56 5.20 2.08E-11
3178 heterogeneous nuclear ribonucleoprotein A1 HNRPA1 20.00 1.73 4.31E-14
2774 guanine nucleotide binding protein (G protein), alpha activating activity polypeptide, olfactory type GNAL 20.00 6.56 5.72E-09
10949 heterogeneous nuclear ribonucleoprotein A0 HNRPA0 21.17 2.99 2.48E-14
27440 cat eye syndrome chromosome region, candidate 5 CECR5 21.33 5.51 3.39E-10
80712 ESX homeobox 1 ESX1 22.33 11.06 6.61E-07
Table S4. Mean !H2AX foci in GFP-positive U2OS cells following co-transfection of pCMV-SPORT6 cDNA and GFP expression plasmids.   The p value 
was calculated in comparison to an empty vector control using an unpaired, two-tailed t-test and was adjusted for a false discover rate of 0.05 using the Benjamini 
and Hochberg procedure (n!3).
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2118 ets variant gene 4 (E1A enhancer binding protein, E1AF) ETV4 23.67 2.08 2.47E-14
1994 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 (Hu antigen R) ELAVL1 24.67 7.77 2.49E-09
5883 RAD9 homolog A (S. pombe) RAD9A 25.33 11.24 1.57E-07
55249 YY1 associated protein 1 YY1AP1 25.67 11.02 1.05E-07
81620 chromatin licensing and DNA replication factor 1 CDT1 27.00 4.24 2.04E-13
3191 heterogeneous nuclear ribonucleoprotein L HNRPL 27.00 6.00 3.29E-11
126272 EP300 interacting inhibitor of differentiation 2B EID-3 30.33 8.74 6.12E-10
54828 breast carcinoma amplified sequence 3 BCAS3 31.67 3.21 1.24E-14
22827 poly-U binding splicing factor 60KDa PUF60 32.00 7.79 5.10E-11
284004 hexosaminidase (glycosyl hydrolase family 20, catalytic domain) containing HEXDC 33.67 4.04 2.20E-14
8139 giant axonal neuropathy (gigaxonin) GAN 35.00 4.36 2.39E-14
51125 golgi autoantigen, golgin subfamily a, 7 GOLGA7 36.50 5.13 7.65E-14
9937 DNA cross-link repair 1A (PSO2 homolog, S. cerevisiae) DCLRE1A 38.17 14.43 1.04E-08
92335 protein kinase LYK5 LYK5 39.86 6.84 2.26E-14
6434 splicing factor, arginine/serine-rich 10 (transformer 2 homolog, Drosophila) SFRS10 41.33 5.51 2.37E-14
2078 v-ets erythroblastosis virus E26 oncogene homolog (avian) ERG 50.67 5.51 7.15E-15
6432 splicing factor, arginine/serine-rich 7, 35kDa SFRS7 52.00 22.52 7.46E-08
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APPENDIX B 
 
DEFINING GENOME MAINTENANCE PATHWAYS USING  
FUNCTIONAL GENOMIC APPROACHES3 
 
Introduction 
 
 Our knowledge of the genome maintenance activities that happen in 
human cells comes from the study of all kingdoms of life since most of these 
activities are highly evolutionarily conserved. Genetic and biochemical studies of 
bacteria provide insights into replication and DNA repair proteins that also 
operate in eukaryotic systems.  Archaebacteria provide a rich resource for 
structural biologists since it is often easier to purify and crystallize proteins from 
the thermophilic species.  The genetics of simple eukaryotes like 
Schizosaccharomyces pombe and Saccharomyces cerevisiae that can divide as 
either haploid or diploid cells provided some of our first mechanistic 
understanding of the cell division cycle (148,149).   
 Higher eukaryotes including the invertebrates Caenorhabditis elegans and 
Drosophila, as well as the vertebrates Xenopus and zebrafish have unique 
strengths as research models.  For example, Xenopus eggs contain 
highconcentrations of genome maintenance proteins and have been used to 
                                            
3 The majority of this chapter has previously been published in reference 147.
 Bansbach, C.E. and Cortez, D. (2011) Defining genome maintenance 
pathways using functional genomic approaches. Crit Rev Biochem Mol Biol, 46, 
327-341.  
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understand the mechanisms of DNA damage checkpoints using complex 
biochemical strategies. Finally, mammalian systems have been historically 
important and are increasingly providing resources for new discovery. 
 Some genome maintenance discoveries came directly from human 
systems through bedside to bench research.  This is especially true in the DNA 
damage response field since many human diseases are caused by mutations in 
DDR genes.  For example, clinicians studying patients with the cancer 
predisposition disease ataxia telangiectasia described how at the cellular level 
this disease is characterized by an inability to properly arrest the cell cycle in 
response to ionizing radiation (150) (151).  These were some of the first 
descriptions of cell cycle checkpoints.  Positional cloning of the gene responsible 
for ataxia telangiectasia (ATM), identified one of the most important kinases that 
signals in response to DNA DSBs (152).   
Other notable examples include the identification of DSB repair and 
signaling proteins like breast and ovarian cancer susceptibility protein 1 (BRCA1) 
and Nijmegen breakage syndrome protein (NBS1) (153-156); the identification of 
the DNA crosslink repair proteins defective in patients with Fanconi anemia 
(FANC proteins) (157); and the description of proteins involved in the repair of 
ultraviolet (UV)-radiation damage via nucleotide excision repair pathways from 
people with xeroderma pigmentosum (XP proteins) (158). The primary limitations 
of this approach for understanding genome maintenance are that it is time and 
resource-intensive and restricted by the size of the human population.   
 175 
 Yeast systems historically provided the simplest methods to identify genes 
involved in genome maintenance pathways.  Classic mutagenesis screens 
including the Hartwell and Nurse cell division cycle screens (148,149,159), DNA 
damaging agent sensitivity screens (160-162), and mitotic arrest deficient 
screens (163,164) generated lists of yeast strains that were converted to lists of 
genes as the mutant alleles were identified.  As DNA sequencing provided a 
complete sequence of the yeast genome, these mutagenesis screens gave way 
to more systematic functional genomic approaches based on libraries of yeast 
strains with targeted knockouts in every open reading frame (ORF) or tags 
integrated at every ORF to allow high-throughput protein-protein interaction and 
localization studies (165-167). 
 Recent technological advances including high-density microarrays, mass 
spectrometry, and especially RNA interference (RNAi) have made functional 
genomic approaches feasible in diploid organisms including human cells.  In 
many cases, these approaches have been copied from the work done in yeast.  
For example, cell division cycle (168-171), mitotic arrest (172), and DNA damage 
sensitivity screens (173-176) have all been completed with RNAi approaches in 
cell culture (see Table 3.1 for a list of screens discussed in this review).  
Some of the experimental advantages of human cell culture such as the 
ease of imaging are now being exploited to complete novel high content 
microscopy screens (66,177-181).  Furthermore, other screens like the proteomic 
identification of hundreds of ATM substrates have been pioneered in human cell 
culture and only later translated into yeast (88,115,116,182).  Overall, these high-
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throughput approaches have identified hundreds of new proteins in genome 
maintenance pathways and rapidly accelerated genome maintenance research. 
 In this Appendix, I will review functional genomic approaches to identify 
and characterize genome maintenance pathways.  A brief introduction of each 
approach will be followed by specific examples of their successful use in 
discovery.  I will focus primarily on approaches in diploid, multi-cellular eukaryotic 
system and direct readers interested in functional genomics using yeast systems 
to other excellent reviews (183,184).   
 
Gene expression profiling 
 
  One of the first functional genomic approaches used in higher eukaryotic 
organisms was gene expression profiling (185).  The general idea is to track 
transcriptional changes in response to a genome maintenance challenge.  This is 
most commonly done using microarrays to measure mRNA abundance.  Many 
investigators analyzed relative mRNA expression levels as a function of cell cycle 
position, time after exposure to a DNA- or spindle-damaging agent, or genetic 
background (i.e. p53 overexpression or ATM-deficiency) (186-188).   
  There are two rationales for gene expression profiling in the interrogation 
of genome maintenance pathways.  First, genes with activities in a specific cell 
cycle phase or in response to DNA damage may be more highly expressed in 
cells under these conditions.  Second, the outcome of many genome 
maintenance pathways such as the DDR depends on a change in transcription, 
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so tracking transcriptional changes can be used as an assay to monitor signaling 
through these pathways.   
  A well-studied example is the G1 arrest or apoptosis induced by p53 in 
response to DNA damage, which is mediated by p53-dependent transcriptional 
changes in multiple genes (189,190). DNA damage leads to activation of p53 
through post-translational modifications that promote its stabilization. By 
identifying p53-target genes, investigators have learned how cells regulate the 
G1-S transition and apoptosis. These studies have been complemented by the 
identification of p53 response elements throughout the genome using chromatin 
immunoprecipitation experiments.  The reader is directed to several recent 
reviews to learn more about these methods to study p53 function (190,191). 
  The limitations of this type of approach are that regulation of genome 
maintenance pathways often proceeds through transcriptional-independent 
mechanisms and that many transcriptional changes may be only indirectly 
related to the process being studied.  Proteins like ATM that initiate signaling in 
response to DNA damage are largely unregulated at the transcriptional level.  
Also, many transcriptional changes occur as a general reaction to any type of 
environmental stress so they may not be particularly useful in dissecting a 
specific pathway (192).  Finally, expression profiling provides little information on 
the function of the identified genes.  
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High throughput proteomics 
 
  Proteomic approaches to studying genome maintenance pathways include 
techniques that measure protein abundance, protein-protein interactions, post-
translational modifications, and/or subcellular localization. Assays include protein 
microarrays, yeast two-hybrid, mass spectrometry, and fluorescent imaging.  
These are inherently more technically difficult, expensive, and lower throughput 
than expression profiling. However, they offer the significant advantage of easier 
functional interpretation.   
 
Protein microarrays 
   Protein microarrays or protein chips are arrays of proteins or peptides 
deposited on a glass or silicon surface (193).  They are useful to measure protein 
abundance, protein-protein interactions, and post-translational modifications 
(Figure B.1).  This technology has seen only limited use largely due to issues of 
cost and robustness of the assays.  However, a recent publication on the use of 
protein microarrays to identify ubiquitination substrates of the anaphase 
promoting complex (APC) highlights the potential of this emerging technology 
(194).    
  The APC is an E3 ubiquitin ligase that polyubiquitinates proteins to 
regulate the cell cycle (195).  For example, APC-dependent ubiquitination of 
cyclin B is responsible for the cycling of its abundance and required for exit from 
mitosis (196-198).  The Kirschner group used what they termed extract-based 
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Figure B.1.  Protein microarrays. (A) Protein microarrays can be used to 
identify post-translational modifications.  For example, Merbl et al., identified 
substrates of the APC ubiquitin conjugating enzyme using protein microarrays 
(194). (B) Protein microarrays can also be used to identify protein-protein 
interactions using fluorescently tagged proteins as the probe. 
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functional assays combined with protein microarrays to define APC substrates 
(194).  They isolated extracts from HeLa cells that were arrested at the mitotic 
checkpoint.  These extracts catalyzed the ubiquitination of protein spotted on a 
solid surface that was detectable using an anti-polyubiquitin antibody.  They 
defined APC substrates by comparing the activities of these extracts on the 
protein microarray to extracts in which the APC was inactivated.  Of the 8,000 
proteins arrayed on the chips, they found that 132 were differentially modified.   
  To validate the methodology for the identification of APC substrates, they 
selected six mitotic proteins from their list that were previously unknown targets 
of the APC complex (Nek9, Calm2, p27, RPS6KA4, cyclin G2, and DDA3) and 
demonstrated through more standard assays that they were indeed APC 
substrates.  In addition, four proteins not previously linked to mitosis (Zap-70, 
MAP3K11, RPL30, and Dyrk3) were chosen for validation. Strikingly, two of four 
(RPL30 and Dyrk3) were also shown to be APC substrates.  RPL30 is a 
component of the 60S ribosome.  Dyrk3 is a dual specificity protein kinase that 
has functions in regulating cell survival in response to energy stresses and in 
modulating erythropoiesis (199,200).  It is unclear why these proteins would be 
regulated by the APC, but their identification in this screening effort points to 
either an unappreciated function for them in the cell cycle or a broader function 
for the APC. 
  This example provides several lessons about the use of protein 
microarrays.  First, the power of working directly with proteins is that results 
immediately lead to some mechanistic understanding of the pathway. The 
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example also demonstrates that complex cell extracts can be used to 
recapitulate a genome maintenance activity.  This provides several advantages 
especially when a genome maintenance activity has yet to be fully reconstituted 
with purified proteins.  However, it also illustrates the current limitations of this 
technology.  The most obvious limitation is the current protein chips, which 
contain only a small fraction of the proteome. It is also difficult to know the 
percentage of active, folded, and sterically unhindered proteins retained on the 
microarray.  
 
Methods for identifying protein-protein interactions  
  Many genome maintenance pathways depend on assemblies of multi-
subunit protein machines.  Thus, the identification of protein-protein interactions 
is a primary method for discovering new genome maintenance proteins and 
understanding their regulation.  While there are many methodologies to 
accomplish this goal, the standard methods rely on interrogating proteins or 
complexes individually in a one protein per project fashion.  More recently, 
investigators have worked to convert these approaches into higher throughput 
formats and to create a full “interactome” description of protein-protein 
interactions that occur within a cell (201).   
  The two most common interactome methodologies are yeast two-hybrid 
(Y2H) and affinity purification combined with mass spectrometry.  Efforts began 
in yeast systems (202) and expanded to other organisms.  One impediment to 
using these methods in higher eukaryotes is the need for full-length ORFs cloned 
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into appropriate vectors.  Fortunately, orfeome cloning projects using 
recombination-based vectors are rapidly removing this obstacle. Y2H is a 
sensitive method to detect binary interactions (Figure B.2) while affinity 
purification followed by mass spectrometry (Figure B.3) is better suited to identify 
stable protein complexes that occur in the native context. 
Vidal and colleagues used interactome mapping to generate a protein-
protein interaction map for proteins involved in the DDR in Caenorhabditis 
elegans (203).  They focused on 75 worm orthologs of known DDR proteins, and 
initially used Y2H to generate pairwise protein interaction maps among these 
proteins. From this data they concluded that they had approximately a 50% 
success rate in identifying predicted interactions.  More importantly they used 67 
of the genes to perform unbiased proteome-wide Y2H screens. A total of 165 
interacting sequences were recovered, many encoding novel proteins not 
previously linked to the DDR.   
  This example illustrates both the power of interactome mapping and the 
current deficiencies in the technologies.  The major limitation of the technology is 
that it is not easily scaled to a high-throughput approach.  Thus, we only see a 
very limited portion of the interactome landscape in any single study.  A second 
problem is the issue of false-positives.  Each of the “hits” from a Y2H or mass 
spectrometry experiment can only be considered a potential protein-protein 
interaction.  Performing these experiments with large numbers of baits helps 
eliminate the false-positives through the identification of common contaminants.  
However, validation using an independent method is essential. Finally, false- 
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Figure B.2.  Yeast two-hybrid (Y2H) methods for generating interactomes.  
Yeast 2 hybrid screens detect interactions between bait proteins and prey 
proteins. Although useful to interrogate pairs of proteins (B1), these screens are 
easily easily expanded to screen cDNA libraries to generate interactome maps 
(B2) 
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negatives will be difficult to avoid using any single method so combining results 
from multiple methods will be important. 
 
Mass spectrometry methods for identifying post-translational modifications 
    In addition to identifying protein complexes, mass spectrometry can be 
used to detect post-translational modifications such as phosphorylation sites 
(Figure B.3). Unbiased phosphoproteomic screens have yielded large databases 
of thousands of phosphorylation sites (see (204) and references therein). 
Typically, these studies employ a phospho-protein enrichment strategy using 
technologies such as metal affinity chromatography.  More recently, they have 
been combined with quantitative mass spectrometry methodologies to compare 
cells or tissues from two or more conditions.    
  This methodology was applied to identify cell cycle-related 
phosphorylation (205).  In this study, the authors combined stable isotope 
labeling in cell culture (SILAC) with affinity purification of kinases using resins 
attached to five kinase inhibitors.  They differentially labeled cells synchronized in 
S or M phase with isotopes, performed the kinase enrichment strategy, and after 
trypsinization, enriched phosphopeptides prior to identification by mass 
spectrometry.  This technique yielded 1182 phosphopeptides about 50% of which 
are upregulated in mitotic cells and 10% upregulated in replicating cells. Many 
new sites on known mitotic regulatory proteins were described including sites on 
CDC2, PLK1, and AurB.  Further experiments will be needed to understand their 
functional significance.  The large number of changes in phosphopeptides
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Figure B.3. Affinity purification coupled to mass spectrometry. This 
proteomic approach is useful to interrogate protein complexes purified from their 
native cellular context or as depicted, to identify differential post-translational 
modifications following genotoxic stress. 
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identified indicates that progression through mitosis involves large changes in the 
phospho-proteome.   
 A second example comes from the study of the kinases that operate in the 
DNA damage response.  The DDR kinases ATM and ATR have a strong 
preference for phosphorylating serines or threonines that are followed by 
glutamines (206).  This bias can be used to pinpoint putative phosphorylation 
sites within known substrates.  More importantly, it can be exploited to identify 
novel ATM and ATR substrates.  The first example where this strategy was used 
successfully was our identification of MCM2 and MCM3 as substrates of ATM 
and ATR (207).  In that proof-of-concept study, we raised a phosphopeptide 
specific antibody to random phosphopeptides that contained a phosphorylated 
SQ motif.  This antibody was then used to immunopurify proteins from damaged 
cells followed by mass spectrometry to identify the phosphorylated proteins. 
Another group followed a similar approach to identify MCM3 phosphorylation 
sites (208).  Importantly, these proof of concept studies have now been extended 
to identify hundreds of potential ATM- or ATR-catalyzed phosphorylation sites. 
  Elledge and colleagues performed the largest study of this kind (88). They 
assembled a large panel of phosphopeptide specific antibodies that recognized 
phospho-SQ or -TQ epitopes.  Reasoning that these antibodies likely cross-react 
with other phospho-SQ/TQ epitopes, they used them to immunopurify tryptic 
peptides derived from undamaged and ionizing-radiation treated cells.  By 
performing quantitiative mass spectrometry, they defined over 900 regulated 
phosphorylation sites in a little over 700 proteins.  This study greatly expanded 
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the number of phosphorylated residues identified on known components of the 
DDR.  For example, they identified 27 new sites on the BRCA1, 53BP1, and 
TOPBP1 proteins.  The sites identified on MDC1 have since been defined as 
ATM-dependent phosphorylation sites and shown to be required for MDC1 to 
promote 53BP1 foci formation at DNA DSBs (178).   
  In addition to identifying new sites on known DDR proteins, the method 
also identified damage-dependent phosphorylation events on proteins not 
previously implicated in the cellular response to DNA damage.  These include 
proteins linked to RNA processing, gene expression, chromatin remodeling, and 
developmental processes. Additional studies by other laboratories using similar 
approaches have further increased the total of number of potential ATM and ATR 
substrates (115,182).   
  Although further experimentation is necessary to validate that any one of 
these phosphorylation sites is really catalyzed by ATM/ATR and determine 
whether these phosphorylations are functionally important, these lists provide a 
rich resource for investigators using other genomic or reductionist approaches to 
understanding DDR mechanisms.  Finally, this general strategy can be used for 
other post-translational modifications like methylation, ubiquitylation, sumoylation, 
or acetylation provided that efficient affinity purifications can be achieved.  See 
Boisvert et al., for an example in which several arginine methylated DNA repair 
proteins were identified (209). 
  The primary drawback of the mass spectrometry approach is that it is 
biased to identify the most abundant post-translationally modified peptides.  Low 
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abundant proteins that are only modified transiently and sub-stoichiometrically 
are likely to be poorly represented. The second issue is that there may be 
significant amounts of post-translational modifications that have no or redundant 
functional consequences. Thus, the catalogue of modifications is only a starting 
point for reductionist methods of studying function. 
 
Screens examining protein subcellular localization  
  The subcellular localization of a protein provides a powerful indicator of 
whether it functions in a genome maintenance pathway.  For example, proteins 
localized to the kinetochore likely regulate chromosome segregation during 
mitosis.  Proteins localized to telomeres may be important in chromosome end 
replication or protection.  Proteins localized to replisomes likely function in DNA 
replication.   
  There are two general strategies for using subcellular localization to 
identify genome maintenance proteins (Figure B.4).  The first is to make a library 
of tagged cDNAs and examine localization by fluorescence microscopy (Figure 
B.4A).  The second is to purify cellular structures like telomeres and identify the 
associated proteins by mass spectrometry (Figure B.4B).  The first approach has 
seen only limited application primarily as a secondary screening strategy for 
other functional genomic approaches.  The second approach, however, has seen 
widespread application with great success. 
 Dejardin and Kingston developed a technique they called proteomics of 
isolated chromatin segments (PICh) to selectively purify proteins associated with 
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Figure B.4.  Analysis of protein localization.   Determining the subcellular 
localization of a protein may indicate whether it is likely to function in a genome 
maintenance pathway. (A) Fluorescence microscopy to examine subcellular 
localization can identify proteins that change localization in response to genotoxic 
drugs like hydroxyurea (HU). (B) Biochemical purification of cellular components 
coupled to mass spectrometry provides an alternative method of defining 
proteins that reside in cellular structures relevant to genome maintenance 
activities. 
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specific DNA loci (210). The steps of PICh include formaldehyde-crosslinking 
cells to crosslink DNA-protein and protein-protein complexes, solubilizing 
chromatin, denaturing the DNA to allow for DNA probe hybridization, purification 
of hybrids, elution, and finally analysis of eluted proteins by mass spectrometry. 
Since DNA hybridization for capture is not sensitive to high concentrations of 
ionic detergent, PICh allows for stringent capture and purification conditions that 
reduce non-specific binding of proteins. They applied this technique to identify 
proteins associated with mammalian telomeres.  Their experiments successfully 
identified 85% of known telomere binding proteins and over 100 new proteins. 
Several of these are orphan nuclear receptors including COUP-TF2 and TR4.  
These proteins actually ranked higher on their abundance list than two known 
shelterin components.    Interestingly, these proteins were found in telomere 
preparations from cells using the ALT method of telomere elongation specifically 
suggesting they have some function at ALT telomeres.   
A few technical challenges must be overcome to use PICh for the 
classification of chromatin composition relevant to other genome maintenance 
activities.  One of the primary concerns with this methodology is DNA-probe 
design.  In many cases such as damage caused by a genotoxic agent, site-
specificity is not available. The other major hurdle is that it may not be easily 
adapted to identifying proteins at DNA sequences that are found at one or few 
copies in the genome.  
  A second localization-based screen identified proteins whose localization 
to chromatin increased after cells were exposed to ionizing radiation (211).  Both 
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DSB repair and DDR signaling proteins accumulate at the site of the DSB.  This 
accumulation is often sufficient to observe a significant redistribution of the 
protein to the chromatin.  Biochemical cell fractionation into soluble and 
chromatin compartments can be used to measure this change in localization.  In 
this example, the authors determined that several subunits of the NuRD 
(nucleosome remodeling and histone deacetylation) chromatin-remodeling 
complex (CHD4, CHD3, MTA1 and MTA2) were recruited to chromatin after IR.  
These proteins have been best studied in the context of transcription where they 
work to remodel nucleosomes and thereby change gene expression (212).  DSB 
repair, especially homology-directed repair, requires access of the DSB repair 
proteins to the DNA surrounding the break (213). Chromatin remodeling proteins 
likely work to regulate this access.  Chromatin remodeling proteins are frequently 
identified in other functional genomic screens for genome maintenance proteins 
(see below) emphasizing that genome maintenance also requires chromatin 
maintenance. 
   
RNAi screening 
   
Genetics are difficult in diploid organisms because two copies of a gene 
must be manipulated to study loss of function phenotypes. Since RNAi-mediated 
silencing of genes occurs independently of gene copy number, it provides an 
opportunity to perform loss of function genetic screens in diploid cells. Thus, the 
genetic screens that were previously limited to organisms like S. cerevisiae and 
 192 
S. pombe can now be done in human, mouse, and insect cell culture or even 
whole organisms like C. elegans.   
 There are currently three primary genome-wide RNAi platforms. Small 
interfering RNAs (siRNAs) are chemically synthesized silencing reagents that 
can be arrayed in multi-well plates. Formats include individual siRNAs per well or 
pools of multiple siRNAs targeting a gene in each well.  Enzymatically prepared 
siRNAs (esiRNAs) are produced through enzymatic methodologies instead of 
chemical synthesis and create arrayed pools of siRNAs targeting each gene.  
Finally, short-hairpin RNA (shRNA) vectors are DNA vectors encoding RNAs that 
are processed to yield the silencing RNA.  These are often produced in viral 
vector systems allowing stable integration into the genome of infected cells.  Both 
arrayed and large pool formats of shRNA libraries are available. 
 
Drug hypersensitivity screens  
Designing an RNAi screen begins with an assay suitable for high-
throughput screening. The simplest screen designs relevant to genome 
maintenance pathways are drug hypersensitivity screens. The rationale is that by 
treating cells with a drug that places a high burden on a specific genome 
maintenance pathway, researchers can identify genes whose loss of function 
causes hypersensitivity to the drug. These types of screens have been used in 
many genetically tractable organisms like yeast for decades, are simple to 
execute, and are compatible with all RNAi formats.  
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 Since drug hypersensitivity screens rely on growth inhibition or cell death 
as the primary assay, they are compatible with pooled libraries of shRNAs 
(Figure B.5).  In this format, a population of cells is infected at a low multiplicity of 
infection such that each cell harbors only a single shRNA.  Since the shRNA 
should produce a stable knockdown, the cell population can be split in half, 
treated with a drug, and then examined for the relative abundance of each 
shRNA in the two populations.  If a shRNA silences a gene required for cells to 
survive or proliferate in the presence of the drug, then that shRNA will be lost 
from the treated cell population but retained in the control population.  The 
abundance of each shRNA can be determined by sequencing the shRNAs 
recovered from the two populations.  Alternatively, microarrays can be used to 
detect barcodes incorporated into the shRNA library. 
 Using a pooled hypersensitivity screen, Elledge and colleagues sought to 
identify novel components of the DDR using cellular sensitivity to ionizing 
radiation as the assay (173,176). The screen conducted in the human U2OS 
osteosarcoma cell line used a library of approximately 75,000 shRNA vectors 
pooled into six sub-libraries.  850 shRNAs targeting 813 genes were identified 
that caused significant hypersensitivity to ionizing radiation. These genes were 
grouped into functional categories using the PANTHER (214).  Unclassified 
genes accounted for 30% of the gene set. Multiple genes known to function in 
DDR networks were identified, and two new components of the DSB repair and 
DNA damage checkpoint signaling pathways were examined at the mechanistic
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Figure B.5.  Pooled RNAi screening.  Pooled format screens facilitate drug 
hyper-sensitivity screening. (1) Barcoded shRNA vector libraries are introduced 
into a population of cells, (2) split into treated and untreated groups,  (3) grown 
for several generations to allow selection against a subset of the shRNA 
expressing cells; and (4) analyzed by sequencing or microarray technology to 
identify differences in shRNA abundance. 
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level, NBA1 and the Triple T complex.  NBA1 localizes to sites of DNA damage, 
associates with BRCA1 and is required for the recruitment of BRCA1 to damage 
sites (173).  The Triple T complex consists of three proteins TTI1, TTI2, and 
TEL2 that regulates the stability of the phosphoinositide-3-kinase-related protein 
kinases ATM and ATR (176). 
Drug hypersensitivity screens can also be performed using libraries of 
arrayed shRNA, siRNAs or esiRNAs.  Arrayed hypersensitivity screens measure 
the effects of single gene knockdown on cells in each well of a multi-well plate 
(Figure B.6A). Individual or pools of siRNAs targeting a single gene are typically 
introduced into cells by reverse transfection using lipid-based methods. Reagents 
that change color or fluorescence relative to the number of proliferating cells in a 
well can be used as a measure of cell viability. Microplate spectrophotometers 
enable multi-well processing of this assay endpoint.  
 Whitehurst and colleagues used an arrayed RNAi hyper-sensitivity screen 
to identify gene functions that drive the cellular response to paclitaxel in lung 
cancer cells (215).  Paclitaxel is a chemotherapeutic drug that targets 
microtubules to inhibit mitosis and is commonly used to treat patients with non-
small lung cancers. Four unique siRNAs targeting each of 21,127 genes were 
transfected into a non-small lung cancer cell line in a one gene per well format 
with each well containing a pool of four siRNAs.   A concentration below the half 
maximal inhibitory concentration for paclitaxel was selected to enrich for genes 
that when silenced rendered cells hypersensitive to low doses of drug. The 
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Figure B.6.  Arrayed RNAi screening.  Arrayed format RNAi libraries can be 
used both for (A) hyper-sensitivity or (B) high-content screens. 
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screen was completed in triplicate and normalizations to internal plate controls 
were made to eliminate plate-to-plate technical variations.   
 To identify significant hits, a statistical algorithm was applied to calculated 
viability ratios yielding an estimated false discovery rate below 5%.  As validation 
for their analysis, siRNAs targeting core proteasome components were identified 
as hits and proteasome inhibitors have already been demonstrated to enhance 
the sensitivity of paclitaxel in cancer cells (216). They identified 87 genes that fit 
their criteria and reconfirmed that silencing caused sensitivity to paclitaxel with 
four additional siRNAs in pools and individually.  Importantly, they confirmed 
these affects across multiple cell lines and defined genes that when silenced 
specifically sensitized cancer cells to low doses of paclitaxel compared to normal 
cell lines.  Thus, the hits from this screen are potential drug targets for lung 
cancer since they selectively sensitize cancer cells and not normal cells 
(217,218).   
These screens offer several lessons about RNAi-based functional 
genomics approaches.  It is striking that in the shRNA pooled screen for IR 
sensitivity the vast majority of genes found in the primary screen were only 
identified by a single shRNA despite multiple shRNAs per gene being present in 
the library (173,176).  This suggests that the shRNA targeting was inefficient, or 
a large number of the hits were due to off-target effects. The pooled screens 
require that a single shRNA vector inserted into the cellular genome produces 
sufficient shRNA to silence the gene effectively. Even with optimal vector designs, 
this requirement may not often be fulfilled.  This issue will increase the false-
 198 
negatives in the screen.  Off-target effects leading to false-positives are also a 
concern necessitating that further follow-up experimentation be performed to rule 
them out.  Finally, the large pooled format cannot ensure that every shRNA 
vector is equally represented or expressed in the library. 
The arrayed screens likely suffer less from the issue of insufficient 
targeting.  Algorithms for designing siRNAs are sufficiently robust to yield high 
percentages of highly effective siRNAs.  Furthermore, they are transfected into 
the cells at very high copy number.  However, off-target effects are also a 
concern in this format.  In the paclitaxel arrayed screen on-target effects were 
confirmed by validating hits from the pooled siRNA primary screen with four 
individual siRNAs (215). Alternatively, if the library is arrayed such that several 
individual siRNAs are used independently, then the results can be quickly 
scanned for genes that have at least two siRNAs yielding the same 
hypersensitive phenotype.  This raises the largest obstacle to the arrayed 
screens – cost.  Typically, whole genome screens are done in formats where 
small pools of siRNAs targeting a single gene are combined into a single well.  
This saves money in performing the screen but necessitates de-convolution of 
the pools to eliminate off-target effects. The arrayed screens also require 
specialized liquid handling systems that may not be available to a typical 
laboratory. 
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Synthetic genetic interaction screens 
 Synthetic genetic interactions arise when the phenotype from the loss of 
function of two genes are compared to the phenotypes of the individual gene 
effects.  Often these interactions take the form of synthetic lethality.  Synthetic 
genetic interaction screens in yeast are currently being done using synthetic 
genetic array (SGA) technologies and are very useful for dissecting complex 
biological pathways (72,219,220).  SGA provides a format for the high-throughput 
construction of double mutants at the genome-wide level.  Similar methodologies 
are not available in higher eukaryotes.  Instead, investigators are turning to three 
approaches to perform synthetic genetic interaction screens:  drug sensitivity 
screens, screens combining RNAi molecules targeting two different genes, and 
screens using matched pairs of cell lines in which a specific gene is mutated or 
wild-type.   
  The first involves using selective drugs in combination with RNAi to target 
proteins in the cell and is particularly useful in identifying drug targets or genetic 
backgrounds where a drug might be useful in treating cancer. For example, 
several synthetic lethal screens have been performed with recently developed 
inhibitors of the poly-ADP ribose polymerase (PARP) enzymes (221-223).  These 
inhibitors selectively kill cells deficient in homologous recombination (HR) based 
repair mechanisms.  Thus, they are being developed for treating BRCA-deficient 
tumors since BRCA1 and BRCA2 are required for HR repair.  Investigators 
reasoned that loss of function mutations in other genes are likely to yield defects 
in HR and performed synthetic lethal screens with PARP inhibitors to identify 
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these genes.  These screens not only define novel HR genes but also may point 
to additional clinical settings where PARP inhibitors can be useful. 
  The alternative two approaches to perform synthetic genetic interaction 
screens do not use selective drugs. The first is to combine two RNAi molecules 
targeting different genes.  The second is to use matched pairs of cell lines in 
which a specific gene is mutated or wild-type.  The first approach may be more 
quickly applied to any gene but suffers from issues of whether the simultaneous 
knockdown of two genes is as efficient as the single knockdown.  It also suffers 
from the potential for synthetic off-target effects, which may be very difficult to 
control.  Thus, the superior results that can be obtained from the second 
approach using matched pairs of cell lines with a defined loss of function 
mutation at the gene level may be worth the added time and cost of generating 
the cell lines.  
 
High content RNAi screens 
 Hypersensitivity and synthetic lethal screens have relatively low 
information content because cell proliferation or viability is not a phenotype 
specific to genome maintenance pathways. Thus, large numbers of genes are 
identified in these types of screens.  Even in yeast, these screens often identify 
large percentages of the genome as being required to survive or proliferate in 
response to a drug.  Thus, higher-content assays are increasingly being 
employed.  Essentially, anything that can be imaged can be tested using high 
content microscopy (HCM).  High-resolution images can be generated rapidly in 
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microtiter plates containing up to 1536 wells.  Image processing software can 
yield information as varied as DNA content, cell size, and protein localization. 
Thus high content screening can be used to interrogate specific genome 
maintenance pathways at high resolution, and the screens typically yield smaller 
numbers of “hits”.  These types of screens are best suited to arrayed RNAi library 
formats (Figure B.6B). 
 One example of a high content screen relevant to genome maintenance is 
a screen to define cell division cycle genes in human cells (170). In this study, 
video microscopy was used to measure changes in the timing of cell division in 
HeLa cells in real time.  In addition, fixed cells were stained for tubulin and DNA 
to visualize physical aberrations in mitotic structures. Screening a set of esiRNAs 
representing 5,305 genes led to the classification of genes with functional roles in 
spindle formation, mitotic arrest, and cytokinesis, including 7 genes with no 
previous assigned function and 23 with annotated functions other than cell 
division. The functional readouts for this study were specific and facilitated direct 
classification of gene groups.   
  Additional examples of high content screens include several recent 
screens that studied the DNA damage response by microscopy. Two screens 
were reported that used the detection of phosphorylated ATM/ATR substrates as 
the primary assay (66,181).  The largest of these screens used an siRNA library 
targeting the entire genome and visualized phosphorylation of the histone variant 
H2AX. H2AX is dispersed throughout the genome in approximately 10% of 
nucleosomes (224).  Phosphorylation of H2AX at serine 139 ($H2AX) by ATM 
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and ATR is a well-defined early event at or near the site of DDR activation (225-
227). $H2AX spreads kilobases of DNA beyond the break site, which allows 
visualization of bright $H2AX nuclear foci by microscopy (228). $H2AX has 
classically been used as a marker for DNA DSBs but is also phosphorylated at 
stalled replication forks and perhaps at other lesions where ATR is active.  
The Cimprich group monitored $H2AX phosphorylation following gene 
silencing in the absence of any added genotoxic agent with the rationale that 
genes involved in genome maintenance pathways like DNA repair or replication 
prevent DNA damage from accumulating in cells (181). Silencing these genes 
would increase the DNA damage burden, thereby increasing the activation of 
ATM or ATR and phosphorylation of H2AX.  The authors grouped their results 
into confidence levels defined by the strength of the phenotype, reproducibility, 
and numbers of individual siRNAs that yielded the same results.  They defined 
581 genes as high confidence hits.  In addition to genes that function in the 
known genome maintenance pathways, they identified genes predicted to 
function in many other cellular metabolism activities including a large group of 
RNA processing proteins. After further investigation, they determined that at least 
a subset of these genes are needed to prevent RNA-DNA hybrids from forming 
during transcription which presumably lead to RNA polymerase stalling followed 
by collisions with the replication machinery in S-phase.  Importantly, RNA 
processing proteins were also enriched in ATM/ATR substrate identification 
screens (88) suggesting that RNA processing is a critical component of genome 
maintenance.    
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DNA damage also causes the recruitment of many DDR proteins to 
intranuclear foci that are easily visualized by immunofluoresence, including p53 
binding protein (53BP1) (229,230). 53BP1 localizes to sites of DNA DSBs and 
functions in DSB repair via end joining (231-236).  The recruitment of 53BP1 to 
DNA damage foci depends on $H2AX and MDC1 (237).  The underlying 
mechanisms of focal recruitment and retention of these DNA repair factors at 
DNA breaks has been a major question in the field.  RNAi screens based on 
imaging 53BP1 localization were designed to address this question and led to the 
discovery of RNF8 and RNF168, which are ubiquitn conjugating enzymes that 
regulate the chromatin microenvironment important for DNA DSB repair (178-
180). 
Durocher and colleagues identified RNF8 in a genome-wide siRNA screen 
for the abundance of 53BP1 foci in U2OS cells 24hrs after IR (178).  They 
reasoned that gene functions required upstream of 53BP1 foci formation at DSBs 
would result in significant changes in abundance of 53BP1 foci when silenced.  
Pools of four siRNAs per gene were arrayed in 384 well formats and transfected 
into cells in quadruplicate.  Using the high throughput acquisition and analysis 
capabilities of the Opera imaging system, they identified 500 siRNAs resulting in 
significant reduction in 53BP1 foci compared to controls.  RNF8 was the top 
scoring hit following known upstream regulators of 53BP1 like $H2AX and MDC1.  
In a follow up study, 59 candidate genes from the original screen were targeted 
with additional esiRNAs to further validate 53BP1 loss.  RNF168 was the top hit 
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in this secondary validation and was subsequently defined to act downstream of 
RNF8, to assemble K63-linked ubiquitin chains at sites of DNA damage (180).  
Lukas and colleagues also identified RNF168 in a screen based on similar 
rationale and functional readout but using distinct screening methodologies (179).  
They applied a protocol that was developed for screening siRNAs spotted on 
chambered slides (238).  This technique represents another method for siRNA 
arrayed screens, siRNA microarrays.  In this particular screen, U2OS were 
seeded in chambers containing 384 individual siRNA spots that were embedded 
in optimized transfection mixtures.  After three days, the central area of each spot, 
containing approximately 150 cells, was analyzed for number of 53BP1 foci.  A 
total of 21541 human genes were targeted with multiple siRNAs.  When the 
screen was published, 15000 genes had been analyzed and 42 had at least one 
siRNA that resulted in reduced 53BP1 foci.  Only three of 42 hits had two siRNAs 
score positive, MDC1, RNF8, and the previously uncharacterized RING finger 
protein, RNF168. These results may reflect a current disadvantage of this 
methodology, a high false negative rate.  This problem may be due to inefficient 
siRNA knockdown or the small numbers of cells that were analyzed per data 
point. Increasing replicates or cells analyzed may suffice for reducing false-
negatives. 
 
RNAi screens in multi-cellular organisms 
  The benefits of RNAi genetic screens are not limited to cell culture. RNAi 
screens in the C. elegans worm provide a method for analyzing loss of function 
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phenotypes in an intact animal. Delivery of RNAi into worms is performed either 
by injection of dsRNA directly into head or tail, soaking the worms in a solution of 
RNAi molecules, or by feeding animals bacteria that express dsRNA targeting a 
specific gene (239). The effects of RNAi in C.elegans can be analyzed by whole 
mount staining or other phenotypic assays.   
  A genome-wide RNAi screen in C. elegans identified genes that protect 
animal cells against IR (240).  The screen was completed with worm larvae 
cultured in the presence of bacteria expressing RNAi molecules.   19000 C. 
elegans genes were screened in an arrayed, multi-well format.  Worm cultures 
were exposed to IR and subsequently imaged to measure for IR-induced cell 
cycle arrest and apoptosis in germ cells. After undergoing stringent filtering using 
dose response analyses, 45 genes emerged as IR protective genes. 43 of the 45 
have clear human homologs emphasizing the extent to which the DDR pathway 
is conserved across evolution.  Genes were cataloged based on their previously 
known functions, requirement for resistance to other DNA damaging agents, and 
homology across human, fly, and yeast.   
  Importantly, the human homologs of seven genes (ATM, ITGA6, NIPBL, 
CAND1/TIP120, NOB1, WWP2, and TOPBP1) were targeted by siRNA and 
measured for IR sensitivity, and all seven were confirmed as genes required for 
IR resistance in human cells.  Several of these genes like ATM and TOPBP1 are 
not surprising since they were already known to function in DNA damage 
response pathways.  However, less clear was why NOB1 (a protein implicated in 
ribosome assembly) or WWP2 (a ubiquitin ligase) were identified. Interestingly, 
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WWP2 has since been shown to function as an E3 ligase for PTEN (241).  This 
may provide a link to the DNA damage response since PTEN function may 
modulate DNA repair activities (242).   
  Another C. elegans screen used a gfp-LacZ reporter of frameshifts and 
small insertions/deletions to screen for DNA instability in somatic cells (243).  
This method enabled visual screening of cells harboring mutations that reverted 
the out of frame LacZ gene to the correct reading frame.  The authors found 61 
out of 16,606 genes screened resulted in a mutator phenotype.  The orthologs of 
the DNA mismatch repair genes were among this list as would be expected.  In 
addition to DNA repair genes, they found genes such as the histone 
deacetylases HDAC1 and HDAC2 which regulate chromatin organization and 
genes like cdc5 and cdc14 that regulate cell cycle checkpoints.  29 of the genes 
were not described previously but several have interesting protein domains such 
as exonuclease, histone acetyltransferase, and SET domains suggesting they 
could be involved in DNA metabolism.   
 
General considerations about RNAi screens 
 RNAi screens provide an increasingly important source of discovery for 
genome maintenance researchers (Table B.1).  A question like how do cells 
repair a double-strand break can be approached at multiple levels with RNAi 
screens.  The simplest but least specific may be the ionizing radiation sensitivity 
screens. The most specific, but also most technologically difficult will be screens 
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Table B.1. Examples of RNAi screens for genome maintenance discussed 
in text. 
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based on direct measurements of repair.  In between are the high content 
imaging screens scoring for markers like $H2AX or 53BP1 foci.  The choice of 
screen assay in part determines the optimal screening platform.  In practice, the 
most useful information may come from combining the results of multiple screens. 
Certainly the confidence that any previously unstudied gene functions in a DSB 
repair pathway is significantly increased by the independent identification of that 
gene in more than one screen. 
  Eliminating false-positives is critical for the results of the screen to be 
useful.  The most common source of false-positives is off-target effects of the 
RNAi.  Since silencing does not require perfect base pair complementarity 
between the siRNA and the mRNA, each RNAi molecule has the potential to 
silence multiple genes. The most common method to eliminate off-target effects 
is to require that more than one RNAi molecule targeting the same gene yield the 
same phenotypic consequence.  If antibodies to the targeted protein are 
available then correlating protein knockdown efficiency with strength of 
phenotype adds further confidence.  Finally, complementation of the knockdown 
phenotype with a resistant cDNA is the best method of demonstrating an on-
target effect.  However, this approach is not feasible in a high-throughput format. 
  RNAi screens likely suffer from high rates of false-negatives. Even when 
two investigators use similar methodologies, the overlap in gene hits is often low.  
False-negatives come from inefficient knockdown, cell type specific effects, and 
deficiencies in the genome-wide libraries. The cell-type specific effects are likely 
to be large since most screens use tumor-derived cells that have large numbers 
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of genetic abnormalities already.  These differences can be exploited especially 
in synthetic lethal type screens where the important question is what makes two 
or more cell types behave differently.    
  All of these RNAi screens depend on a statistical determination of what is 
a “hit”. Defining the hits requires a measurement of difference from the control, 
variability, and elimination of off-target effects.  Many different statistical methods 
have been developed but determining biological significance requires more in-
depth analyses.  Functional annotation programs such as PANTHER can help 
but these issues point out the need for secondary screens to validate hits and 
provide further guidance on future directions. Ideally, these secondary screens 
should also be amenable to high-throughput assays. Ultimately, more traditional 
reductionist approaches are needed to fully validate and understand the results 
of any RNAi screen. 
 
Conclusion 
 
Expression profiling, proteomics, and RNAi screening methodologies have 
proven successful in the investigation of genome maintenance activities. When 
considering the power of these methodologies for discovery, it is important to 
realize that in many cases they were made with first generation technologies.  In 
the next ten years we can expect the development of arrayed full-genome 
epitope-tagged cDNA libraries for faster genome-wide proteomics; protein 
microarray chips will expand to include a much higher percentage of the 
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proteome; and RNAi libraries will continue to improve.  
 The amount of data being generated is quickly outpacing the ability of a 
single investigator to assimilate.  Thus, bioinformatic analyses must be 
developed alongside of improving high-throughput screening technologies. Better 
databases to store, report, search, and integrate data sets from RNAi screens 
are also needed.  
 The rapidly expanding data sets from expression profiling, proteomics, 
and RNAi screening methods are generating lists of new genome maintenance 
proteins. These lists contain genes that function in pathways like chromatin 
regulation that have obvious links to the DNA metabolic processes that maintain 
the genome.  But they also contain evidence that many other intracellular 
pathways impact genome integrity. Our challenge is to complete the catalogue 
and explain at a mechanistic level how these activities are integrated within the 
cell to protect genome stability and prevent disease.   
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